Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

ABSTRACT

The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is divisional of U.S. patent application Ser. No.10/580,962, filed on May 31, 2006, which is a national stage entry under35 U.S.C. §371 of PCT International Application No. PCT/BE2004/000172,filed Dec. 2, 2004, and claims priority of U.S. patent application Ser.No. 10/725,965, filed Dec. 2, 2003, Canadian Patent Application No.2,451,798, filed Dec. 2, 2003, European Patent Application No.03447279.5, filed Dec. 2, 2003, European Patent Application No.04447001.1, filed Jan. 5, 2004, U.S. patent application Ser. No.10/752,423, filed Jan. 6, 2004, European Patent Application No.04447066.4, filed Mar. 18, 2004, U.S. patent application Ser. No.10/803,793, filed Mar. 18, 2004, Canadian Patent Application No.2,461,248, filed Mar. 18, 2004, European Patent Application No.04025035.9, filed Oct. 21, 2004, Japanese Patent Application No.2004-349085, filed Nov. 4, 2004, U.S. patent application Ser. No.10/984,683, filed Nov. 9, 2004, and Canadian Patent Application No.2,487,529, filed Nov. 15, 2004.

FIELD OF THE INVENTION

The invention relates to the field of neuropsychiatry. Morespecifically, the invention relates to the use of compounds, which haveD4 and 5-HT2A antagonist, inverse agonist or partial agonist activity,for the preparation of medicaments.

BACKGROUND OF THE INVENTION

Conventionally, mental disorders are divided into types based oncriteria sets with defining features. DSM-IV (American PsychiatricAssociation, (1993—ISBN 0-89042-061-0)) is the in the art well-knowngolden standard of such a categorical classification. In DSM-IV, thereis no assumption that each category of mental disorder is a completelydiscrete entity with absolute boundaries dividing it from other mentaldisorders or from no mental disorder. There is also no assumption thatall individuals described as having the same mental disorder are alikein all important ways. Individuals sharing a diagnosis are likely to beheterogeneous even in regard to the defining features of the diagnosis.Thus, the categorical defined mental disorders as mood and anxietydisorders are having an external and even internal variable co-incidenceof symptoms concerning e.g. mood, anxiety, perception, feeding, somaticsensations, sexual functions, sleep, cognitive functioning, impulsecontrol, attention, substance use, personality, bereavement, identity,phase of life, abuse or neglect and other aspects of behavior.

In a dimensional system, clinical presentations are classified based onquantification of attributes i.e. dysfunctions rather than theassignment to categories and works best in describing phenomena that aredistributed continuously and that do not have clear boundaries.

Emotion dysregulation is known as such an attribution or dysfunctionthat plays an important role in the development and course of mentaldisorders (Gross, J. J. & Munoz, R. F., 1995, Emotion regulation andmental health, Clinical Psychology: Science and Practice, 2, 151-164;Mennin, D. S., Heimberg, R. G., Turk, C. L. & Fresco, D. M., 2002,Applying an emotion regulation framework to integrative approaches togeneralized anxiety disorder, Clinical Psychology: Science and Practice,9, 85-90; Linehan, M. M., 1993, Cognitive-behavioral treatment ofborderline personality disorder, New York, The Guilford Press; Gratz, K.L., Roemer, L., 2001 & 2004, Multidimensional assessment of emotionregulation and dysregulation: development, factor structure, and initialvalidation of the Difficulties in Emotion Regulation Scale, Annualmeeting of the Association for Advancement of Behavior Therapy, November2001 & Journal of Psychopathology and Behavioral Assessment, Vol. 26,No. 1, March 2004) besides behavioural and cognitive dysfunctions. D4dopamine receptors (D4DR), almost exclusively present in themesocortical and mesolimbic systems (O'Malley, K. L., Harmon, S., Tang,L., Todd, R. D., The rat dopamine D4 receptor: sequence, gene structure,and demonstration of expression in the cardiovascular system, New Biol.,4, 137-46, 1992), are in the art known as modulators of emotion andcognition. D4DR agonistic activity gives a behavioural sensitisation;D4DR antagonistic activity leads to an emotion modulation (Svensson, T.H., Mathé, A. A., Monoaminergic Transmitter Systems, BiologicalPsychiatry (eds. D'Haenen, H., et al.), 45-66, 2002, John Wiley & Sons,Ltd). Data demonstrate that agonism of the dopamine D4 receptors play animportant role in the induction of behavioral sensitization toamphetamine and accompanying adaptations in pre- and postsynaptic neuralsystems associated with the mesolimbocortical dopamine projections (D.L. Feldpausch et al.; The Journal of Pharmacology and ExperimentalTherapeutics Vol. 286, Issue 1, 497-508, July 1998).

Results suggest that the antagonisms of cortical D2 dopamine receptorsare a common target of traditional and atypical antipsychotics fortherapeutic action. Higher in vivo binding to the D2 receptors in thecortex than in the basal ganglia is suggested as an indicator offavorable profile for a putative antipsychotic compound (X. Xiberas andJ. L. Martinot; The British Journal of Psychiatry (2001) 179: 503-508).Results show that dopamine D4 receptor antagonism in the brain does notresult in the same neurochemical consequences (increased dopaminemetabolism or hyperprolactinemia) observed with typical neuroleptics(Smita Patel et al., The Journal of Pharmacology and ExperimentalTherapeutics Vol. 283, Issue 2, 636-647, 1997). The selective D4dopamine receptor antagonist L-745,870 was ineffective as anantipsychotic for the treatment of neuroleptic responsive patients withacute schizophrenia (Kramer, M. S. et al., Arch. Gen. Psychiatry 1997December; 54(12):1080).

Finally, in the biological system, mental disorders are defined on otherlevels of abstraction than in the categorical and dimensional system.Structural pathology (e.g. amyloid plaques in Alzheimer Disease),etiology (e.g. HIV Dementia) and deviance from a physiological norm(e.g. reduced cerebral blood flow) are often used as indicativebiological markers for a mental disorder. The underlying dysregulationof various neurotransmitter systems (glutaminergic, GABAergic,cholinergic, monoaminergic (nor-adrenergic, dopaminergic, serotonergic),etc.) is the in the art used model for the explanation of the biologicaldeterminants of the clinical presentation of mental disturbances. It isknown that the Serotonin 2A Receptor (5-HT2A receptor)—which iswidespread in the Central Nervous System (CNS)—has a regulating role onthe dysregulation of various neuro-transmitter systems. 5-HT2A agonismgives several behavioural disturbances; 5-HT2A antagonism leads to agovernance of mood, social behaviour, anxiety, cognitive function,stress, sleep functions, nociception, sexual functions, feeding andother aspects of behaviour (J. E. Leysen (2004) 5-HT2 Receptors; CurrentDrug Targets—CNS & Neurological Disorders, 2004, 3, 11-26).

Dysregulation of the HPA axis (hypothalamic-pituitary-adrenal axis) hasfrequently been reported in patients with psychiatric disorders, and isamong the most robustly demonstrated neurobiological changes amongpsychiatric patients (D. A. Gutman and C. B. Nemeroff,Neuroendocrinology, Biological Psychiatry (eds. D'Haenen, H., et al),99, 2002, John Wiley & Sons, Ltd). The resulting elevated plasmacortisol concentrations leads to an enhanced binding of serotonin forthe 5-HT2A receptor (E. A. Young, Mineralocorticoid Receptor Function inMajor Depression, Arch. Gen. Psychiatry, January 2003; 60: 24-28) andthus agonism.

Additionally 5-HT2A antagonism gives a des-inhibiting of the inhibitoryeffect of the 5-HT2A receptor on (i) the 5-HT1A receptor stimulation byserotonin (S. M. Stahl, Newer Antidepressants and Mood Stabilizers,Essential Psychopharmacology, 265, University Press; 2 edition (Jun. 15,2000); ISBN: 0521646154) and on (ii) the dopamine release in themesocortical systems (S. M. Stahl, Classical Antidepressants, SerotoninSelective and Noradrenargic Reuptake Inhibitors, EssentialPsychopharmacology, 233, University Press; 2 edition (Jun. 15, 2000);ISBN: 0521646154).

Clinical or real effectiveness of psychopharma is very rare via commonpooping-out; many treatment-refractory patients and up to half ofpatients fail to attain remission (S. M. Stahl, EssentialPsychopharmacology, Depression and Bipolar Disorders, 151, UniversityPress; 2 edition (Jun. 15, 2000); ISBN: 0521646154). Implications of notattaining remission for Mental Disorders are increased relapse rates,continuing functional impairment and increased suicide rate (S. M.Stahl, Essential Psychopharmacology, Depression and Bipolar Disorders,152, University Press; 2 edition (Jun. 15, 2000); ISBN: 0521646154).Clinical causes of not attaining remission by the CurrentPsychopharmacological Compounds are inadequate early treatment,underlying emotion dysregulation (affectinginstability-hypersensitivity-hyperaesthesia-dissociative phenomena,etc.) and competitive antagonism. There is thus a growing need for amore efficient therapy and more efficient, selective and efficaciousmedicaments for treating mental disorders.

SUMMARY OF THE INVENTION

The present invention relates to the use of compounds and pharmaceuticalcompositions having D4 and 5-HT2A antagonistic, partial agonistic orinverse agonistic activity for the treatment of the underlying emotiondysregulation of mental disorders (e.g. affectinginstability-hypersensitivity-hyperaesthesia-dissociative phenomena-etc.)and to methods entailing administering to a patient diagnosed as havinga mental disorder a pharmaceutical composition containing (i) compoundshaving specific high selective D4 and 5-HT2A antagonistic, partialagonistic or inverse agonistic activity and (ii) a known medicinalcompound and/or compositions of compounds. The combined D4 and 5-HT2Aantagonistic, partial agonistic or inverse agonistic effects may residewithin the same chemical or biological compound.

Taken into account the above mentioned (i) rare clinical or realeffectiveness of psycho tropics, (ii) the governance of the features anddysfunctions responsible—in a variable co-incidentally—for the clinicalstate of the mental disorders by D4 dopamine receptor (D4DR) and 2Aserotonin receptor (5-HT2A) antagonism and (iii) the fact that 5-HT2Aantagonism gives a des-inhibiting of the inhibitory effect of the 5-HT2Areceptor on (a) the 5-HT1A receptor stimulation by serotonin and on (b)the dopamine release in the mesocortical systems, the present inventionrelates to the use of a compound for the preparation of a medicament fortreating a disease or disorder with an underlying emotion dysregulation,characterised in that said compound has (i) a selective affinity for theDopamine-4 (D4) receptor with a pKi value equal to or higher than 8towards the D4 receptor and less than 8 towards other Dopaminereceptors, and (ii) a selective affinity for the 5-HT2A receptor with apKi value equal to or higher than 8 towards the 5-HT2A receptor and lessthan 8 towards other 5-HT receptors and wherein said compound isadministered to a patient in a dose ranging between 5 and 15 mg of theactive ingredient. Preferably, said compound is pipamperon.

In a preferred embodiment, in a mono therapeutic context, the inventionrelates to the use of a compound as defined above, preferablypipamperon, for preparing a medicament for treating a disease ordisorder selected from the group comprising anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders, factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, cognitive disorders, impulsecontrol disorders, pervasive development, attention-deficit anddisruptive behaviour disorders, substance-related disorders, personalitydisorders, psychological factors affecting medical conditions,malingering, antisocial behaviour, bereavement, occupational, identity,phase of life; academic problem, problems related to abuse or neglect.

According to a further embodiment the invention relates to the use of afirst compound as defined above for the preparation of a medicament fortreating a mental disease or disorder with an underlying emotiondysregulation whereby a second compound is administered simultaneouslywith, separate from or sequential to said first compound to augment thetherapeutic effect of said second compound on said disease, or toprovide a faster onset of the therapeutic effect of said second compoundon said disease.

The mental diseases or disorders characterized by an underlying emotiondysregulation can be grouped into subclasses as follows: (i)non-cognitive mental disorders comprising mood disorders, anxietydisorders, psychotic disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, attention-deficit disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problems, identityproblem, phase of life problem, academic problem and problems related toabuse or neglect; (ii) cognitive diseases comprising delirium, AlzheimerDisease, substance-related persisting dementia, vascular dementia,dementia due to HIV disease, dementia due to head trauma, dementia dueto Parkinson Disease, dementia due to Huntington Disease, dementia dueto Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnesticdisorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder, othercognitive disorders; (iii) pain disorders; and (iv) Parkinson Disease.

In a preferred embodiment, the first compound is administered daily atleast one day before administering said second compound.

Preferably, said second compound is characterized by the physiologicalproperty of influencing positively the activity of the Central NervousSystem.

The invention also relates to a method for preparing a compound having aselective D4 and 5-HT2A antagonist, reverse agonist or partial agonistactivity comprising the following steps: (a) measuring the selectiveaffinity of a test compound to the D4 receptor and selecting a compoundthat has a pKi value equal to or greater than 8 towards the D4 receptorin respect to all the other D receptors, and measuring the selectiveefficacy of the selected compound to the D4 receptor and selecting acompound which is a selective antagonist, inverse agonist or partialagonist of the D4 receptor; (b) measuring the selective affinity of atest compound to the 5-HT2A receptor and selecting a compound that has apKi value equal to or greater than 8 towards the 5-HT2A receptor inrespect to all the other 5HT receptors, and measuring the selectiveefficacy of the selected compound to the 5-HT2A receptor and selecting acompound which is a selective antagonist, inverse agonist or partialagonist of the 5-HT2A receptor; (c) identifying a compound which isselected in (a) and (b), (d) preparing the compound identified in (c).

The invention further also relates to a compound prepared by thedescribed method.

DETAILED DESCRIPTION OF THE INVENTION

The present inventors surprisingly found that compounds which have ahigh selective affinity towards the 5-HT2A receptor and which, at thesame time have a high selective affinity towards the dopamine-4 (D4)receptor show an improved effect in treating underlying emotiondysregulation of mental disorders.

The compounds according to the invention may be chemical or biologicalin nature, or may be chemically synthesised. Preferably, the compoundsof the invention are provided as a pharmaceutically acceptable salt.

One example of such a compound which has both a selective affinity forthe 5-HT2A receptor with a pKi value equal to or higher than 8 towardsthe 5-HT2A receptor and less than 8 towards other 5HT receptors, and aselective affinity for the D4 receptor with a pKi value equal to orhigher than 8 towards the D4 receptor and less than 8 towards otherdopamine receptors is pipamperon. Pipamperon is the conventional namegiven for the compound of the formula1′-[3-(p-Fluorobenzoyl)propyl]-[1,4′-bipiperidine]-4′-carboxamide.Pipamperon is also the active ingredient of for instance thecommercially available Dipiperon (Janssen, Cilag B.V).

Further, the present inventors surprisingly found that the dosage ofactive ingredient for pipamperon in treatment (in monotherapy as well asin combination therapy as described in more detail further) could bevery low compared to conventionally used dosages. Preferred dosageswhich, according to the invention, have been shown to be effective fortreating these mental disorders, range between 5 and 15 mg per day orbetween 5 and 10 mg per day. More preferably, dosages of 5, 6, 7, 8, 9,10, 11, 12, 13, 14 or 15 mg per day are used in treatment of thediseases of the invention. In conventional pipamperon treatment, theactive ingredient is available in tablets of 40 mg per tablet or insolutions of 2 mg per drop. Conventional usage of high doses rangingfrom 40 to 360 mg is prescribed. For instance, for children up to theage of 14, doses corresponding with 2 to 6 mg per kg body weight areconventionally prescribed. The high selective affinity of pipamperontowards the 5-HT2A receptor and the D4 receptor is reflected in the lowdosage which is needed for the treatment of the mental diseases listedbelow and also contributes to the efficacy of the treatment.

The mental disorders which can be treated using pipamperon in a monotherapy at such low doses are for instance anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders, factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, cognitive disorders, impulsecontrol disorders, pervasive development, attention-deficit anddisruptive behaviour disorders, substance-related disorders, personalitydisorders, psychological factors affecting medical conditions,malingering, antisocial behaviour, bereavement, occupational, identity,phase of life, academic problem, problems related to abuse or neglect.

Mental disorders such as depression are commonly treated with serotoninre-uptake inhibitors. Unfortunately, however, these compounds can giverise to side effects in use. Moreover, a substantial problem in mosttreatment of mental disorders is the non-response to selective serotoninre-uptake inhibitors (SSRIs). Also the onset of the therapeutic effectcan be delayed undesirable.

A problem to be solved by the present invention is thus the provision ofa more efficient therapy and efficient, highly selective and efficaciousmedicaments for treating mental disorders.

The inventors found that, for instance, the non-response to selectiveserotonin re-uptake inhibitors (SSRIs) in depression may be declared by(partial) inhibition of the 5-HT1A stimulation via 5-HT2A stimulation.Des-inhibition thereof via 5-HT2A antagonism seems to be an answer tothis problem.

The present inventors found that a simultaneous or foregoing treatmentwith a compound having a high selective 5-HT2A antagonist, inverseagonist or partial agonist activity, could lead to a greater responsetowards, for instance, SSRIs. However, not all compounds exhibiting5-HT2A antagonism are useful: competition between 5-HT2A stimulation viaserotonin and 5-HT2A antagonism via the compound could be responsiblefor the lack of more efficacy of compounds which have both a selectiveserotonin re-uptake inhibitory and 5-HT2A antagonist profile, such astrazodone and nefazodone.

The present inventors further surprisingly found that a simultaneous orforegoing treatment with a compound having a high selective D4antagonist, inverse agonist or partial agonist activity in combinationwith a compound having a high selective 5-HT2A antagonist, inverseagonist or partial agonist activity could lead to a greater responsetowards, for instance, SSRIs, or any of the compounds listed in Table 6or below. In addition, the inventors found that a combination treatmentprovides less residual symptoms and more remission relative to a monotherapy with these compounds.

As such, in a combination treatment, the doses of the compounds listedin Table 6 for treating patients with mental disorders may be decreasedto about 10-90% of the conventional dose, preferably to about 20-80%, or30-70%, or 40-60% or to about 50% of the conventional dose. Even if theadministered dose of the compound is decreased in the combinationtherapy, the therapeutical effect may be sustained or amelioratedrelative to the conventional dose. The danger of side effects of atreatment with such compounds can be decreased or minimized in thecombination therapy of the invention. In this regard, the termconventional dose refers to the dose used heretofor for a particularcompound in treating patients with a mental disorder, for instance,according to the supplier's or physician's description or as listed inTable 6.

In this invention, the term “antagonist” refers to an interactionbetween chemicals in which one partially or completely inhibits theeffect of the other, in particular agents having high affinity for agiven receptor, but which do not activate this receptor.

In this invention, the term “inverse agonist” refers to a ligand whichproduces an effect opposite to that of the agonist by occupying the samereceptor.

In this invention, the term “agonist” relates to an agent which bothbinds to a receptor and has an intrinsic effect.

In this invention, the term “partial agonist” relates to an agent withlower intrinsic activity than a full agonist, and which produces a lowermaximum effect.

The present inventors found that a compound which binds to the 5-HT2Areceptor with a pKi of at least 8 but for which the binding affinity,i.e. pKi, towards other 5HT receptors is less than 8 in combination witha high selective affinity for the D4 receptor, i.e. which bind to the D4receptor with a pKi of at least 8 but for which the binding affinity,i.e. pKi, towards other dopamine receptors is less than 8 also show suchan improved effect in treatment. These effects, i.e. D4 antagonism,inverse agonism or partial agonism and 5-HT2A antagonism, inverseagonism or partial agonism, may reside in the same compound.

The term “other 5HT receptors” as used herein relate to for instance5-HT1 receptors (e.g. 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), 5-HT2B,5-HT2C, 5-HT6 (rat) and 5-HT7 (rat).

By the expression “selective affinity for the 5-HT2A receptor” is meantthat the receptor has a higher affinity for the 5-HT2A receptor than forother 5-HT receptors.

The expression “selective affinity for the D4 receptor” means that thereceptor has a higher affinity for the dopamine D4 receptor than forother dopamine receptors.

The term “other dopamine receptors” are, for instance, D1, D2 and D3dopamine receptors.

pKi values of test compounds for dopamine receptors as well as 5-HT2Areceptors can be measured using commonly known assays.

Compounds which have a selective affinity for the D4 receptor preferablyhave a pKi value equal to or higher than 8 towards the D4 receptor andless than 8 towards other dopamine receptors.

Preferably, the compounds of the invention which have a selectiveaffinity for the 5-HT2A receptor (or the D4 receptor), are compoundswhich have a pKi value equal to or higher than 8 towards the 5-HT2Areceptor and the D4 receptor, and less than 8 towards other 5-HTreceptors or dopamine receptors, respectively, as can be measured, forinstance by methods known in the art. For instance, the “NIMHPsychoactive Drug Screening Program (PDSP)” K_(i) database(http://kidb.cwru.edu/nimh/5htp.php), is a unique resource in the publicdomain which provides information on the abilities of drugs to interactwith an expanding number of molecular targets. The PDSP K_(i) databaseserves as a data warehouse for published and internally-derived pKi, oraffinity, values for a large number of drugs and drug candidates at anexpanding number of G-protein coupled receptors, ion channels,transporters and enzymes. The PDSP internet site also provides forcommonly used protocols and assays for measuring pKi values of 5-HT anddopamine receptors.

A preferred example of a compound which has both a selective affinityfor the 5-HT2A receptor with a pKi value equal to or higher than 8towards the 5-HT2A receptor and less than 8 towards other 5-HTreceptors, and a selective affinity for the D4 receptor with a pKi valueequal to or higher than 8 towards the D4 receptor and less than 8towards other Dopamine receptors and which is therefore useful in acombination therapy is pipamperon.

Table 1 illustrates the selective affinity of for instance pipamperonfor the 5-HT2A and for the D4 receptor. In addition, Table 1 alsoillustrates the low or absence of affinity of pipamperon for otherreceptors such as the adrenergic receptors Alpha 1A, Alpha 2A, Alpha 2B,Alpha 2C, Beta 1, Beta 2, and the histamine receptor H1. As such,treating patients with pipamperon will provide for less side effectswhich otherwise result from simultaneous stimulation of other receptors.Therefore, and according to preferred embodiments, useful compoundsaccording to the invention not only have a selective 5-HT2A and/or D4affinity but also a low affinity for other receptors such as theadrenergic and histamine receptors.

The low dosage which can be used in pipamperon treatment, as alreadydescribed earlier, contributes to the high selective affinity of thecompound towards the 5-HT2A receptor and the D4 receptor and thereforealso to the efficacy of the treatment.

The mental diseases or disorders characterized by an underlying emotiondysregulation can be grouped into subclasses as follows: (i) thenon-cognitive mental disorders comprising mood disorders, anxietydisorders, psychotic disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, attention-deficit disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problems, identityproblem, phase of life problem, academic problem and problems related toabuse or neglect; (ii) cognitive diseases comprising delirium, AlzheimerDisease, substance-related persisting dementia, vascular dementia,dementia due to HIV disease, dementia due to head trauma, dementia dueto Parkinson Disease, dementia due to Huntington Disease, dementia dueto Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnesticdisorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder, othercognitive disorders; (iii) the pain disorders; and (iv) ParkinsonDisease. In Table 5, this classification has been used for summarizingthe diseases and disorders relative to known psychotropics. In Table 6,an overview of pharmacological grouping is provided, indicating thepharmalogical profile numbering, the pharmalogical profile, the maindisease or disorder indication(s), the name of the compound, the doserange, and the company producing or selling said compound.

These diseases and their diagnosis are very clearly defined in the“Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)”published by the American Psychiatric Association. This manual setsforth diagnostic criteria, descriptions and other information to guidethe classification and diagnosis of mental disorders and is commonlyused in the field of neuropsychiatry. It is for instance available onthe internet under:

http://www.behavenet.com/capsules/disorders/dsm4tr.htm.

The expression “non-cognitive diseases or disorders” used in some of theembodiments of the invention comprises the following group of diseasesor disorders: mood disorders, anxiety disorders, psychotic disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, pervasive development disorders,attention-deficit disorders, disruptive behaviour disorders,substance-related disorders, personality disorders, psychologicalfactors affecting medical conditions, malingering, antisocial behaviour,bereavement, occupational problems, identity problem, phase of lifeproblem, academic problem and problems related to abuse or neglect.

In other embodiments of the invention, the mental diseases or disordersthat are characterized by an underlying emotion dysregulation belong tothe group of pain disorders. For instance, the combination therapy withpipamperon is especially advantageous for management of acute pain indiseases such as, but not limited to, musculoskeletal diseases,rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. For theclassification of pain disorders, reference is also made to the DSM-IVwhere these disorders are clearly described in the section of somatoformdisorders by way of internationally accepted diagnostic criteria.

In other embodiments of the invention, the 5-HT2A receptor and/orDopamine-4 receptor antagonist, inverse agonist or partial agonist (e.g.pipamperon) is used in treatment of patients having neuro-degenerativediseases or disorders, or related cognitive diseases or disorders. Thediseases or disorders of the present invention are characterized by anunderlying degeneration of the Central Nervous System (CNS), preferablyselected from the group consisting of, but not limited to,neurodegenerative diseases such as Parkinson Disease, and in otherembodiments of the invention, selected from the group of (related)cognitive diseases or disorders such as Alzheimer Disease.

For instance, Parkinson Disease, which is a chronic progressive nervousdisease chiefly of later life, is linked to decreased dopamineproduction in the substantia nigra and is marked by tremor and weaknessof resting muscles and by a shuffling gait. Dopamine agonists and evenlevodopa, widely used in Parkinson Disease, gives via a dopamine D4receptor stimulation psychiatric manifestations. The induced release ofserotonin acts via 5-HT2A stimulation as a “brake” on dopamine release(Young B. K., Camicioli R., Ganzini L., Neuropsychiatric adverse effectsof antiparkinsonian drugs. Characteristics, evaluation and treatment.Drugs Aging. 1997 May; 10(5): 367-83). Because of the need of specificD4 and 5-HT2A antagonism in the treatment of Parkinson Disease withdopamine agonists and even levodopa, it seems reasonable to combine witha compound with a high selective D4 and 5-HT2A antagonism i.e. havingmerely no activity towards the other receptors especially the D2receptor because of the primary need of the relieve of the excessiveburden of remaining dopaminergic neurons. Therefore, the use of theso-called atypical anti-psychotics or serotonin-dopamine antagonists(SDAs) is absolutely contra-indicated since their high affinity for theD2 receptor. Even the use of serotonin releasing compounds such as SSRIsin the absence of an effective 5-HT2A antagonism are contra-productivetowards the Parkinson Disease symptoms although many Parkinson patientsare in need for an antidepressant since major depression is a verycommon and disabling condition in this kind of patients.

The expression “(related) cognitive diseases or disorders” according tothe invention comprises, the following group of diseases or disorders:delirium (F05), dementia (such as Alzheimer Disease (F00), vasculardementia (F01), dementia due to other general medical conditions (HIVdisease (F02.4), head trauma (F06.8), Parkinson Disease (F02.3),Huntington Disease (F02.2), Pick Disease (F02.0), Creutzfeldt-JacobDisease (F02.1) and other (F02.8)), substance-induced persistingdementia (F1x.6)), amnestic disorders due to a general medical condition(F06.8) or a substance-induced persisting amnestic disorder (F1x.6),mild cognitive impairment disorder (F06.7) and other cognitive disorders(F04). The above list of diseases is provided by way of example and isnot intended to limit the invention.

For instance, Alzheimer Disease is a degenerative brain disease ofunknown cause that is the most common form of dementia. AlzheimerDisease usually starts in late middle age or in old age as a memory lossfor recent events spreading to memories for more distant events andprogresses over the course of five to ten years to a profoundintellectual decline characterized by dementia and personalhelplessness. The disease is marked histologically by the degenerationof brain neurons especially in the cerebral cortex and by the presenceof neurofibrillary tangles and plaques containing beta-amyloid. Becausedopamine receptor D4 (DRD4) antagonism can inhibit the behavioraldisturbances—merely aggression and confusion—caused by the degenerationof dopamine D2 receptors (Esiri, M. M., The basis for behaviouraldisturbances in dementia, J. Neurol. Neurosurg. Psychiatry, 1996;61(2):127-130.2) accompanied with Alzheimer disease and 5-HT2Aantagonism has an important boosting effect towards the effect ofcholinesterase inhibitors such as used in the treatment by facilitatingthe affected dopamine release in the mesocortical dopamine pathways, ahigh selective D4/5-HT2A-antagonist would be a more preferable compoundto combine with a cholinesterase inhibitor since this avoids thecounteracting effect of the in the art used SDAs on the cognitivefunctioning by its dopamine receptor D2-antagonism.

These diseases and their diagnoses are very clearly defined in the“International Statistical Classification of Diseases and Related HealthProblems, 1989 Revision, Geneva, World Health Organization, 1992(ICD-10). This manual sets forth diagnostic criteria, descriptions andother information to guide the classification and diagnosis ofneurodegenerative disorders and is commonly used in the field ofneurology. According to the ICD-10 classification, the cognitivedisorders are classified under several classes of disorders, i.e.dispersed under categories F00 to F19 (see above: respectiveclassification between parentheses). Following the DSM classification,however, they are grouped in one class of diseases or disorders.

The terms “treatment”, “treating”, and the like, as used herein includeamelioration or elimination of a developed mental disease or conditiononce it has been established or alleviation of the characteristicsymptoms of such disease or condition. As used herein these terms alsoencompass, depending on the condition of the patient, preventing theonset of a disease or condition or of symptoms associated with a diseaseor condition, including reducing the severity of a disease or conditionor symptoms associated therewith prior to affliction with said diseaseor condition. Such prevention or reduction prior to affliction refers toadministration of the compound or composition of the invention to apatient that is not at the time of administration afflicted with thedisease or condition. “Preventing” also encompasses preventing therecurrence or relapse-prevention of a disease or condition or ofsymptoms associated therewith, for instance after a period ofimprovement. It should be clear that mental conditions may beresponsible for physical complaints. In this respect, the term“treating” also includes prevention of a physical disease or conditionor amelioration or elimination of the developed physical disease orcondition once it has been established or alleviation of thecharacteristic symptoms of such conditions.

As used herein, the term “medicament” also encompasses the terms “drug”,“therapeutic”, “potion” or other terms which are used in the field ofmedicine to indicate a preparation with therapeutic or prophylacticeffect.

The present inventors not only found that the selective 5-HT2A and D4antagonists, inverse agonists or partial agonists have an effect inaugmenting the therapeutic effect or in providing a faster onset of thetherapeutic effect of a diversity of other pharmaceutical compounds,i.e. also named “second compounds” in the present invention, in thetreatment of specific diseases or disorders. A few examples of otherpharmaceutical compounds whose effects are augmented or where the onsetof the effect is fastened upon simultaneous or fore-going treatment witha selective 5-HT2A and D4 antagonist, preferably pipamperon in a lowdose, are nor-epinephrine re-uptake inhibitors, neuroleptic agents,dopamine antagonists, or compounds used for treating or alleviatingmusculoskeletal diseases or disorders. A further list of otherpharmaceutical compounds or second compounds useful according to theinvention is provided in Table 5. It should be clear, given the generalapplicable character of the invention, that this list of otherpharmaceutical compounds is very brief and that the invention should notbe restricted to the ones exemplified herein. It should be clear that inthe present invention, pipamperon is never to be seen as a “secondcompound”.

According to the invention, it thus has been found that the compoundshaving a selective 5-HT2A and D4 antagonist, inverse agonist or partialagonist activity as described above are useful for augmenting thetherapeutic effect of a second compound on a disease.

According to another embodiment of the invention, it has also been foundthat the compounds having a selective 5-HT2A and D4 antagonist, inverseagonist or partial agonist activity as described above are useful forproviding a faster onset of the therapeutic effect of a second compoundon a disease.

From the above it should be clear that the selective 5-HT2A and D4antagonist, inverse agonist or partial agonist is also named ‘the firstcompound’ in the embodiments of the invention.

According to the invention, when the 5-HT2A and D4 antagonist, inverseagonist or partial agonist activity reside in separate compounds, theterm “composition” may be used. Compositions of the invention comprise afirst element having (i) a selective affinity for the D4 receptor with apKi value equal to or higher than 8 towards the D4 receptor and lessthan 8 towards other dopamine receptors, and a second element having(ii) a selective affinity for the 5-HT2A receptor with a pKi value equalto or higher than 8 towards the 5-HT2A receptor and less than 8 towardsother 5-HT receptors.

The expression “the 5-HT2A and D4 antagonist, inverse agonist or partialagonist” is used herein to indicate a single compound having bothactivities or to indicate the composition comprising the activities inseparate elements.

It should be clear that when, in the present invention, a composition ofseparate elements is used instead of a single compound, this compositionof separate elements may be used in combination with another, i.e. asecond, compound to augment the therapeutic effect of the other, i.e.the second, compound on the same or another disease.

When the 5-HT2A and D4 antagonist, inverse agonist or partial agonist orthe composition comprising both elements and the second compound areadministered simultaneously, the compounds or active ingredients may bepresent in a single pharmaceutical composition or formulation.Alternatively the compounds or active ingredients are administered inseparate pharmaceutical compositions or formulations for simultaneous orseparate use. The invention thus also relates to pharmaceuticalcompositions comprising pipamperon and a second compound of theinvention and to the uses of these pharmaceutical compositions.

When the 5-HT2A and D4 antagonist, inverse agonist or partial agonist orthe composition comprising both elements of the invention areadministered prior to the second compound as defined, the 5-HT2A and D4antagonist, inverse agonist or partial agonist or the compositioncomprising both elements is administered at least during 1 day prior tosaid second compound. Preferably, the 5-HT2A and D4 antagonist, inverseagonist or partial agonist (e.g. pipamperon) or the compositioncomprising both elements is administered for at least 1, 2, 3, 4, 5, 6,7, 8, 9 or 10 days prior to the administration of the second compound.Preferably, the 5-HT2A and D4 antagonist, inverse agonist or partialagonist (e.g. pipamperon) or the composition comprising both elements isadministered for at least 2, 3, 4 or 5 weeks prior to the administrationof the second compound, or even for at least 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11 or 12 months prior to the administration of the second compound.

According to a preferred embodiment of the invention, the abovedescribed compounds or the composition comprising both elements having a5-HT2A and D4 antagonist, inverse agonist or partial agonist activityare useful for augmenting the therapeutic effect of citalopram or forproviding a faster onset of the therapeutic effect of citalopram.

Citalopram or citalopram hydrobromide is a selective serotonin(5-hydroxytryptamine/5-HT) re-uptake inhibitor (SSRI) and is theconventional name given for the compound of the formula(RS)-1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrilehydro-bromide.

According to an embodiment, a daily dose of active ingredient of SSRI,preferably citalopram, ranges between 10 and 40 mg per day. Preferably,daily doses of active ingredient ranging between 20 and 30 mg per dayare administered. More preferably, a daily dose of 10, 15, 20, 25, 30,35 or 40 mg per day is administered.

According to another preferred embodiment of the invention, the abovedescribed compounds or the composition comprising both elements having a5-HT2A and D4 antagonist, inverse agonist or partial agonist activityare useful for augmenting the therapeutic effect of fluvoxamine or forproviding a faster onset of the therapeutic effect of fluvoxamine.

Fluvoxamine or fluvoxamine maleate (luvox, fevarin) is a selectiveserotonin (5-HT) reuptake inhibitor (SSRI) belonging to a new chemicalseries, the 2-aminoethyl oxime ethers of aralkylketones. It ischemically unrelated to other SSRIs and clomipramine. It is chemicallydesignated as 5-methoxy-4′-(trifluoromethyl)valerophenone(E)-O-(2-aminoethyl)oxime maleate (1:1).

According to an embodiment, a daily dose of active ingredient offluvoxamine maleate ranges between 100 and 300 mg per day. Preferably,daily doses of active ingredient ranging between 150 and 200 mg per dayare administered. More preferably, a daily dose of 100, 150, 200, 250 or300 mg per day is administered.

According to a preferred embodiment of the invention, the abovedescribed compounds or the composition comprising both elements having a5-HT2A and D4 antagonist, inverse agonist or partial agonist activityare useful for augmenting the therapeutic effect of selegiline or forproviding a faster onset of the therapeutic effect of selegiline.

Selegiline or L-deprenyl or phenylisopropyl methyl propynyl amine is amonoamine oxidase B inhibitor (MAO-B inhibitor) and is the conventionalname given for the compound of the formula(R)-(−)-N,α-dimethyl-N-(2-propynyl)phenethylamine—HCl.

According to an embodiment, a daily dose of active ingredient of MAO-Binhibitor, preferably selegiline, ranges between 5 and 60 mg per day.Preferably, daily doses of active ingredient ranging between 20 and 40mg per day are administered. More preferably, a daily dose of 10, 15,20, 25, 30, 35 or 40 mg per day is administered.

Most of the second compounds herein described are known in the art andmay be used in doses according to the supplier's or physician'sprescription, or may be used according to specific embodiments describedherein.

Also encompassed by the invention are pro-drugs to these secondcompounds or active metabolites of these compounds. For instance, forrisperidone it is known that, among other products, bio transformationin the liver produces 9-hydroxyrisperidone, which is of the samepharmacological activity and intensity as parent risperidone. Therefore,also 9-hydroxyrisperidone, naturally produced or chemically synthesizedmay be used in the methods and uses according to the invention.

The term “active metabolite” as used herein relates to a therapeuticallyactive compound produced by the metabolism of a parent drug. Drugsadministered to treat diseases are usually transformed (metabolized)within the body into a variety of related chemical forms (metabolites),some of which may have therapeutic activity (an active metabolite).

The present invention also encompasses the use of these secondcompounds, administered in the form of a pharmaceutically acceptablesalt in admixture with a suitable pharmaceutically acceptable excipient.

To prepare the pharmaceutical compositions, comprising the compounds orthe combination of the first and second compound described herein, aneffective amount of the active ingredients, in acid or base additionsalt form or base form, is combined in admixture with a pharmaceuticallyacceptable carrier, which can take a wide variety of forms depending onthe form of preparation desired for administration. These pharmaceuticalcompositions are desirably in unitary dosage form suitable, foradministration orally, nasal, rectally, percutaneously, transdermally,by parenteral, intramuscular, intravascular injection or intrathecaladministration. For example, in preparing the compositions in oraldosage form, any of the usual pharmaceutical media may be employed, suchas, for example, water, glycols, oils, alcohols and the like in the caseof oral liquid preparations such as suspensions, syrups, elixirs andsolutions; or solid carriers such as starches, sugars, kaolin,lubricants, binders, disintegrating agents and the like in the case ofpowders, pills, capsules and tablets. Because of their ease inadministration, tablets and capsules represent the most advantageousoral dosage unit form, in which case solid pharmaceutical carriers areobviously employed. For parenteral compositions, the carrier willusually comprise sterile water, at least in large part, though otheringredients, for example, to aid solubility, may be included.

The pharmaceutical compounds for treatment are intended for parenteral,topical, oral or local administration and generally comprise apharmaceutically acceptable carrier and an amount of the activeingredient sufficient to reverse or prevent the bad effects of mentaldisorders. The carrier may be any of those conventionally used and islimited only by chemico-physical considerations, such as solubility andlack of reactivity with the compound, and by the route ofadministration.

Examples of pharmaceutically acceptable acid addition salts for use inthe present inventive pharmaceutical composition include those derivedfrom mineral acids, such as hydrochloric, hydrobromic, phosphoric,metaphosphoric, nitric and sulfuric acids, and organic acids, such astartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic,gluconic, succinic, p-toluenesulphonic acids, and arylsulphonic, forexample.

The pharmaceutically acceptable excipients described herein, forexample, vehicles, adjuvants, carriers or diluents, are well-known tothose who are skilled in the art and are readily available to thepublic. It is preferred that the pharmaceutically acceptable carrier beone that is chemically inert to the active compounds and one that has nodetrimental side effects or toxicity under the conditions of use.

The following formulations for oral, aerosol, parenteral, subcutaneous,intravenous, intramuscular, interperitoneal, rectal, and vaginaladministration are merely exemplary and are in no way limiting. Overall,the requirements for effective pharmaceutical carriers for parenteralcompositions are well known to those of ordinary skill in the art. SeePharmaceutics and Pharmacy Practice, J.B. Lippincott Company,Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250, (1982), andASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630(1986). Topical formulations, including those that are useful fortransdermal drug release, are well-known to those of skill in the artand are suitable in the context of the present invention for applicationto skin.

Formulations suitable for oral administration require extraconsiderations considering the nature of the compounds and the possiblebreakdown thereof if such compounds are administered orally withoutprotecting them from the digestive secretions of the gastrointestinaltract. Such a formulation can consist of (a) liquid solutions, such asan effective amount of the compound dissolved in diluents, such aswater, saline, or orange juice; (b) capsules, sachets, tablets,lozenges, and troches, each containing a predetermined amount of theactive ingredient, as solids or granules; (c) powders; (d) suspensionsin an appropriate liquid; and (e) suitable emulsions. Liquidformulations may include diluents, such as water and alcohols, forexample, ethanol, benzyl alcohol, and the polyethylene alcohols, eitherwith or without the addition of a pharmaceutically acceptablesurfactant, suspending agent, or emulsifying agent. Capsule forms can beof the ordinary hard- or soft-shelled gelatin type containing, forexample, surfactants, lubricants, and inert fillers, such as lactose,sucrose, calcium phosphate, and corn starch. Tablet forms can includeone or more of lactose, sucrose, mannitol, corn starch, potato starch,alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum,colloidal silicon dioxide, croscarmellose sodium, talc, magnesiumstearate, calcium stearate, zinc stearate, stearic acid, and otherexcipients, colorants, diluents, buffering agents, disintegratingagents, moistening agents, preservatives, flavoring agents, andpharmacologically compatible excipients. Lozenge forms can comprise theactive ingredient in a flavor, usually sucrose and acacia or tragacanth,as well as pastilles comprising the active ingredient in an inert base,such as gelatin and glycerin, or sucrose and acacia, emulsions, gels,and the like containing, in addition to the active ingredient, suchexcipients as are known in the art.

The compounds of the present invention, alone or in combination withother suitable components, can be made into aerosol formulations to beadministered via inhalation. For aerosol administration, the compoundsare preferably supplied in finely divided form along with a surfactantand propellant. Typical percentages of compounds are 0.01%-20% byweight, preferably 1%-10%. The surfactant must, of course, be nontoxic,and preferably soluble in the propellant. Representative of such agentsare the esters or partial esters of fatty acids containing from 6 to 22carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic,linoleic, linolenic, olesteric and oleic acids with an aliphaticpolyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixedor natural glycerides may be employed. The surfactant may constitute0.1%-20% by weight of the compounds, preferably 0.25-5%. The balance ofthe compounds is ordinarily propellant. A carrier can also be includedas desired, e.g., lecithin for intranasal delivery. These aerosolformulations can be placed into acceptable pressurized propellants, suchas dichlorodifluoromethane, propane, nitrogen, and the like. They alsomay be formulated as pharmaceuticals for non-pressured preparations,such as in a nebulizer or an atomizer. Such spray formulations may beused to spray mucosa.

It will be understood that, apart from daily doses, the compounds can beadministered by other schedules. For instance, the present inventionalso contemplates depot injection, in which a long acting form of theactive compound is injected into the body, such as the muscles. Fromthere the active compound slowly enters the rest of the body, so oneinjection can last from 1 to 4 weeks or even multiple months. Other formof dosage administrations relate to “once-a-week” pills, in which theingredient is slowly released over a period of a week, and slow-releasepatches, e.g. a CDS (Continuous Delivery System), or Once-a-DayTransdermal Patches.

According to a further embodiment, the invention also relates to amethod for preparing a compound or composition having a selective D4 and5-HT2A antagonist, reverse agonist or partial agonist. The inventionalso relates to the compounds prepared by the claimed method, with theproviso that said compound is not an already known compound, such aspipamperon.

It should be clear that the compounds and compositions described hereinare useful for treating any patient in need thereof. As used herein theterm “patient” is not restricted to humans but also to other mammals,for instance, domestic animals which may also suffer from any form of amental disease or disorder described herein.

The second compounds of the invention can be further grouped accordingto their pharmacological profile, which is summarized in Table 6.

The present invention is now described in more detail by the followingembodiments. The compounds belonging to different pharmacologicalprofiles can be further grouped according to their action on the samepathway or system as follows.

1: Combination Therapy with a 5-HT (Serotonin) Reuptake Enhancer

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT (serotonin) reuptakeenhancer, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,substance related disorder, personality disorders, antisocial behaviour,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases or disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorder, personalitydisorders, antisocial behaviour, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of a5-HT (serotonin) reuptake enhancer compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of said5-HT (serotonin) reuptake enhancer compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a 5-HT (serotonin) reuptakeenhancer compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said 5-HT (serotonin) reuptakeenhancer compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said 5-HT (serotonin) reuptake enhancercompound is tianeptine or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof. Preferably, tianeptine is tobe administered in a daily dose ranging between 25 and 50 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT (serotonin) reuptake enhancer, preferablytianeptine or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance relateddisorder, personality disorder, antisocial behaviour, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

A pharmaceutical composition as described above wherein pipamperon isprovided in a unitary dose of between 5 and 15 mg of the activeingredient and wherein said 5-HT (serotonin) reuptake enhancer istianeptine, preferably provided in a unitary dose of between 25 and 50mg of the active ingredient.

2: Combination Therapy with a 5-HT1 Autoreceptor Agonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT1 autoreceptor agonist,are chosen from the group of diseases or disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders, substancerelated disorder, personality disorders, antisocial behaviour,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases or disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorder, personalitydisorders, antisocial behaviour, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of a5-HT1 autoreceptor agonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said 5-HT1autoreceptor agonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a 5-HT1 autoreceptor agonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said 5-HT1 autoreceptor agonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said 5-HT1 autoreceptor agonist compound issunepitron or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT1 autoreceptor agonist, preferablysunepitron or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance relateddisorder, personality disorder, antisocial behaviour, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

3: Combination Therapy with a 5-HT1A (Serotonin 1A Receptor) AgonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT1A (serotonin 1Areceptor) agonist compound, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender disorders, sleep disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorder,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, attention-deficit disorders, substance-relateddisorder, personality disorders, antisocial behaviour, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a 5-HT1A (serotonin 1A receptor) agonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said 5-HT1A (serotonin 1A receptor) agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention further also relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a 5-HT1A (serotonin 1A receptor)agonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said 5-HT1A (serotonin 1Areceptor) agonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said 5-HT1A (serotonin 1A receptor) agonistcompound is chosen from the group consisting of MN-305, zalospirone,xaliproden, VPI-013 (also known as OPC-14523), tandospirone, sarizotan,PRX-00023, metanospirone, lesopitron, gepirone, flesinoxan, EMD 68843,buspirone, bupropion (preferably controlled release formulation) andalnespirone, preferably xaliproden, sarizotan, gepirone, flesinoxan andbupropion (preferably controlled release formulation) or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof. More preferably, said 5-HT1A (serotonin 1A receptor) agonist isxaliproden and is to be administered in a daily dose ranging between 1and 2 mg of the active ingredient. Even more preferably, said 5-HT1A(serotonin 1A receptor) agonist is bupropion (controlled releaseformulation) and is to be administered in a daily dose ranging between150 and 450 mg of the active ingredient. Even more preferably, said5-HT1A (serotonin 1A receptor) agonist is gepirone and is to beadministered in a daily dose, ranging between 20 and 80 mg of the activeingredient per day.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT1A (serotonin 1A receptor) agonist,preferably chosen from the group consisting of MN-305, zalospirone,xaliproden, VPI-013 (also known as OPC-14523), tandospirone, sarizotan,PRX-00023, metanospirone, lesopitron, gepirone, flesinoxan, EMD 68843,buspirone, bupropion (preferably controlled release formulation) andalnespirone, more preferably xaliproden, sarizotan, gepirone, flesinoxanand bupropion (preferably controlled release formulation), or a pro-drugor an active metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender disorders, sleep disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorder,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders.

The present invention also relates to a pharmaceutical composition asdescribed above wherein pipamperon is provided in a unitary dose ofbetween 5 and 15 mg of the active ingredient and wherein said 5-HT1A(serotonin 1A receptor) agonist is xaliproden, preferably provided in aunitary dose of between 1 and 2 mg of the active ingredient.

The present invention also relates to a pharmaceutical composition asdescribed above wherein pipamperon is provided in a unitary dose ofbetween 5 and 15 mg of the active ingredient and wherein said 5-HT1A(serotonin 1A receptor) agonist is bupropion (controlled releaseformulation), preferably provided in a unitary dose of between 150 and450 mg of the active ingredient.

The present invention also relates to a pharmaceutical composition asdescribed above wherein pipamperon is provided in a unitary dose ofbetween 5 and 15 mg of the active ingredient and wherein said 5-HT1A(serotonin 1A receptor) agonist is gepirone, preferably provided in aunitary dose of between 20 and 80 mg of the active ingredient.

4: Combination Therapy with a 5-HT1A (Serotonin 1A Receptor) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT1A (serotonin 1Areceptor) antagonist compound, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender disorders, adjustment disorders, impulse control disorders,substance-related disorder, personality disorders, antisocial behaviour,bereavement, occupational problem and problems related to abuse orneglect.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender disorders, adjustment disorders, impulse control disorders,substance-related disorder, personality disorders, antisocial behaviour,bereavement, occupational problem and problems related to abuse orneglect, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a 5-HT1A antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said 5-HT1A antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said 5-HT1A antagonist compound is chosenfrom the group consisting of robalzotan tartrate hydrate and NAD299 or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT1A antagonist, preferably chosen from thegroup consisting of robalzotan tartrate hydrate and NAD299, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder which ischosen from the group of diseases or disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender disorders, adjustmentdisorders, impulse control disorders, substance-related disorder,personality disorders, antisocial behaviour, bereavement, occupationalproblem and problems related to abuse or neglect.

5: Combination Therapy with a 5-HT1B (Serotonin 1B Receptor) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT1B (serotonin 1Breceptor) antagonist compound, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender disorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorder, personality disorders, antisocialbehaviour, bereavement, occupational problem and problems related toabuse or neglect.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, substance-related disorder, personality disorders,antisocial behaviour, bereavement, occupational problem and problemsrelated to abuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a 5-HT1Bantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said 5-HT1B antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said 5-HT1B antagonist compound is chosen fromthe group consisting of elzasonan, AZD1134 and AR-A2, preferablyelzasonan, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT1B antagonist, preferably chosen from thegroup consisting of elzasonan, AZD1134 and AR-A2, preferably elzasonan,or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder which ischosen from the group of diseases or disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorder, personality disorders, antisocial behaviour, bereavement,occupational problem and problems related to abuse or neglect.

6: Combination Therapy with a 5-HT2B (Serotonin 2B Receptor) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT2B (serotonin 2Breceptor) antagonist compound, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender disorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorder, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, substance-related disorder, personality disorders,antisocial behaviour, bereavement, occupational problem, problemsrelated to abuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a 5-HT2Bantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said 5-HT2B antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a 5-HT2B antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said 5-HT2B antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said 5-HT2B antagonist compound isaglomelatine or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, aglomelatine is tobe administered in a daily dose ranging between 25 and 50 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT2B antagonist, preferably aglomelatine ora pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup of diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender disorders, sleep disorders, adjustmentdisorders, impulse control disorders, substance-related disorder,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders.

A pharmaceutical composition as described above wherein pipamperon isprovided in a unitary dose of between 5 and 15 mg of the activeingredient and wherein said 5-HT2B antagonist is aglomelatine,preferably provided in a unitary dose of between 25 and 50 mg of theactive ingredient.

7: Combination Therapy with a 5-HT2C (Serotonin 2C Receptor) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT2C (serotonin 2Creceptor) antagonist compound, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender disorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorder, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, substance-related disorder, personality disorders,antisocial behaviour, bereavement, occupational problem, problemsrelated to abuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a 5-HT2Cantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said 5-HT2C antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a 5-HT2C antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said 5-HT2C antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said 5-HT2C antagonist compound is chosenfrom the group consisting of SB 243213 and aglomelatine or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof. Preferably, aglomelatine is to be administered in a daily doseranging between 25 and 50 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT2C antagonist, preferably chosen from thegroup consisting of SB 243213 and aglomelatine or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender disorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorder, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention also relates to a pharmaceutical composition asdescribed above wherein pipamperon is provided in a unitary dose ofbetween 5 and 15 mg of the active ingredient and wherein said 5-HT2Cantagonist is aglomelatine, preferably provided in a unitary dose ofbetween 25 and 50 mg of the active ingredient.

8: Combination Therapy with a 5-HT3 (Serotonin 3 Receptor) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT3 (serotonin 3 receptor)antagonist compound, are substance-related disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofsubstance-related disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a 5-HT3 antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said 5-HT3 antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said 5-HT3 antagonist compound is ondansetronor a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. Preferably, ondansetron is to be administeredin a daily dose ranging between 8 and 32 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT3 antagonist, preferably ondansetron or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of substance-related disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said 5-HT3 antagonist isondansetron, preferably provided in a unitary dose of between 8 and 32mg of the active ingredient.

9: Combination Therapy with a 5-HT6 (Serotonin 6 Receptor) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a 5-HT6 (serotonin 6 receptor)antagonist compound, are chosen from the group of diseases or disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive disorder selected from the group of diseases and disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a 5-HT6 antagonist compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of said5-HT6 antagonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said 5-HT6 antagonist compound is chosen fromthe group consisting of SB-271046, 742457 and 271046 or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a 5-HT6 antagonist, preferably chosen from thegroup consisting of SB-271046, 742457 and 271046 or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of Alzheimer Disease, substance-induced persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

10: Combination Therapy with an Acetylcholinesterase Inhibitor Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an acetylcholinesteraseinhibitor compound, are chosen from the group of diseases or disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive disorder selected from the group of diseases and disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder, other cognitive disorders, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of an acetylcholinesterase inhibitor compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said acetylcholinesterase inhibitor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said acetylcholinesterase inhibitor compound ischosen from the group consisting of tacrine, rivastigmine tartrate,rivastigmine, physostigmine, phenserine tartrate, metrifonate, huperzineA, galantamine (preferably extended release formulation), donezepil,dichlorvos and anseculin hydrochloride, preferably tartrate, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. Preferably, rivastigmine tartrate is to beadministered in a daily dose ranging between 3 and 12 mg of the activeingredient. Preferably, phenserine tartrate is to be administered in adaily dose ranging between 20 and 30 mg of the active ingredient.Preferably, galantamine (extended release formulation) is to beadministered in a daily dose ranging between 8 and 24 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an acetylcholinesterase inhibitor, preferablychosen from the group consisting of tacrine, rivastigmine tartrate,rivastigmine, physostigmine, phenserine tartrate, metrifonate, huperzineA, galantamine (preferably extended release formulation), donezepil,dichlorvos and anseculin hydrochloride, preferably tartrate, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup of diseases or disorders consisting of Alzheimer Disease,substance-related persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said acetylcholinesteraseinhibitor is rivastigmine tartrate, preferably provided in a unitarydose of between 3 and 12 mg of the active ingredient.

The invention further relates to a pharmaceutical composition asdescribed above wherein pipamperon is provided in a unitary dose ofbetween 5 and 15 mg of the active ingredient and wherein saidacetylcholinesterase inhibitor is phenserine tartrate, preferablyprovided in a unitary dose of between 20 and 30 mg of the activeingredient.

In addition, the invention relates to a pharmaceutical composition asdescribed above wherein pipamperon is provided in a unitary dose ofbetween 5 and 15 mg of the active ingredient and wherein saidacetylcholinesterase inhibitor is galantamine (preferably extendedrelease formulation), preferably provided in a unitary dose of between 8and 24 mg of the active ingredient.

11: Combination Therapy with an Adenosine A2a Receptor AntagonistCompound

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an adenosine A2a receptorantagonist compound, is Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of an adenosine A2areceptor antagonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said adenosine A2areceptor antagonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said adenosine A2a receptor antagonist compoundis KW-6002 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, KW-6002 is to beadministered in a daily dose ranging between 40 and 80 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an adenosine A2a receptor antagonist, preferablyKW-6002 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of Parkinson disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said acetylcholinesteraseinhibitor is KW-6002, preferably provided in a unitary dose of between40 and 80 mg of the active ingredient.

12: Combination Therapy with an Adrenergic Transmitter Releaser

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an adrenergic transmitterreleaser, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,adjustment disorders, impulse control disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of anadrenergic transmitter releaser compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidadrenergic transmitter releaser compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of an adrenergic transmitterreleaser compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said adrenergic transmitterreleaser compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said adrenergic transmitter releasercompound is pipoxazole or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof. Preferably, pipoxazole is tobe administered in a daily dose ranging between 30 and 60 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an adrenergic transmitter releaser, preferablypipoxazole, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said adrenergic transmitterreleaser is pipoxazole, preferably provided in a unitary dose of between30 and 60 mg of the active ingredient.

13: Combination Therapy with an Alpha 1 Adrenoreceptor Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an alpha 1 adrenoreceptorantagonist, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect, pain disorders and Parkinsondisease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a alpha 1 adrenoreceptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said alpha 1 adrenoreceptor antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of an alpha 1 adrenoreceptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said alpha 1 adrenoreceptorantagonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of an alpha 1adrenoreceptor antagonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said alpha 1adrenoreceptor antagonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said alpha 1 adrenoreceptor antagonistcompound is chosen from the group consisting of SDZ NVI 085 andflesinoxan or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an alpha 1 adrenoreceptor antagonist, preferablychosen from the group consisting of SDZ NVI 085 and flesinoxan or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup of diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglect,pain disorders and Parkinson disease.

14: Combination Therapy with an Alpha 2 Adrenoreceptor Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an alpha 2 adrenoreceptorantagonist, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, psychotic disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance relateddisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of aalpha 2 adrenoreceptor antagonist compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidalpha 2 adrenoreceptor antagonist compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of an alpha 2 adrenoreceptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said alpha 2 adrenoreceptorantagonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said alpha 2 adrenoreceptor antagonistcompound is chosen from the group consisting of UK-14304, sunepitron,mirtazapine, idazoxan, fluparoxan, A75200 and (R)-A 75200, preferablysunepitron or idazoxan, or a pro-drug or an active metabolite thereof,or a pharmaceutically acceptable salt thereof. Preferably, idazoxan isto be administered in a daily dose ranging between 5 and 40 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an alpha 2 adrenoreceptor antagonist, preferablychosen from the group consisting of UK-14304, sunepitron, mirtazapine,idazoxan, fluparoxan, A75200 and (R)-A 75200, preferably sunepitron oridazoxan, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, psychotic disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,substance related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said alpha 2 adrenoreceptorantagonist is idazoxan, preferably provided in a unitary dose of between5 and 40 mg of the active ingredient.

15: Combination Therapy with an AMPA Receptor Mediator Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an AMPA(alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptormediator compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, psychotic disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders,substance-included disorders, personality disorders, psychologicalfactors affecting medical conditions, malingering, antisocial behaviour,bereavement, occupational problem, identity problem, problems related toabuse or neglect, pain disorders, delirium, Alzheimer Disease,substance-related persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem and problems related to abuse or neglect, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of an AMPA receptor mediator compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said AMPA receptor mediator compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of an AMPA receptor mediatorcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said AMPA receptor mediator compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of delirium, Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of an AMPA receptormediator compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said AMPA receptor mediatorcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said AMPA receptor mediator compound ischosen from the group consisting of ampakine ORG 24448/CX-619, ampakineCX-717, ampakine CX-691 and ampakine CX-516, preferably ampakine ORG24448/CX-619, ampakine CX-717 or ampakine CX-691, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an AMPA receptor mediator, preferably chosenfrom the group consisting of ampakine ORG 24448/CX-619, ampakine CX-717,ampakine CX-691 and ampakine CX-516, preferably ampakine ORG24448/CX-619, ampakine CX-717 or ampakine CX-691, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, psychoticdisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders, delirium,Alzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders.

16: Combination Therapy with an Amphetamine Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an amphetamine compound, areattention-deficit disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofattention deficit disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of an amphetaminecompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said amphetamine compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said amphetamine compound is methylphenidate(preferably administered by a transdermal system) or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an amphetamine, preferably methylphenidate(preferably administered by a transdermal system) or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation ofattention deficit disorders.

17: Combination Therapy with an Amyloid Aggregation-Inhibitor Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an amyloidaggregation-inhibitor compound, are chosen from the group of diseases ordisorders consisting of Alzheimer Disease, substance-related persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-relatedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of an amyloid aggregation-inhibitor compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said amyloid aggregation-inhibitor compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said amyloid aggregation-inhibitor compound ischosen from the group consisting of APAN and Alzhemed, or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof. Preferably, Alzhemed is to be administered in a daily dose ofbetween 200 and 300 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an amyloid aggregation-inhibitor, preferablychosen from the group consisting of APAN and Alzhemed, or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of Alzheimer Disease, substance-related persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said amyloidaggregation-inhibitor is Alzhemed, preferably provided in a unitary doseof between 200 and 300 mg of the active ingredient.

18: Combination Therapy with an Androgen Receptor Modulator Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an androgen receptor modulatorcompound, are sexual and gender identity disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of sexualand gender identity disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of an androgenreceptor modulator compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said androgenreceptor modulator compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said androgen receptor modulator compound isLGD2226 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an androgen receptor modulator, preferablyLGD2226 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of sexual and gender identity disorders.

19: Combination Therapy with an Beta 3 Adrenoreceptor Agonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an beta 3 adrenoreceptoragonist, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,substance related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a beta 3adrenoreceptor agonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said beta 3adrenoreceptor agonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of an beta 3 adrenoreceptor agonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said beta 3 adrenoreceptor agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said beta 3 adrenoreceptor agonist compoundis SR 58611 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a beta 3 adrenoreceptor agonist, preferably SR58611 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

20: Combination Therapy with a Calcium Channel Modulator Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a calcium channel modulatorcompound, are chosen from the group of diseases or disorders consistingof Alzheimer Disease, substance-related persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder, othercognitive disorders and Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-relatedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a calcium channel modulator compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said calcium channel modulator compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a calcium channelmodulator compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said calcium channel modulatorcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said calcium channel modulator compound ischosen from the group consisting of safinamide and MEM 1003, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a calcium channel modulator, preferably chosenfrom the group consisting of safinamide and MEM 1003, or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of Alzheimer Disease, substance-related persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder, other cognitive disorders and Parkinsondisease.

21: Combination Therapy with a Cannabioid Receptor 1 (CBI) Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a cannabioid receptor 1 (CBI)antagonist, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, psychotic disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders anddelirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting mood disorders, anxiety disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a cannabioid receptor 1 antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said cannabioid receptor antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a cannabioid receptor 1antagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said cannabioid receptor 1antagonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofdelirium, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a cannabioid receptor 1antagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said cannabioid receptor 1antagonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said cannabioid receptor antagonist compoundis SR 141716 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a cannabioid receptor antagonist, preferably SR141716 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, psychotic disorders, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders, substance-relateddisorders, personality disorders, psychological factors affectingmedical conditions, malingering, antisocial behaviour, bereavement,occupational problem, identity problem, problems related to abuse orneglect, pain disorders and delirium.

22: Combination Therapy with a Cathepsin K Inhibitor Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a cathepsin K inhibitorcompound, are pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a cathepsin K inhibitor compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said cathepsin K inhibitor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said cathepsin K inhibitor compound is 462795or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a cathepsin K inhibitor, preferably 462795 or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of pain disorders.

23: Combination Therapy with a Choline Uptake Enhancer Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a choline uptake enhancercompound, are chosen from the group of diseases or disorders consistingof Alzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a choline uptake enhancer compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said choline uptake enhancer compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said choline uptake enhancer compound isMKC-231 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, MKC-231 is to beadministered in a daily dose of between 20 and 160 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a choline uptake enhancer, preferably MKC-231 ora pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup of diseases or disorders consisting of Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said choline uptake enhanceris MKC-231, preferably provided in a unitary dose of between 20 and 160mg of the active ingredient.

24: Combination Therapy with a COX-2 Inhibitor Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a COX-2 inhibitor compound,are pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a COX-2 inhibitor compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said COX-2 inhibitor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said COX-2 inhibitor compound is chosen fromthe group consisting of valdecoxib, rofecoxib, parecoxib, etoricoxib,COX 189, celecoxib and ABT-963, preferably parecoxib, etoricoxib or COX189, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, parecoxib is to beadministered in a daily dose of between 20 and 80 mg of the activeingredient. Preferably, etoricoxib is to be administered in a daily doseof between 20 and 120 mg of the active ingredient. Preferably, COX 189is to be administered in a daily dose of between 100 and 800 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a COX-2 inhibitor, preferably chosen from thegroup consisting of valdecoxib, rofecoxib, parecoxib, etoricoxib, COX189, celecoxib and ABT-963, preferably parecoxib, etoricoxib or COX 189,or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said COX-2 inhibitor isparecoxib, preferably provided in a unitary dose of between 20 and 80 mgof the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said COX-2 inhibitor isetoricoxib, preferably provided in a unitary dose of between 20 and 120mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said COX-2 inhibitor is COX189, preferably provided in a unitary dose of between 100 and 800 mg ofthe active ingredient.

25: Combination Therapy with a COX-Inhibiting Nitric Oxide Donator(CINOD) Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a COX-inhibiting nitric oxidedonator (CINOD) compound, are pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a COX-inhibiting nitric oxidedonator (CINOD) compound to augment the therapeutic effect or to providea faster onset of the therapeutic effect of said COX-inhibiting nitricoxide donator (CINOD) compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said COX-inhibiting nitric oxide donator(CINOD) compound is chosen from the group consisting of AZD4717 andAZD3582 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, AZD3582 is to beadministered in a daily dose ranging between 93.75 and 750 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a COX-inhibiting nitric oxide donator (CINOD),preferably chosen from the group consisting of AZD4717 and AZD3582 or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said COX-inhibiting nitricoxide donator (CINOD) is AZD3582, preferably provided in a unitary doseof between 93.75 and 750 mg of the active ingredient.

26: Combination Therapy with a CRF1 (Corticoid-Releasing FactorReceptor 1) Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a CRF1(Corticotropin-Releasing Factor receptor 1) antagonist, are chosen fromthe group of diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a CRF1 antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said CRF1 antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a CRF1 antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said CRF1 antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said CRF1 antagonist compound is chosen fromthe group consisting of R121919, NBI-34041, elzasonan, CP-448,187,CP-154-526, AAG 561 and 723620, preferably R121919, elzasonan or AAG561, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, R121919 is to beadministered in a daily dose of between 5 and 80 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a CRF1 antagonist, preferably chosen from thegroup consisting of R121919, NBI-34041, elzasonan, CP-448,187,CP-154-526, AAG 561 and 723620, preferably R121919, elzasonan or AAG561, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said CRF1 antagonist isR121919, preferably provided in a unitary dose of between 5 and 80 mg ofthe active ingredient.

27: Combination Therapy with a D1 (Dopamine 1) Receptor Agonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a D1 (dopamine 1) receptoragonist, are chosen from the group of diseases or disorders consistingof substance related disorders and Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofsubstance related disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a D1 receptoragonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said D1 receptor agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a D1 receptoragonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said D1 receptor agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said D1 receptor agonist compound is DAS-431or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a D1 receptor agonist, preferably DAS-431 or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup of diseases or disorders consisting of substance related disordersand Parkinson disease.

28: Combination Therapy with D2 (Dopamine 2) Receptor Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with D2 (dopamine 2) receptorantagonist, are chosen from the group of diseases or disordersconsisting of mood disorders, psychotic disorders, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders anddelirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting mood disorders, psychotic disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem and problems related to abuse or neglect, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a D2 receptor antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said D2 receptor antagonist compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a D2 receptor antagonist compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said D2 receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofdelirium, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a D2 receptor antagonist compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said D2 receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said D2 receptor antagonist compound ischosen from the group consisting of bifeprunox and amisulpride,preferably bifeprunox, or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a D2 receptor antagonist, preferably chosen fromthe group consisting of bifeprunox and amisulpride, preferablybifeprunox, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem, problems related to abuse or neglect, paindisorders and delirium.

29: Combination Therapy with D3 (Dopamine 3) Receptor Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with D3 (dopamine 3) receptorantagonist, are chosen from the group of diseases or disordersconsisting of psychotic disorders, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders, substance-relateddisorders, personality disorders, psychological factors affectingmedical conditions, malingering, antisocial behaviour, bereavement,occupational problem, identity problem, problems related to abuse orneglect, pain disorders, delirium and Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of psychotic disorders, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a D3 receptor antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said D3 receptor antagonist compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a D3 receptor antagonist compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said D3 receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofdelirium, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a D3 receptor antagonist compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said D3 receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a D3 receptoragonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said D3 receptor agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said D3 receptor antagonist compound ischosen from the group consisting of BSF-201640 and PD 58491, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a D3 receptor antagonist, preferably chosen fromthe group consisting of BSF-201640 and PD 58491, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of psychotic disorders, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders, deliriumand Parkinson disease.

30: Combination Therapy with a DA (Dopamine) Uptake Inhibitor

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a DA (dopamine) uptakeinhibitor, are chosen from the group of diseases or disorders consistingof substance related disorders and Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofsubstance related disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a DA uptakeinhibitor compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said DA uptake inhibitorcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a DA uptakeinhibitor compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said DA uptake inhibitorcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said DA uptake inhibitor compound is chosenfrom the group consisting of safinamide and GBR 12909, or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a D2 receptor antagonist, preferably chosen fromthe group consisting of safinamide and GBR 12909, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of substance related disorders and Parkinsondisease.

31: Combination Therapy with an Dopamine (Receptor) Agonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an dopamine (receptor)agonist, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorders,personality disorders, problems related to abuse or neglect, paindisorders and Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders,adjustment disorders, impulse control disorders, attention-deficitdisorders, substance-related disorders, personality disorders andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of adopamine (receptor) agonist compound to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said dopamine(receptor) agonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a dopamine (receptor) agonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said dopamine (receptor) agonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a dopamine(receptor) agonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said dopamine(receptor) agonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said dopamine (receptor) agonist compound ischosen from the group consisting of sumanirole, SLV 308, sarizotan,S32504, rotigotine (preferably a Once-a-Day Transdermal Patch),ropinirole HCL (preferably controlled-release formulation), pramipexole,DAB452, cabergoline, bromocriptine, alaptide, cabergoline, lisuride,preferably sumanirole, rotigotine (preferably a Once-a-Day TransdermalPatch), pergolide or ropinirole HCL (preferably controlled-releaseformulation), or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, sumanirole is tobe administered in a daily dose of between 4 and 16 mg of the activeingredient. Preferably, rotigotine (Once-a-Day Transdermal Patch) is tobe administered in a daily dose of between 4.5 and 13.5 mg of the activeingredient. Preferably, ropinirole HCL (controlled-release formulation)is to be administered in a daily dose of between 0.75 and 24 mg of theactive ingredient. Preferably, pergolide is to be administered in adaily dose of between 0.5 and 10 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a dopamine (receptor) agonist, preferably chosenfrom the group consisting of sumanirole, SLV 308, sarizotan, S32504,rotigotine (preferably a Once-a-Day Transdermal Patch), ropinirole HCL(preferably controlled-release formulation), pramipexole, DAB452,cabergoline, bromocriptine, alaptide, cabergoline, lisuride andpergolide, more preferably sumanirole, rotigotine (preferably aOnce-a-Day Transdermal Patch), ropinirole HCL (preferablycontrolled-release formulation) or pergolide, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, adjustment disorders,impulse control disorders, attention-deficit disorders,substance-related disorders, personality disorders, problems related toabuse or neglect, pain disorders and Parkinson disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said dopamine (receptor)agonist is sumanirole, preferably provided in a unitary dose of between4 and 16 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said dopamine (receptor)agonist is rotigotine (Once-a-Day Transdermal Patch), preferablyprovided in a unitary dose of between 4.5 and 13.5 mg of the activeingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said dopamine (receptor)agonist is ropinirole HCL (controlled-release formulation), preferablyprovided in a unitary dose of between 0.75 and 24 mg of the activeingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said dopamine (receptor)agonist is pergolide, preferably provided in a unitary dose of between0.5 and 10 mg of the active ingredient.

32: Combination Therapy with a Compound Activating ERK (ExtracellularSignal-Related Kinase)

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound that activates ERK(extracellular signal-related kinase), are chosen from the group ofdiseases or disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound that activates ERK (extracellularsignal-related kinase) to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said compound that activatesERK (extracellular signal-related kinase), further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said compound that activates ERK (extracellularsignal-related kinase) is CPI-1189 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof. Preferably,CPI-1189 is to be administered in a daily dose of between 50 and 100 mgof the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound that activates ERK (extracellularsignal-related kinase), preferably CPI-1189 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group of diseases or disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said compound that activatesERK (extracellular signal-related kinase) is CPI-1189, preferablyprovided in a unitary dose of between 50 and 100 mg of the activeingredient.

33: Combination Therapy with a GABA (Gamma-Aminobutyric Acid) AgonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a GABA (gamma-aminobutyricacid) agonist compound, are chosen from the group of diseases ordisorders consisting of Alzheimer Disease, substance-induced persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a GABA agonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said GABA agonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said GABA agonist compound is nefiracetam or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a GABA agonist, preferably nefiracetam or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup of diseases or disorders consisting of Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

34: Combination Therapy with a GABA-A Agonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a GABA-A (gamma-aminobutyricacid receptor A) agonist compound, are sleep disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of sleepdisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a GABA-A agonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said GABA-A agonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said GABA-A agonist compound is gaboxadol or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. Preferably, gaboxadol is to be administered ina daily dose of between 5 and 20 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an GABA-A agonist, preferably gaboxadol or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of sleep disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GABA-A agonist isGaboxadol, preferably provided in a unitary dose of between 5 and 20 mgof the active ingredient.

35: Combination Therapy with a GABA-A Modulator Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a GABA-A (gamma-aminobutyricacid receptor A) modulator compound, are chosen from the group ofdiseases or disorders consisting of anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a GABA-A modulator compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said GABA-A modulator compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said GABA-A modulator compound is chosen fromthe group consisting of zolpidem (preferably MR sustained-releaseversion), zaleplon (preferably extended-release formulation), SL65.1498, SEP174559, pagoclone, NGD 96-3, indiplon, eszopiclone,CP-730,330 (NGD 96-3) and ocinaplon, preferably zolpidem (preferably MRsustained-release version), zaleplon (preferably extended-releaseformulation), pagoclone, indiplon or eszopiclone, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof. Preferably, zolpidem MR sustained-release version is to beadministered in a daily dose of between 10 and 20 mg of the activeingredient. Preferably, zaleplon extended-release is to be administeredin a daily dose ranging between 2.5 and 20 mg of the active ingredient.Preferably, pagoclone is to be administered in a daily dose rangingbetween 7.5 and 60 mg of the active ingredient. Preferably, indiplon isto be administered in a daily dose of between 10 and 20 mg of the activeingredient. Preferably, eszopiclone is to be administered in a dailydose of between 2 and 3 mg of the active ingredient. Preferably,ocinaplon is to be administered in a daily dose of between 10 and 60 mgof the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a GABA-A modulator, preferably chosen from thegroup consisting of zolpidem (preferably MR sustained-release version),zaleplon (preferably extended-release formulation), SL 65.1498,SEP174559, pagoclone, indiplon, eszopiclone, CP-730,330 (NGD 96-3) andocinaplon, preferably zolpidem (preferably MR sustained-releaseversion), zaleplon (preferably extended-release formulation), pagoclone,NGD 96-3, indiplon or eszopiclone, or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a mental disease or disorderwhich is chosen from the group of diseases or disorders consisting ofanxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, personality disorders,bereavement, occupational problem and problems related to abuse orneglect.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GABA-A modulator iszolpidem MR sustained-release version, preferably provided in a unitarydose of between 10 and 20 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GABA-A modulator iszaleplon extended-release, preferably provided in a unitary dose ofbetween 2.5 and 20 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GABA-A modulator isPagoclone, preferably provided in a unitary dose of between 7.5 and 60mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GABA-A modulator isindiplon, preferably provided in a unitary dose of between 10 and 20 mgof the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GABA-A modulator iseszopiclone, preferably provided in a unitary dose of between 2 and 3 mgof the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GABA-A modulator isocinaplon, preferably provided in a unitary dose of between 10 and 60 mgof the active ingredient.

36: Combination Therapy with a GABA-B Antagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a GABA-B (gamma-aminobutyricacid receptor B) antagonist compound, are chosen from the group ofdiseases or disorders consisting of anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a GABA-B antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said GABA-B antagonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said GABA-B antagonist compound is AVE 7398 ora pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a GABA-B antagonist, preferably AVE 7398 or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup of diseases or disorders consisting of anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect.

37: Combination Therapy with a Glial-Cell Line Derived NeurotrophicFactor Compound

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a Glial-cell Line DerivedNeurotrophic Factor compound, is Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a Glial-cell LineDerived Neurotrophic Factor compound to augment the therapeutic effector to provide a faster onset of the therapeutic effect of saidGlial-cell Line, Derived Neurotrophic Factor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said Glial-cell Line Derived NeurotrophicFactor compound is GDNF or a pro-drug or an active metabolite thereof,or a pharmaceutically acceptable salt thereof. Preferably, GDNF is to beadministered in a daily dose ranging between 3.75 and 30 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a Glial-cell Line Derived Neurotrophic Factor,preferably GDNF or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of Parkinson disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said Glial-cell Line DerivedNeurotrophic Factor is GDNF, preferably provided in a unitary dose ofbetween 3.75 and 30 mg of the active ingredient.

38: Combination Therapy with a Glucocorticoid Synthesis InhibitorCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a glucocorticoid synthesisinhibitor compound, are chosen from the group of diseases or disordersconsisting of substance related disorders and Parkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofsubstance related disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a glucocorticoidsynthesis inhibitor compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said glucocorticoidsynthesis inhibitor compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a glucocorticoidsynthesis inhibitor compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said glucocorticoidsynthesis inhibitor compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said glucocorticoid synthesis inhibitorcompound is metyrapone or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a glucocorticoid synthesis inhibitor, preferablymetyrapone or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of substance relateddisorders and Parkinson disease.

39: Combination Therapy with a Glutamate Receptor Antagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a glutamate receptorantagonist compound, are chosen from the group of diseases or disordersconsisting of anxiety disorders, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, adjustmentdisorders, impulse control disorders, substance-related disorders,personality disorders, bereavement, occupational problem, problemsrelated to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem, and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a glutamate receptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said glutamate receptor antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a glutamate receptor antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said glutamate receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said glutamate receptor antagonist compoundis LY354740 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a glutamate receptor antagonist, preferablyLY354740 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of anxiety disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

40: Combination Therapy with an GPCR (G-Protein-Coupled Receptor)Modulator

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an GPCR (G-protein-coupledreceptor) modulator, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a GPCR modulatorcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said GPCR modulator compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a GPCR modulator compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said GPCR modulator compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said GPCR modulator compound is R1204 or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a GPCR modulator, preferably R1204 or a pro-drugor an active metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

41: Combination Therapy with an GR (Glucocorticoid Receptor) Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an GR (glucocorticoidreceptor) antagonist, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a GR antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said GR antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a GR antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said GR antagonist compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said GR antagonist compound is chosen from thegroup consisting of ORG 34517/34850 and mifepristone, preferablymifepristone, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, mifepristone is tobe administered in a daily dose of between 600 and 1200 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a GR antagonist, preferably chosen from thegroup consisting of ORG 34517/34850 and mifepristone, preferablymifepristone, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders; substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said GR antagonist isMifepristone, preferably provided in a unitary dose of between 600 and1200 mg of the active ingredient.

42: Combination Therapy with a Histamine H3-Receptor Antagonist

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a histamine H3-receptorantagonist, are chosen from the group of diseases or disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a histamine H3-receptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said histamine H3-receptor antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said histamine H3-receptor antagonistcompound is chosen from the group of compounds consisting of ABT-834 andABT-239, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a histamine H3-receptor antagonist, preferablychosen from the group consisting of ABT-834 and ABT-239 or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is chosen from the groupconsisting of Alzheimer Disease, substance-related persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

43: Combination Therapy with a Hormonal Substance

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a hormonal substance, arechosen from the group of diseases or disorders consisting ofpremenstrual syndrome and sexual and gender identity disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of premenstrual syndrome and sexual and genderidentity disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a hormonalsubstance to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said hormonal substance, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said hormonal substance is chosen from thegroup consisting of a testosterone transdermal spray, a testosteronegel, a female testosterone patch, synthetic conjugated estrogen A,methyltestosterone, a estrogens/methyltestosterone and adrosiperone/ethinyl estradiol composition, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof. Morepreferably, said hormonal substance is synthetic conjugated estrogen Aand is to be administered in a daily dose ranging between 0.075 and 0.6mg of the active ingredient. More preferably, said hormonal substance isa drosiperone/ethinyl estradiol composition and is to be administered asa daily dose in tablets, preferably comprising 3 mg drosiperone and 0.02mg ethinyl estradiol of the active ingredients, respectively.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and

(b) a hormonal substance, preferably chosen from the group consisting ofa testosterone transdermal spray, a testosterone gel, a femaletestosterone patch, synthetic conjugated estrogen A, methyltestosterone,a estrogens/methyltestosterone and a drosiperone/ethinyl estradiolcomposition, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a cognitive mental disease or disorder which ischosen from the group consisting of premenstrual syndrome and sexual andgender identity disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said hormonal substance issynthetic conjugated estrogen A, preferably provided in a unitary doseof between 0.075 and 0.6 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said hormonal substance is adrosiperone/ethinyl estradiol composition, preferably provided intablets comprising a unitary dose of 3 mg drosiperone and 0.02 mgethinyl estradiol of the active ingredients, respectively.

44: Combination Therapy with a Compound which Increases BrainConcentrations of 5-HT

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which increasesbrain concentrations of 5-HT (serotonin), are chosen from the group ofdiseases or disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of a noncognitive mental disease or disorder selected from the group of diseasesand disorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compound whichincreases brain concentrations of 5-HT (serotonin) to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said compound which increases brain concentrations of 5-HT(serotonin), further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of pain,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound which increases brain concentrationsof 5-HT (serotonin) to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said compound which increasesbrain concentrations of 5-HT (serotonin), further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said compound which increases brainconcentrations of 5-HT (serotonin) is chosen from the group consistingof triptosine, SP 186, PMD 145 and KW 6055, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which increases brain concentrationsof 5-HT (serotonin), preferably chosen from the group consisting oftriptosine, SP 186, PMD 145 and KW 6055, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group of diseases and disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

45: Combination Therapy with a Compound which Increases InsulinSensitivity

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which increasesinsulin sensitivity, are chosen from the group of diseases or disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound which increases insulin sensitivityto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said compound which increases insulin sensitivity,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said compound which increases insulinsensitivity is rosiglitazone maleate, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which increases insulin sensitivity,preferably rosiglitazone maleate or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a cognitive mental disease ordisorder which is chosen from the group consisting of Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

46: Combination Therapy with a Compound Inhibiting the Mixed LineageKinase Family

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which is aninhibitor of the mixed lineage kinase family is Parkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compound whichis an inhibitor of the mixed lineage kinase family to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said compound which is an inhibitor of the mixed lineagekinase family, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said compound which is an inhibitor of themixed lineage kinase family is CEP-1347 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which is an inhibitor of the mixedlineage kinase family, preferably CEP-1347 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of Parkinson Disease.

47: Combination Therapy with an Interleukin-1 Beta Converting EnzymeInhibitor Compound

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an interleukin-1 betaconverting enzyme inhibitor compound, is a pain disorder.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of a paindisorder, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of an interleukin-1 beta convertingenzyme inhibitor compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said interleukin-1beta converting enzyme inhibitor compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said interleukin-1 beta converting enzymeinhibitor is pralnacasan or a pro-drug or an active metabolite thereof,or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an interleukin-1 beta converting enzymeinhibitor, preferably pralnacasan or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a pain disorder.

48: Combination Therapy with a Levodopa/Decarboxylase Inhibitor Compound

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a levodopa/decarboxylaseinhibitor compound, is Parkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of alevodopa/decarboxylase inhibitor compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidlevodopa/decarboxylase inhibitor compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said levodopa/decarboxylase inhibitor compoundis chosen from the group consisting of levodopa/carbidopa,levodopa/benserazide, etilevodopa/carbidopa or etilevodopa/benserazide,or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. Preferably, levodopa/carbidopa is to beadministered in a daily dose between 250 to 600 mg/25 to 150 mg of theactive ingredients. Preferably, levodopa/benserazide is to beadministered in a daily dose between 100 to 600 mg/25 to 150 mg of theactive ingredients.

According to a further preferred embodiment, the invention relates tothe use as described above, wherein said levodopa/decarboxylaseinhibitor compound is (eti)levodopa/carbidopa, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable salt thereofin combination with entacapone, which is an inhibitor ofcatechol-O-methyltransferase (COMT), or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof.Preferably, said levodopa/decarboxylase inhibitor compound islevodopa/carbidopa and is to be administered in a dose ranging between2000 mg/50 mg and 100 mg/10 mg of the active ingredients. Preferablysaid entacapone is to be administered in a dose ranging between 1000mg/50 mg, more preferably between 500 mg/100 mg, and most preferably 200mg of the active ingredients per day.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a levodopa/decarboxylase inhibitor compound,preferably levodopa/carbidopa, levodopa/benserazide,etilevodopa/carbidopa or etilevodopa/benserazide, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation ofParkinson Disease. The invention also relates to a pharmaceuticalcomposition comprising (a) pipamperon, and (b) a levodopa/decarboxylaseinhibitor compound, preferably is (eti)levodopa/carbidopa, or a pro-drugor an active metabolite thereof, or a pharmaceutically acceptable saltthereof in combination with entacapone, which is an inhibitor ofcatechol-O-methyltransferase (COMT), or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of Parkinson Disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said levodopa/decarboxylaseinhibitor compound is levodopa/carbidopa, preferably provided in aunitary dose of between 250 to 600 mg and 25 to 150 mg of the activeingredients.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said levodopa/decarboxylaseinhibitor compound is levodopa/benserazide, preferably provided in aunitary dose of between 100 to 600 mg and 25 to 150 mg of the activeingredients.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said levodopa/decarboxylaseinhibitor compound is levodopa/carbidopa or etilevodopa/carbidopa incombination with entacapone, of which the latter is preferably providedin a unitary dose of between 500 mg and 100 mg of the active ingredient.

49: Combination Therapy with a Lipid-DNA Complex

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a lipid-DNA complex, isParkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of lipid-DNA complexto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said lipid-DNA complex, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said lipid-DNA complex is GR213487B or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a lipid-DNA complex, preferably GR213487B or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of Parkinson Disease.

50: Combination Therapy with a Monoamine Oxidase (MAO) ReuptakeInhibitor

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a monoamine oxidase (MAO)reuptake inhibitor, are chosen from the group of diseases or disordersconsisting of substance related disorders and attention-deficitdisorders (ADHD).

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofnon-cognitive mental disease or disorder which are substance relateddisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a monoamine oxidase (MAO)reuptake inhibitor compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said monoamineoxidase (MAO) reuptake inhibitor compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofattention-deficit disorders (ADHD), characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of amonoamine oxidase (MAO) reuptake inhibitor compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said monoamine oxidase (MAO) reuptake inhibitor compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said monoamine oxidase (MAO) reuptakeinhibitor compound is NS 2359 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a monoamine oxidase (MAO) reuptake inhibitor,preferably NS 2359 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group consisting of substance related disorders andattention-deficit disorders (ADHD).

51: Combination Therapy with a MAO-A and a MAO-B Reuptake Inhibitor

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a monoamine oxidase A (MAO-A)and a monoamine oxidase B (MAO-B) reuptake inhibitor, wherein saiddisorders are attention-deficit disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofattention-deficit disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a monoamineoxidase A (MAO-A) and a monoamine oxidase B (MAO-B) reuptake inhibitorcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said monoamine oxidase A (MAO-A) and amonoamine oxidase B (MAO-B) reuptake inhibitor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said monoamine oxidase A (MAO-A) and amonoamine oxidase B (MAO-B) reuptake inhibitor compound is SPD473 or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a monoamine oxidase A (MAO-A) and a monoamineoxidase B (MAO-B) reuptake inhibitor, preferably SPD473 or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of attention-deficit disorders.

52: Combination Therapy with a Monoamine Oxidase B (MAO-B) Inhibitor

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a monoamine oxidase B (MAO-B)inhibitor, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorders,personality disorders, problems related to abuse or neglect, paindisorder and Parkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders,adjustment disorders, impulse control disorders, attention-deficitdisorders, substance-related disorders, personality disorders, problemsrelated to abuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a monoamineoxidase B (MAO-B) inhibitor compound to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said monoamineoxidase B (MAO-B) inhibitor compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a monoamine oxidase B (MAO-B)inhibitor compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said monoamine oxidase B(MAO-B) inhibitor compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a monoamineoxidase B (MAO-B) inhibitor compound to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said monoamineoxidase B (MAO-B) inhibitor compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said monoamine oxidase B (MAO-B) inhibitorcompound is chosen from the group consisting of selegiline, rasagiline(TVP-1012) and EmSam (transdermal selegiline), or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof. More preferably, said monoamine oxidase B (MAO-B) inhibitor isselegiline and is to be administered in a daily dose ranging between 5and 60 mg or possibly between 5 and 10 mg of the active ingredient. In afurther preferred embodiment, selegiline is to be administered in atransdermal application in a daily dose ranging between 5 and 60 mg ofthe active ingredient. In another preferred embodiment, selegiline is tobe administered orally in a daily dose ranging between 5 and 10 mg ofthe active ingredient. More preferably, said monoamine oxidase B (MAO-B)inhibitor is rasagiline (TVP-1012) and is to be administered in a dailydose ranging between 1 and 2 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a monoamine oxidase B (MAO-B) inhibitor,preferably chosen from the group consisting of selegiline, rasagiline(TVP-1012) and EmSam (transdermal selegiline), or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation of amental disease or disorder which is chosen from the group consisting ofmood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorders,personality disorders, problems related to abuse or neglect, paindisorder and Parkinson Disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said monoamine oxidase B(MAO-B) inhibitor is selegiline, preferably provided in a unitary doseof between 5 and 10 mg or between 5 and 60 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said monoamine oxidase B(MAO-B) inhibitor is rasagiline (TVP-1012), preferably provided in aunitary dose of between 1 and 2 mg of the active ingredient.

53: Combination Therapy with a Monoamine Oxidase B (MAO-B) ReuptakeInhibitor

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a monoamine oxidase B (MAO-B)reuptake inhibitor, is Parkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a monoamineoxidase B (MAO-B) reuptake inhibitor to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said monoamineoxidase B (MAO-B) reuptake inhibitor, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said monoamine oxidase B (MAO-B) reuptakeinhibitor is safinamide or a pro-drug or an active metabolite thereof,or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a monoamine oxidase B (MAO-B) reuptakeinhibitor, preferably safinamide or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of Parkinson Disease.

54: Combination Therapy with a Melanocortin-4 (MC4) Receptor AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a melanocortin-4 (MC4)receptor antagonist compound, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a melanocortin-4(MC4) receptor antagonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of saidmelanocortin-4 (MC4) receptor antagonist compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a melanocortin-4 (MC4) receptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said melanocortin-4 (MC4)receptor antagonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said melanocortin-4 (MC4) receptorantagonist compound is MCL0129, or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a melanocortin-4 (MC4) receptor antagonistcompound, preferably MCL0129 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a mental disease or disorderwhich is chosen from the group consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

55: Combination Therapy with a MCH Receptor Antagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a melanin concentratinghormone (MCH) receptor antagonist compound, are chosen from the group ofdiseases or disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a melaninconcentrating hormone (MCH) receptor antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said melanin concentrating hormone (MCH) receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a melanin concentrating hormone(MCH) receptor antagonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said melaninconcentrating hormone (MCH) receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said melanin concentrating hormone (MCH)receptor antagonist compound is SNAP-7941 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a melanin concentrating hormone (MCH) receptorantagonist compound, preferably SNAP-7941 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

56: Combination Therapy with a Melatonin Receptor (MT) Agonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a melatonin receptor (MT)agonist compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a melatoninreceptor (MT) agonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said melatoninreceptor (MT) agonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a melatonin receptor (MT) agonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said melatonin receptor (MT) agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said melatonin receptor (MT) agonistcompound is chosen from the group consisting of ramelteon andaglomelatine, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, saidmelatonin receptor (MT) agonist compound is aglomelatine and is to beadministered in a daily dose ranging between 25 and 50 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a melatonin receptor (MT) agonist compound,preferably ramelteon or aglomelatine or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said melatonin receptor (MT)agonist compound is aglomelatine, preferably provided in a unitary doseof between 25 and 50 mg of the active ingredient.

57: Combination Therapy with a Metabotropic Glutamate Receptor (MgluR)Agonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a metabotropic glutamatereceptor (MgluR) agonist compound, are chosen from the group of diseasesor disorders consisting of anxiety disorders, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a metabotropic glutamate receptor (MgluR)agonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said metabotropic glutamatereceptor (MgluR) agonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a metabotropic glutamate receptor(MgluR) agonist compound to augment the therapeutic effect or to providea faster onset of the therapeutic effect of said metabotropic glutamatereceptor (MgluR) agonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said metabotropic glutamate receptor (MgluR)agonist compound is PRE703 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a metabotropic glutamate receptor (MgluR)agonist, preferably PRE703 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a mental disease or disorderwhich is chosen from the group consisting of anxiety disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

58: Combination Therapy with a Compound Mimicking the Effect of NerveGrowth Factor (NGF)

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which mimics theeffect of nerve growth factor (NGF), are chosen from the group ofdiseases or disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder, other cognitive disorders and ParkinsonDisease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound which mimics the effect of nervegrowth factor (NGF) to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said compound which mimics theeffect of nerve growth factor (NGF), further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compound whichmimics the effect of nerve growth factor (NGF) to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said compound which mimics the effect of nerve growth factor(NGF), further characterized in that pipamperon is to be administered toa patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said compound which mimics the effect ofnerve growth factor (NGF) is xaliproden or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof. Morepreferably, said compound which mimics the effect of nerve growth factor(NGF) is xaliproden and is to be administered in a daily dose rangingbetween 1 and 2 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which mimics the effect of nervegrowth factor (NGF), preferably xaliproden or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group consisting of Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder, other cognitivedisorders and Parkinson Disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said compound which mimicsthe effect of nerve growth factor (NGF) is xaliproden, preferablyprovided in a unitary dose of between 1 and 2 mg of the activeingredient.

59: Combination Therapy with a Muscarinic Receptor Partial AgonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a muscarinic receptor partialagonist compound, are chosen from the group of diseases or disordersconsisting of Alzheimer Disease, substance-induced persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a muscarinic receptor partial agonist compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said muscarinic receptor partial agonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said muscarinic receptor partial agonistcompound is sevimeline or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a muscarinic receptor partial agonist compound,preferably sevimeline or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof, as a combined preparationfor simultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

60: Combination Therapy with a Selective Nor-Adrenaline Re-UptakeInhibitor (NARI) Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a selective nor-adrenalinere-uptake inhibitor (NARI) compound, are chosen from the group ofdiseases or disorders consisting of mood disorders, anxiety disorders,adjustment disorders, attention-deficit disorders, personalitydisorders, antisocial behaviour, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,adjustment disorders, attention-deficit disorders, personalitydisorders, antisocial behaviour, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of aselective nor-adrenaline re-uptake inhibitor (NARI) compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said selective nor-adrenaline re-uptake inhibitor (NARI)compound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a selective nor-adrenalinere-uptake inhibitor (NARI) compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said selectivenor-adrenaline re-uptake inhibitor (NARI) compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said selective nor-adrenaline re-uptakeinhibitor (NARI) compound is chosen from the group consisting ofreboxetine, atomoxetine hydrochloride, A 75200, 155U88, (S)-A 75200, ora pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. More preferably, said selective nor-adrenalinere-uptake inhibitor (NARI) compound is reboxetine and is to beadministered in a daily dose ranging between 8 and 12 mg of the activeingredient. More preferably, said selective nor-adrenaline re-uptakeinhibitor (NARI) compound is atomoxetine hydrochloride and is to beadministered in a daily dose ranging between 40 and 100 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a selective nor-adrenaline re-uptake inhibitor(NARI) compound, preferably chosen from the group consisting ofreboxetine, atomoxetine hydrochloride, A 75200, 155U88, (S)-A 75200, ora pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of mental disease or disorder which is chosen from thegroup consisting of mood disorders, anxiety disorders, adjustmentdisorders, attention-deficit disorders, personality disorders,antisocial behaviour, bereavement, occupational problem, problemsrelated to abuse or neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective nor-adrenalinere-uptake inhibitor (NARI) compound is reboxetine, preferably providedin a unitary dose of between 8 and 12 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective nor-adrenalinere-uptake inhibitor (NARI) compound is atomoxetine hydrochloride,preferably provided in a unitary dose of between 40 and 100 mg of theactive ingredient.

61: Combination Therapy with a NaSSA Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a noradrenergic/specificserotonergic antidepressant (NaSSA) compound, are chosen from the groupof diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, personality disorders,antisocial behaviour, bereavement, occupational problem, problemsrelated to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, antisocial behaviour,bereavement, occupational problem and problems related to abuse orneglect, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a noradrenergic/specificserotonergic antidepressant (NaSSA) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidnoradrenergic/specific serotonergic antidepressant (NaSSA) compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a noradrenergic/specificserotonergic antidepressant (NaSSA) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidnoradrenergic/specific serotonergic antidepressant (NaSSA) compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said noradrenergic/specific serotonergicantidepressant (NaSSA) compound is ORG 4420 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a noradrenergic/specific serotonergicantidepressant (NaSSA) compound, preferably ORG 4420 or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation ofmental disease or disorder which is chosen from the group consisting ofmood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders.

62: Combination Therapy with a Selective NDRI Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a selective nor-adrenaline anddopamine re-uptake inhibitor (NDRI) compound, are chosen from the groupof diseases or disorders consisting of mood disorders, anxietydisorders, adjustment disorders, attention-deficit disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect, pain disorders, delirium,Alzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,adjustment disorders, attention-deficit disorders, personalitydisorders, antisocial behaviour, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of aselective nor-adrenaline and dopamine re-uptake inhibitor (NDRI)compound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said selective nor-adrenaline and dopaminere-uptake inhibitor (NDRI) compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a selective nor-adrenaline anddopamine re-uptake inhibitor (NDRI) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidselective nor-adrenaline and dopamine re-uptake inhibitor (NDRI)compound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of delirium, Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectivenor-adrenaline and dopamine re-uptake inhibitor (NDRI) compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said selective nor-adrenaline and dopaminere-uptake inhibitor (NDRI) compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said selective nor-adrenaline and dopaminere-uptake inhibitor (NDRI) compound is GW353162 or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof. More preferably, said selective nor-adrenaline and dopaminere-uptake inhibitor (NDRI) compound is GW353162 and is to beadministered in a daily dose ranging between 20 and 60 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a selective nor-adrenaline and dopaminere-uptake inhibitor (NDRI) compound, preferably GW353162 or a pro-drugor an active metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation ofmental disease or disorder which is chosen from the group consisting ofmood disorders, anxiety disorders, adjustment disorders,attention-deficit disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect, pain disorders, delirium, Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective nor-adrenalineand dopamine re-uptake inhibitor (NDRI) compound is GW353162, preferablyprovided in a unitary dose of between 20 and 60 mg of the activeingredient.

63: Combination Therapy with a Compound which is a NeuroimmunophilinLigand

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which is aneuroimmunophilin ligand, is Parkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compound whichis a neuroimmunophilin ligand to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said compound whichis a neuroimmunophilin ligand, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said a compound which is a neuroimmunophilinligand is GPI 1485 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, said acompound which is a neuroimmunophilin ligand is GPI 1485 and is to beadministered in a daily dose ranging between 200 and 1000 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which is a neuroimmunophilin ligand,preferably GPI 1485 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of Parkinson Disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said a compound which is aneuroimmunophilin ligand is GPI 1485, preferably provided in a unitarydose of between 200 and 1000 mg of the active ingredient.

64: Combination Therapy with a Neuromodulator Compound

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a neuromodulator compound, isParkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a neuromodulatorcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said neuromodulator compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said neuromodulator compound is adenosine or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a neuromodulator compound, preferably adenosineor a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of Parkinson Disease.

65: Combination Therapy with a Neurotensin Receptor Antagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a neurotensin receptorantagonist compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, psychotic disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders anddelirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a neurotensin receptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said neurotensin receptor antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a neurotensin receptor antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said neurotensin receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is delirium, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a neurotensin receptor antagonist compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said neurotensin receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said neurotensin receptor antagonist compoundis SR 48692 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, saidneurotensin receptor antagonist compound is SR 48692 and is to beadministered in a daily dose ranging between 90 and 300 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a neurotensin receptor antagonist compound,preferably SR 48692 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group consisting mood disorders, anxiety disorders, psychoticdisorders, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sleep disorders, adjustmentdisorders, impulse control disorders, pervasive development disorders,disruptive behaviour disorders, substance-related disorders, personalitydisorders, psychological factors affecting medical conditions,malingering, antisocial behaviour, bereavement, occupational problem,identity problem, problems related to abuse or neglect, pain disordersand delirium.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said neurotensin receptorantagonist compound is SR 48692, preferably provided in a unitary doseof between 90 and 300 mg of the active ingredient.

66: Combination Therapy with Nerve Growth Factor (NGF) Gene Therapy

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with nerve growth factor (NGF) genetherapy, are chosen from the group of diseases or disorders consistingof Alzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder, othercognitive disorders and Parkinson Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from nervegrowth factor (NGF) gene therapy, to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said nerve growthfactor (NGF) gene therapy, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to nerve growth factor (NGF) gene therapy,to augment the therapeutic effect or to provide a faster onset of nervegrowth factor (NGF) gene therapy, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound useful in nerve growth factor (NGF)gene therapy, preferably xaliproden or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group consisting of Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder, other cognitivedisorders and Parkinson Disease.

It should be understood that “nerve growth factor gene therapy” is wellknown in the art, and the compounds, for instance nucleic acids used innerve growth factor gene therapy are well described (see e.g. Tuszynskiet al., (2002) Journal of Molecular Neuroscience Volume 19, Issue 1-2,pps. 207-208).

67: Combination Therapy with a Nicotinic Acetylcholine ReceptorAntagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a nicotinic acetylcholinereceptor antagonist compound, are chosen from the group of diseases ordisorders consisting of anxiety disorders, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a nicotinic acetylcholine receptor antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said nicotinic acetylcholine receptorantagonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a nicotinic acetylcholinereceptor antagonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said nicotinicacetylcholine receptor antagonist compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said nicotinic acetylcholine receptorantagonist compound is SEP174559 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a nicotinic acetylcholine receptor antagonistcompound, preferably SEP174559 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a mental disease or disorderwhich is chosen from the group consisting of anxiety disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

68: Combination Therapy with a Nicotinic Receptor Agonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a nicotinic receptor agonistcompound, are chosen from the group of diseases or disorders consistingof Alzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a nicotinic receptor agonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said nicotinic receptor agonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said nicotinic receptor agonist compound isABT-089, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, saidnicotinic receptor agonist compound is ABT-089 and is to be administeredin a daily dose ranging between 4 and 40 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a nicotinic receptor agonist compound,preferably ABT-089 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a cognitive mental disease or disorder which ischosen from the group consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove, wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said nicotinic receptoragonist compound is ABT-089, preferably provided in a unitary dose ofbetween 4 and 40 mg of the active ingredient.

69: Combination Therapy with a Neurokinin 2 Receptor (NK2) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a neurokinin 2 receptor (NK2)antagonist compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a neurokinin 2receptor (NK2) antagonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said neurokinin 2receptor (NK2) antagonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a neurokinin 2 receptor (NK2)antagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said neurokinin 2 receptor(NK2) antagonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said neurokinin 2 receptor (NK2) antagonistcompound is saredutant or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof. More preferably, saidneurokinin 2 receptor (NK2) antagonist compound is saredutant and is tobe administered in a daily dose ranging between 25 and 200 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a neurokinin 2 receptor (NK2) antagonistcompound, preferably saredutant or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a mental disease or disorderwhich is chosen from the group consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said neurokinin 2 receptor(NK2) antagonist compound is saredutant, preferably provided in aunitary dose of between 25 and 200 mg of the active ingredient.

70: Combination Therapy with a Neurokinin 3 Receptor (NK3) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a neurokinin 3 receptor (NK3)antagonist compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, psychotic disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders anddelirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a neurokinin 3 receptor (NK3) antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said neurokinin 3 receptor (NK3) antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a neurokinin 3 receptor (NK3)antagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said neurokinin 3 receptor(NK3) antagonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is delirium, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a neurokinin 3 receptor (NK3) antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said neurokinin 3 receptor (NK3) antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said neurokinin 3 receptor (NK3) antagonistcompound is talnetant or osanetant, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof. Morepreferably, said neurokinin 3 receptor (NK3) antagonist compound istalnetant and is to be administered in a daily dose ranging between 1.5and 12 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a neurokinin 3 receptor (NK3) antagonistcompound, preferably talnetant or osanetant, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group consisting mood disorders,anxiety disorders, psychotic disorders, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders, substance-relateddisorders, personality disorders, psychological factors affectingmedical conditions, malingering, antisocial behaviour, bereavement,occupational problem, identity problem, problems related to abuse orneglect, pain disorders and delirium.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said neurokinin 3 receptor(NK3) antagonist compound is talnetant, preferably provided in a unitarydose of between 1.5 and 12 mg of the active ingredient.

71: Combination Therapy with an N-Methyl-D-aspartate (NMDA) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an N-Methyl-D-aspartate (NMDA)antagonist compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, adjustment disorders, impulse control disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect, pain disorders, Alzheimer Disease, substance-relatedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of anN-Methyl-D-aspartate (NMDA) antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said N-Methyl-D-aspartate (NMDA) antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of an N-Methyl-D-aspartate (NMDA)antagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said N-Methyl-D-aspartate(NMDA) antagonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-relatedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of an N-Methyl-D-aspartate (NMDA) antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said N-Methyl-D-aspartate (NMDA) antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said N-Methyl-D-aspartate (NMDA) antagonistcompound is chosen from the group consisting of SEP174559, memantine,delucemine, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, saidN-Methyl-D-aspartate (NMDA) antagonist compound is memantine and is tobe administered in a daily dose ranging between 5 and 40 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an N-Methyl-D-aspartate (NMDA) antagonistcompound, preferably chosen from the group consisting of SEP174559,memantine, delucemine or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof, as a combined preparationfor simultaneous, separate or sequential use for treating the underlyingemotion dysregulation of mental disease or disorder which is chosen fromthe group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect, pain disorders, Alzheimer Disease,substance-related persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said N-Methyl-D-aspartate(NMDA) antagonist compound is memantine, preferably provided in aunitary dose of between 5 and 40 mg of the active ingredient.

72: Combination Therapy with a Non-Steroidal Anti-Inflammatory Drug

The mental disorder which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a non-steroidalanti-inflammatory drug, is a pain disorder or Alzheimer Disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of a paindisorder, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a non-steroidal anti-inflammatorydrug to augment the therapeutic effect or to provide a faster onset ofthe therapeutic effect of said a non-steroidal anti-inflammatory drug,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive disease, such as Alzheimer Disease, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a non-steroidal anti-inflammatory drug to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said a non-steroidal anti-inflammatory drug, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said a non-steroidal anti-inflammatory drugis chosen from the group consisting of piroxicam, MX-1094, meloxicam andflurizan (pure R-enantiomer form of flurbiprofen), or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a non-steroidal anti-inflammatory drug,preferably chosen from the group consisting of piroxicam, MX-1094,meloxicam and flurizan (pure R-enantiomer form of flurbiprofen), or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a pain disorder or Alzheimer Disease.

73: Combination Therapy with an Opoid Receptor Antagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an opoid receptor antagonistcompound, are substance related disorders.

It will be appreciated that the terms “opoid” and “opioid” may be usedinterchangeably.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofsubstance related disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a opoid receptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said opoid receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said opoid receptor antagonist compound isnaltrexone, preferably as a depot formulation, more preferably in theform of microcapsules, or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof. Preferably, said naltrexoneis to be administered in the form of a depot, preferably a depot ofmicrocapsules comprising a daily dose of between 192 and 384 mg.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an opoid receptor antagonist, preferablynaltrexone, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of substance related disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said opoid receptorantagonist compound is naltrexone, preferably provided in a unitary doseof between 192 and 384 mg of the active ingredient.

74: Combination Therapy with an Opoid Agonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with an opoid agonist compound, arechosen from the group of diseases or disorders consisting of anxietydisorders, psychotic disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, psychoticdisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of anopoid agonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said opoid agonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said opoid agonist compound is chosen from thegroup consisting of siramesine, E-5842 and cyclazocine, preferablysiramesine, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) an opoid agonist compound, preferably chosenfrom the group consisting of siramesine, E-5842 and cyclazocine,preferably siramesine, or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof, as a combined preparationfor simultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderwhich is chosen from the group consisting of anxiety disorders,psychotic disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect.

75: Combination Therapy with a Phosphodiesterase-4 (PDE4) InhibitorCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a phosphodiesterase-4 (PDE4)inhibitor compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, adjustment disorders, impulse control disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect, pain disorders, Alzheimer Disease, substance-relatedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration ofphosphodiesterase-4 (PDE4) inhibitor compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidphosphodiesterase-4 (PDE4) inhibitor compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a phosphodiesterase-4 (PDE4)inhibitor compound d to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said phosphodiesterase-4(PDE4) inhibitor compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-relatedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a phosphodiesterase-4 (PDE4) inhibitor compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said phosphodiesterase-4 (PDE4) inhibitorcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said phosphodiesterase-4 (PDE4) inhibitorcompound is chosen from the group consisting of ND1251 and MEM 1917(R1497), or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a phosphodiesterase-4 (PDE4) inhibitorantagonist compound, preferably chosen from the group consisting ofND1251 and MEM 1917 (R1497), or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of mental disease or disorder whichis chosen from the group consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect, paindisorders, Alzheimer Disease, substance-related persisting dementia,vascular dementia, dementia due to HIV disease, dementia due to headtrauma, dementia due to Parkinson Disease, dementia due to HuntingtonDisease, dementia due to Pick Disease, dementia due to Creutzfeldt-JacobDisease, amnestic disorders due to a general medical condition,substance-induced persisting amnestic disorder, mild cognitiveimpairment disorder and other cognitive disorders.

76: Combination Therapy with a Peptidic Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a peptidic compound, arechosen from the group of diseases or disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders, substance relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect, pain disorders, Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, pervasive development disorders, disruptivebehaviour disorders, substance related disorders, personality disorders,bereavement, occupational problem and problems related to abuse orneglect, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a peptidic compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said peptidic compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a peptidic compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said peptidic compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a peptidic compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidpeptidic compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said peptidic compound is chosen from thegroup consisting of secretin, PT-141, INN 00835 and beta sheet breakerpeptide, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, said peptidiccompound is secretin and is to be administered in a daily dose rangingbetween 0.2 and 0.4 mg/kg of the active ingredient. More preferably,said peptidic compound is INN 00835 and is to be administered in a dailydose ranging between 18 and 160 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a peptidic compound, preferably chosen from thegroup consisting of secretin, PT-141, INN 00835 and beta sheet breakerpeptide, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of mental disease or disorder which is chosen fromthe group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, pervasive development disorders, disruptivebehaviour disorders, substance related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglect,pain disorders, Alzheimer Disease, substance-induced persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said peptidic compound issecretin, preferably provided in a unitary dose of 0.2 and 0.4 mg/kg ofthe active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said peptidic compound is INN00835, preferably provided in a unitary dose of 18 and 160 mg of theactive ingredient.

77: Combination Therapy with a Phospholipase A2 Inhibitor Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a phospholipase A2 inhibitorcompound which has caspase inhibitor activity, are chosen from the groupof diseases or disorders consisting of mood disorders, anxietydisorders, psychotic disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect, pain disorders and delirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, bereavement, occupational problem and problemsrelated to abuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a phospholipase A2inhibitor compound which has caspase inhibitor activity to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said phospholipase A2 inhibitor compound which has caspaseinhibitor activity, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a phospholipase A2 inhibitorcompound which has caspase inhibitor activity to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidphospholipase A2 inhibitor compound which has caspase inhibitoractivity, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is delirium, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a phospholipase A2 inhibitor compound which hascaspase inhibitor activity to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said phospholipaseA2 inhibitor compound which has caspase inhibitor activity, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said phospholipase A2 inhibitor compoundwhich has caspase inhibitor activity is chosen from the group consistingof LAX-101a, LAX-101b and LAX-101c, preferably LAX-101c, or a pro-drugor an active metabolite thereof, or a pharmaceutically acceptable saltthereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a phospholipase A2 inhibitor compound which hascaspase inhibitor activity, preferably chosen from the group consistingof LAX-101a, LAX-101b and LAX-101c, more preferably LAX-101c, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup consisting mood disorders, anxiety disorders, psychotic disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, pervasive development disorders, disruptivebehaviour disorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglect,pain disorders and delirium.

78: Combination Therapy with a Compound which is a Prodrug of Uridine

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which is a prodrugof uridine, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound which is a prodrug of uridine toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said compound which is a prodrug of uridine,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a compound which is a prodrug ofuridine to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said compound which is a prodrug ofuridine, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said compound which is a prodrug of uridineis RG2133 (triacetyluridine) or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which is a prodrug of uridine,preferably RG2133 (triacetyluridine) or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

79: Combination Therapy with Prostaglandin E1 Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with prostaglandin E1 compound, aresexual and gender identity disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofsexual and gender identity disorders, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of aprostaglandin E1 compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said prostaglandinE1 compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said prostaglandin E1 is alprostadil or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. More preferably, said prostaglandin E1 compoundis alprostadil, preferably in the form of cream or gel, preferably atopical gel, and is to be administered in a daily dose ranging between50 and 300 microgram per application of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a prostaglandin E1 compound, preferablyalprostadil or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of sexual and gender identity disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said prostaglandin E1compound is alprostadil, preferably provided in the form of a cream orgel, preferably a topical gel, wherein a unitary dose comprises between50 and 300 microgram of the active ingredient per application.

80: Combination Therapy with a Compound Protecting Dopaminergic andCholinergic Neurons

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which protectsdopaminergic and cholinergic neurons, are chosen from the group ofdiseases or disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder, other cognitive disorders and ParkinsonDisease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of Alzheimer Disease, substance-inducedpersisting dementia, vascular dementia, dementia due to HIV disease,dementia due to head trauma, dementia due to Parkinson Disease, dementiadue to Huntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound which protects dopaminergic andcholinergic neurons to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said compound which protectsdopaminergic and cholinergic neurons, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compound whichprotects dopaminergic and cholinergic neurons to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidcompound which protects dopaminergic and cholinergic neurons, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said compound which protects dopaminergicand cholinergic neurons is SR 57667 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which protects dopaminergic andcholinergic neurons, preferably SR 57667 or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of a mental disease ordisorder which is chosen from the group consisting of Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder, other cognitivedisorders and Parkinson Disease.

81: Combination Therapy with a Psycho Stimulant

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a psycho stimulant, are chosenfrom the group of diseases or disorders consisting of sleep disorders,attention-deficit disorders and substance-related disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of sleep disorders, attention-deficitdisorders and substance-related disorders, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a psycho stimulant to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said psychostimulant, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said psycho stimulant is chosen from thegroup consisting of SPD 503, r-modafinil and modafinil, or a pro-drug oran active metabolite thereof, or a pharmaceutically acceptable saltthereof. More preferably, said psycho stimulant is SPE 503, morepreferably said psycho stimulant is modafinil and is to be administeredin a daily dose ranging between 200 and 600 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a psycho stimulant, preferably chosen from thegroup consisting of SPD 503, r-modafinil and modafinil, more preferablysaid SPC 503 or modafinil or a pro-drug or an active metabolite thereof,or a pharmaceutically acceptable salt thereof, as a combined preparationfor simultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderwhich is chosen from the group consisting of sleep disorders,attention-deficit disorders and substance-related disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said psycho stimulant ismodafinil, preferably provided in a unitary dose of between 200 and 600mg of the active ingredient.

82: Combination Therapy with a Compound which is a Reversible Inhibitorof Mono-Amine Oxydase A (RIMA)

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which is areversible inhibitor of mono-amine oxydase A (RIMA), are chosen from thegroup of diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, adjustment disorders,impulse control disorders, personality disorders, antisocial behaviour,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders; dissociative disorders, sexualand gender identity disorders, adjustment disorders, impulse controldisorders, personality disorders, antisocial behaviour, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound which is a reversible inhibitor ofmono-amine oxydase A (RIMA) to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said compound whichis a reversible inhibitor of mono-amine oxydase A (RIMA), furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a compound which is a reversibleinhibitor of mono-amine oxydase A (RIMA) to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidcompound which is a reversible inhibitor of mono-amine oxydase A (RIMA),further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said compound which is a reversibleinhibitor of mono-amine oxydase A (RIMA) is chosen from the groupconsisting of toloxatone, RS 8359, moclobemide, cimoxatone, caroxazone(F.I 6654) and befloxatone, or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof. More preferably,said compound which is a reversible inhibitor of mono-amine oxydase A(RIMA) is befloxatone and is to be administered in a daily dose rangingbetween 2.5 and 20 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which is a reversible inhibitor ofmono-amine oxydase A (RIMA), preferably chosen from the group consistingof toloxatone, RS 8359, moclobemide, cimoxatone, caroxazone (F.I 6654)and befloxatone, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of mental disease or disorder which is chosen fromthe group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, adjustment disorders, impulse controldisorders, personality disorders, antisocial behaviour, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said compound which is areversible inhibitor of mono-amine oxydase A (RIMA) is befloxatone,preferably provided in a unitary dose of between 2.5 and 20 mg of theactive ingredient.

83: Combination Therapy with a Compound which Modulates SCT-11

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound which modulatesSCT-11 (i.e. SCT-11 is a G protein-coupled receptor), are chosen fromthe group of diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound which modulates SCT-11 to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said compound which modulates SCT-11, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a compound which modulates SCT-11to augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said compound which modulates SCT-11, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said compound which modulates SCT-11 is SNEC-2or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound which modulates SCT-11, preferablySNE-2 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

84: Combination Therapy with a Serotonin/Dopamine Antagonist Compound(SDA)

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a serotonin/dopamineantagonist compound (SDA), are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, psychoticdisorders, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sleep disorders, adjustmentdisorders, impulse control disorders, pervasive development disorders,disruptive behaviour disorders, substance-related disorders, personalitydisorders, psychological factors affecting medical conditions,malingering, antisocial behaviour, bereavement, occupational problem,identity problem, problems related to abuse or neglect, pain disordersand delirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a serotonin/dopamine antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said serotonin/dopamine antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a serotonin/dopamine antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said serotonin/dopamine antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is delirium, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a serotonin/dopamine antagonist compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said serotonin/dopamine antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said serotonin/dopamine antagonist compoundis chosen from the group consisting of zotepine, ziprasidone, SM-13496,SL 91.0177, sertindole, S-18327, risperidone, quetiapine fumarate(preferably sustained release formulation), quetiapine fumarate(preferably granules), quetiapine, perospirone, paliperidone,olanzapine, ocaperidone, LU 31-131, iloperidone, clozapine, BSF-190555,blonanserin, bifeprunox, asenapine and aripiprazole, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof. Even more preferably, said serotonin/dopamine antagonistcompound is chosen from the group consisting of SL 91.0177, sertindole,perospirone, paliperidone, blonanserin, bifeprunox and asenapine, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. More preferably, said serotonin/dopamineantagonist compound is sertindole and is to be administered in a dailydose ranging between 12 and 24 mg of the active ingredient. Morepreferably, said serotonin/dopamine antagonist compound is paliperidoneand is to be administered in a daily dose ranging between 3 and 15 mg ofthe active ingredient. More preferably, said serotonin/dopamineantagonist compound is asenapine and is to be administered in a dailydose ranging between 2.5 and 20 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a serotonin/dopamine antagonist compound,preferably chosen from the group consisting of SL 91.0177, sertindole,perospirone, paliperidone, blonanserin, bifeprunox and asenapine, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup consisting mood disorders, anxiety disorders, psychotic disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders anddelirium.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said serotonin/dopamineantagonist compound is sertindole, preferably provided in a unitary doseof between 12 and 24 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said serotonin/dopamineantagonist compound is paliperidone, preferably provided in a unitarydose of between 3 and 15 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said serotonin/dopamineantagonist compound is asenapine, preferably provided in a unitary doseof between 2.5 and 20 mg of the active ingredient.

85: Combination Therapy with a Selective SDRI Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a selective serotonin anddopamine re-uptake inhibitor (SDRI) compound, are chosen from the groupof diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,antisocial behaviour, bereavement, occupational problem, problemsrelated to abuse or neglect, pain disorders, delirium, AlzheimerDisease, substance-induced persisting dementia, vascular dementia,dementia due to HIV disease, dementia due to head trauma, dementia dueto Parkinson Disease, dementia due to Huntington Disease, dementia dueto Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnesticdisorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin and dopamine reuptake inhibitor (SDRI) compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said selective serotonin and dopamine reuptake inhibitor(SDRI) compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a selective serotonin anddopamine reuptake inhibitor (SDRI) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidselective serotonin and dopamine reuptake inhibitor (SDRI) compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of delirium, Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin and dopamine reuptake inhibitor (SDRI) compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said selective serotonin and dopamine reuptake inhibitor(SDRI) compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said selective serotonin and dopaminereuptake inhibitor (SDRI) compound is bazinaprine, or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a selective serotonin and dopamine reuptakeinhibitor (SDRI) compound, preferably bazinaprine or a pro-drug or anactive metabolite thereof, or a pharmaceutically acceptable saltthereof, as a combined preparation for simultaneous, separate orsequential use for treating the underlying emotion dysregulation ofmental disease or disorder which is chosen from the group consisting ofmood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sleep disorders, adjustmentdisorders, impulse control disorders, substance-related disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect, pain disorders, delirium,Alzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders.

86: Combination Therapy with a Second Messenger Beta Agonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a second messenger betaagonist compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a second messenger beta agonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said second messenger beta agonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a second messenger beta agonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said second messenger beta agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said second messenger beta agonist compoundis chosen from the group consisting of SR 57227, rolipram andeplivanserin, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, said secondmessenger beta agonist compound is rolipram and is to be administered ina daily dose ranging between 1.5 and 3 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a second messenger beta agonist compound,preferably chosen from the group consisting of SR 57227, rolipram andeplivanserin or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said second messenger betaagonist compound is rolipram, preferably provided in a unitary dose ofbetween 1.5 and 3 mg of the active ingredient.

87: Combination Therapy with a Secretin Pancreatic Hormone

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a secretin pancreatic hormone,are chosen from the group of diseases or disorders consisting of anxietydisorders, psychotic disorders, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders, substance-relateddisorders, personality disorders, psychological factors affectingmedical conditions, malingering, antisocial behaviour, bereavement,occupational problem, identity problem, problems related to abuse orneglect, pain disorders and delirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, psychoticdisorders, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sleep disorders, adjustmentdisorders, impulse control disorders, pervasive development disorders,disruptive behaviour disorders, substance-related disorders, personalitydisorders, psychological factors affecting medical conditions,malingering, antisocial behaviour, bereavement, occupational problem,identity problem and problems related to abuse or neglect, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a secretin pancreatic hormone to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said secretin pancreatic hormone, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a secretin pancreatic hormone toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said secretin pancreatic hormone, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is delirium, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a secretin pancreatic hormone to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said secretin pancreatic hormone, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said secretin pancreatic hormone is RG1068or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a secretin pancreatic hormone, preferablyRG1068, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group consisting of anxiety disorders, psychotic disorders,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders anddelirium.

88: Combination Therapy with a Sigma Receptor Agonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a sigma receptor agonistcompound, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,attention-deficit disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, attention-deficit disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a sigma receptoragonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said sigma receptor agonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a sigma receptor agonist compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said sigma receptor agonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said sigma receptor agonist compound isVPI-013 (also known as OPC-14523) or PRX-00023, preferably VPI-013 (alsoknown as OPC-14523), or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a sigma receptor agonist compound, preferablyVPI-013 (also known as OPC-14523) or PRX-00023, preferably VPI-013 (alsoknown as OPC-14523), or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder, which is chosenfrom the group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, attention-deficit disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

89: Combination Therapy with a Sigma Receptor Antagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a sigma receptor antagonistcompound, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, psychotic disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, pervasive development disorders, disruptivebehaviour disorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglect,pain disorders and delirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, bereavement, occupational problem and problemsrelated to abuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a sigma receptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said sigma receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a sigma receptor antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said sigma receptor antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is delirium, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a sigma receptor antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said sigma receptor antagonist compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said sigma receptor antagonist compound ischosen from the group consisting of SR 31742 and EMD 68843, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. More preferably, said sigma receptor antagonistcompound is EMD 68843 and is to be administered in a daily dose rangingbetween 5 and 40 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a sigma receptor antagonist compound, preferablychosen from the group consisting of SR 31742 and EMD 68843, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup consisting mood disorders, anxiety disorders, psychotic disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, pervasive development disorders, disruptivebehaviour disorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglect,pain disorders and delirium.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said sigma receptorantagonist compound is EMD 68843, preferably provided in a unitary doseof between 5 and 40 mg of the active ingredient.

90: Combination Therapy with a Selective SNDRI Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a selective serotonin,nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, arechosen from the group of diseases or disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, attention-deficit disorders, substance-relateddisorders, personality disorders, antisocial behaviour, bereavement,occupational problem, problems related to abuse or neglect, paindisorders, delirium, Alzheimer Disease, substance-induced persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder and other cognitive disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,attention-deficit disorders, substance-related disorders, personalitydisorders, antisocial behaviour, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of aselective serotonin, nor-adrenaline and dopamine re-uptake inhibitor(SNDRI) compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said selective serotonin,nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a selective serotonin,nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said selective serotonin, nor-adrenaline anddopamine re-uptake inhibitor (SNDRI) compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder selected from the group of diseasesand disorders consisting of delirium, Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI)compound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said selective serotonin, nor-adrenalineand dopamine re-uptake inhibitor (SNDRI) compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said selective serotonin, nor-adrenaline anddopamine re-uptake inhibitor (SNDRI) compound is selected from the groupconsisting of NS 2330; McN 5652; DOV 216,303 and DOV 21,947; morepreferably NS 2330 or DOV 216,303; or a pro-drug or an active metabolitethereof; or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a selective serotonin, nor-adrenaline anddopamine re-uptake inhibitor (SNDRI) compound, preferably selected fromthe group consisting of NS 2330; McN 5652; DOV 216,303 and DOV 21,947,more preferably NS 2330 or DOV 216,303, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof, as acombined preparation for simultaneous, separate or sequential use fortreating the underlying emotion dysregulation of mental disease ordisorder which is chosen from the group consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect, pain disorders, delirium,Alzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders.

91: Combination Therapy with a Selective SNRI Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a selective serotonin andnor-adrenaline re-uptake inhibitor (SNRI) compound, are chosen from thegroup of diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,attention-deficit disorders, substance-related disorders, personalitydisorders, antisocial behaviour, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of aselective serotonin and nor-adrenaline re-uptake inhibitor (SNRI)compound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said selective serotonin and nor-adrenalinere-uptake inhibitor (SNRI) compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a selective serotonin andnor-adrenaline re-uptake inhibitor (SNRI) compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said selective serotonin and nor-adrenaline re-uptakeinhibitor (SNRI) compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said selective serotonin and nor-adrenalinere-uptake inhibitor (SNRI) compound is selected from the groupconsisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram,nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine andamoxapine, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Even more preferably, saidselective serotonin and nor-adrenaline re-uptake inhibitor (SNRI)compound is chosen from the group consisting of venlafaxine, tomoxetine,milnacipran, duloxetine and desvenlafaxine, or a pro-drug or an activemetabolite thereof, or a pharmaceutically acceptable salt thereof. Morepreferably, said selective serotonin and nor-adrenaline re-uptakeinhibitor (SNRI) compound is venlafaxine and is to be administered in adaily dose ranging between 75 and 300 mg of the active ingredient. Morepreferably, said selective serotonin and nor-adrenaline re-uptakeinhibitor (SNRI) compound is tomoxetine and is to be administered in adaily dose ranging between 0.475 and 3.8 mg/kg of the active ingredient.More preferably, said selective serotonin and nor-adrenaline re-uptakeinhibitor (SNRI) compound is milnacipran and is to be administered in adaily dose ranging between 50 and 200 mg of the active ingredient. Morepreferably, said selective serotonin and nor-adrenaline re-uptakeinhibitor (SNRI) compound is duloxetine and is to be administered in adaily dose ranging between 40 and 60 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a selective serotonin and nor-adrenalinere-uptake inhibitor (SNRI) compound, preferably selected from the groupconsisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram,nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine andamoxapine, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of mental disease or disorder which is chosen fromthe group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,attention-deficit disorders, substance-related disorders, personalitydisorders, antisocial behaviour, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective serotonin andnor-adrenaline re-uptake inhibitor (SNRI) compound is venlafaxine,preferably provided in a unitary dose of between 75 and 300 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective serotonin andnor-adrenaline re-uptake inhibitor (SNRI) compound is tomoxetine,preferably provided in a unitary dose of between 0.475 and 3.8 mg/kg ofthe active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective serotonin andnor-adrenaline re-uptake inhibitor (SNRI) compound is milnacipran,preferably provided in a unitary dose of between 50 and 200 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective serotonin andnor-adrenaline re-uptake inhibitor (SNRI) compound is duloxetine,preferably provided in a unitary dose of between 40 and 60 mg of theactive ingredient.

92: Combination Therapy with a Selective Serotonin Re-Uptake Inhibitor(SSRI) Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a selective serotoninre-uptake inhibitor (SSRI) compound, are chosen from the group ofdiseases or disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin re-uptake inhibitor (SSRI) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidselective serotonin re-uptake inhibitor (SSRI) compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a selective serotonin re-uptakeinhibitor (SSRI) compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said selectiveserotonin re-uptake inhibitor (SSRI) compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said selective serotonin re-uptake inhibitor(SSRI) compound is selected from the group consisting of YM 992, VPI-013(also known as OPC-14523), sertraline, paroxetine, LY 214.281, LU AA21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlledrelease formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram,EMD 68843, cyanodothepine, citalopram, cericlamine and ademethionine(preferably s-adenosylmethionine), or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof. Even morepreferably, said selective serotonin re-uptake inhibitor (SSRI) compoundis chosen from the group consisting of litoxetine, fluvoxamine(controlled release formulation), citalopram and escitalopram, or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. More preferably, said selective serotoninre-uptake inhibitor (SSRI) compound is fluvoxamine (controlled releaseformulation) and is to be administered in a daily dose ranging between100 and 300 mg of the active ingredient. More preferably, said selectiveserotonin re-uptake inhibitor (SSRI) compound is escitalopram and is tobe administered in a daily dose ranging between 10 and 20 mg of theactive ingredient. More preferably, said selective serotonin re-uptakeinhibitor (SSRI) compound is citalopram and is to be administered in adaily dose ranging between 10 and 40 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a selective serotonin re-uptake inhibitor (SSRI)compound, preferably selected from the group consisting of YM 992,VPI-013 (also known as OPC-14523), sertraline, paroxetine, LY 214.281,LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlledrelease formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram,EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran,duloxetine, cericlamine and ademethionine (preferablys-adenosylmethionine), or a pro-drug or an active metabolite thereof, ora pharmaceutically acceptable salt thereof, as a combined preparationfor simultaneous, separate or sequential use for treating the underlyingemotion dysregulation of mental disease or disorder which is chosen fromthe group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective serotoninre-uptake inhibitor (SSRI) compound is fluvoxamine (controlled releaseformulation), preferably provided in a unitary dose of between 100 and300 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective serotoninre-uptake inhibitor (SSRI) compound is escitalopram, preferably providedin a unitary dose of between 10 and 20 mg of the active ingredient.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said selective serotoninre-uptake inhibitor (SSRI) compound is citalopram, preferably providedin a unitary dose of between 10 and 40 mg of the active ingredient.

Citalopram or citalopram hydrobromide is a selective serotonin(5-hydroxytryptamine/5-HT) re-uptake inhibitor (SSRI) and is theconventional name given for the compound of the formula(RS)-1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile-hydro-bromide.According to an embodiment, a daily doses of active ingredient of SSRI,preferably citalopram, ranges between 10 and 40 mg per day. Preferably,daily doses of active ingredient ranging between 20 and 30 mg per dayare administered. More preferably, a daily dose of 10, 15, 20, 25, 30,35 or 40 mg per day is administered.

Fluvoxamine or fluvoxamine maleate (luvox, fevarin) is a selectiveserotonin (5-HT) re-uptake inhibitor (SSRI) belonging to a new chemicalseries, the 2-aminoethyl oxime ethers of aralkylketones. It ischemically unrelated to other SSRIs and clomipramine. It is chemicallydesignated as 5-methoxy-4′-(trifluoromethyl)valerophenone(E)-O-(2-aminoethyl)oxime maleate (1:1).

According to an embodiment, a daily dose of active ingredient offluvoxamine in a controlled release mode ranges between 100 and 300 mgper day. Preferably, daily doses of active ingredient ranging between150 and 200 mg per day are administered in a controlled release mode.More preferably, a daily dose of 100, 150, 200, 250 or 300 mg per day isadministered by controlled release.

93: Combination Therapy with a Substance P Receptor (NK1) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a substance P receptor (NK1)antagonist compound, are chosen from the group of diseases or disordersconsisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a substance Preceptor (NK1) antagonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said substance Preceptor (NK1) antagonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of pain,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a substance P receptor (NK1) antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said substance P receptor (NK1) antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said substance P receptor (NK1) antagonistcompound is chosen from the group consisting of vestipitant, TAK-637,R673, GW823296, GW679769, GW597599, CP-122.721, aprepitant, 823296 and679769, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. More preferably, saidsubstance P receptor (NK1) antagonist compound is aprepitant and is tobe administered in a daily dose ranging between 40 and 160 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a substance P receptor (NK1) antagonistcompound, preferably chosen from the group consisting of vestipitant,TAK-637, R673, GW823296, GW679769, GW597599, CP-122.721, aprepitant,823296 and 679769, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said substance P receptor(NK1) antagonist compound is aprepitant, preferably provided in aunitary dose of between 40 and 160 mg of the active ingredient.

94: Combination Therapy with a Sulfonamide Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a sulfonamide compound, arechosen from the group of diseases or disorders consisting of mooddisorders, psychotic disorders, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders, pervasivedevelopment disorders, disruptive behaviour disorders, substance-relateddisorders, personality disorders, psychological factors affectingmedical conditions, malingering, antisocial behaviour, bereavement,occupational problem, identity problem, problems related to abuse orneglect, pain disorders and delirium.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, psychoticdisorders, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sleep disorders, adjustmentdisorders, impulse control disorders, pervasive development disorders,disruptive behaviour disorders, substance-related disorders, personalitydisorders, psychological factors affecting medical conditions,malingering, antisocial behaviour, bereavement, occupational problem,identity problem and problems related to abuse or neglect, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a sulfonamide compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidsulfonamide compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a sulfonamide compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said sulfonamide compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of acognitive mental disease or disorder which is delirium, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a sulfonamide compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidsulfonamide compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said sulfonamide compound is zonisamide or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. More preferably, said sulfonamide compound iszonisamide and is to be administered in a daily dose ranging between 100and 600 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a sulfonamide compound, preferably zonisamide,or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup consisting mood disorders, psychotic disorders, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorders anddelirium.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said sulfonamide compound iszonisamide, preferably provided in a unitary dose of between 100 and 600mg of the active ingredient.

95: Combination Therapy with a Tachykinin Antagonist Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a tachykinin antagonistcompound, are chosen from the group of diseases or disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a tachykininantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said tachykinin antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a tachykinin antagonist compoundto augment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said tachykinin antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said tachykinin antagonist compound is SR 48968or a pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a tachykinin antagonist compound, preferably SR48968 or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

96: Combination Therapy with a Compound Selected from the GroupConsisting of R228060 (YKP-10A), Palanpanel, ORG 39479/PH80, ORG 34167,DP 543 and CJ-017.493

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a compound selected from thegroup consisting of R228060 (YKP-10A), palanpanel, ORG 39479/PH80, ORG34167, DP 543 and CJ-017.493, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, psychoticdisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, attention-deficit disorders, disruptive behaviour disorders,substance-related disorders, personality disorders, psychologicalfactors affecting medical conditions, malingering, antisocial behaviour,bereavement, occupational problem, identity problem, phase of lifeproblem, academic problem, problems related to abuse or neglect, paindisorders, delirium, Alzheimer Disease, substance-induced persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder, other cognitive disorders and ParkinsonDisease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, attention-deficit disorders, disruptive behaviour disorders,substance-related disorders, personality disorders, psychologicalfactors affecting medical conditions, malingering, antisocial behaviour,bereavement, occupational problem, identity problem, phase of lifeproblem, academic problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a compound selected from the group consistingof R228060 (YKP-10A), palanpanel, ORG 39479/PH80, ORG 34167, DP 543 andCJ-017.493, to augment the therapeutic effect or to provide a fasteronset of the therapeutic effect of said compound selected from the groupconsisting of R228060 (YKP-10A), palanpanel, ORG 39479/PH80, ORG 34167,DP 543 and CJ-017.493, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a compound selected from thegroup consisting of R228060 (YKP-10A), palanpanel, ORG 39479/PH80, ORG34167, DP 543 and CJ-017.493, to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said compoundselected from the group consisting of R228060 (YKP-10A), palanpanel, ORG39479/PH80, ORG 34167, DP 543 and CJ-017.493, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of delirium, Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compoundselected from the group consisting of R228060 (YKP-10A), palanpanel, ORG39479/PH80, ORG 34167, DP 543 and CJ-017.493, to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidcompound selected from the group consisting of R228060 (YKP-10A),palanpanel, ORG 39479/PH80, ORG 34167, DP 543 and CJ-017.493, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compoundselected from the group consisting of R228060 (YKP-10A), palanpanel, ORG39479/PH80, ORG 34167, DP 543 and CJ-017.493, to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidcompound selected from the group consisting of R228060 (YKP-10A),palanpanel, ORG 39479/PH80, ORG 34167, DP 543 and CJ-017.493, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a compound selected from the group consisting ofR228060 (YKP-10A), palanpanel, ORG 39479/PH80, ORG 34167, DP 543 andCJ-017.493, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of mental disease or disorder which is chosen fromthe group consisting of mood disorders, anxiety disorders, psychoticdisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, attention-deficit disorders, disruptive behaviour disorders,substance-related disorders, personality disorders, psychologicalfactors affecting medical conditions, malingering, antisocial behaviour,bereavement, occupational problem, identity problem, phase of lifeproblem, academic problem, problems related to abuse or neglect, paindisorders, delirium, Alzheimer Disease, substance-induced persistingdementia, vascular dementia, dementia due to HIV disease, dementia dueto head trauma, dementia due to Parkinson Disease, dementia due toHuntington Disease, dementia due to Pick Disease, dementia due toCreutzfeldt-Jacob Disease, amnestic disorders due to a general medicalcondition, substance-induced persisting amnestic disorder, mildcognitive impairment disorder, other cognitive disorders and ParkinsonDisease.

97: Combination Therapy with a Vasopressin 1B Receptor (V1B) AntagonistCompound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a vasopressin 1B receptor(V1B) antagonist compound, are chosen from the group of diseases ordisorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a vasopressin 1Breceptor (V1B) antagonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said vasopressin1B receptor (V1B) antagonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a vasopressin 1B receptor (V1B)antagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said vasopressin 1B receptor(V1B) antagonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said vasopressin 1B receptor (V1B)antagonist compound is SSR149415 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a vasopressin 1B receptor (V1B) antagonistcompound, preferably SSR149415 or a pro-drug or an active metabolitethereof, or a pharmaceutically acceptable salt thereof, as a combinedpreparation for simultaneous, separate or sequential use for treatingthe underlying emotion dysregulation of a mental disease or disorderwhich is chosen from the group consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

98: Combination Therapy with a Voltage-Gated Calcium Channel α(2)δSubunit Modulator Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a voltage-gated calciumchannel alpha(2)delta subunit modulator compound, are chosen from thegroup of diseases or disorders consisting of mood disorders, anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem,problems related to abuse or neglect and pain disorders.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a voltage-gatedcalcium channel alpha(2)delta subunit modulator compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said voltage-gated calcium channel alpha(2)delta subunitmodulator compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a voltage-gated calcium channelalpha(2)delta subunit modulator compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidvoltage-gated calcium channel alpha(2)delta subunit modulator compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said voltage-gated calcium channelalpha(2)delta subunit modulator compound is pregabalin or PD-200,390; ora pro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof. More preferably, said voltage-gated calciumchannel alpha(2)delta subunit modulator compound is pregabalin, and isto be administered in a daily dose ranging between 50 and 600 mg of theactive ingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a voltage-gated calcium channel alpha(2)deltasubunit modulator compound, preferably pregabalin or PD-200,390; or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a mental disease or disorder which is chosen from thegroup consisting of mood disorders, anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, substance-related disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said voltage-gated calciumchannel alpha(2)delta subunit modulator compound is pregabalin,preferably provided in a unitary dose of between 50 and 600 mg of theactive ingredient.

99: Combination Therapy with a Vomeropherin Compound

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a vomeropherin compound, arechosen from the group of diseases or disorders consisting of anxietydisorders, eating disorders, premenstrual syndrome, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, personality disorders,bereavement, occupational problem and problems related to abuse orneglect.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of vomeropherin compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said vomeropherin compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.

According to a preferred embodiment, the invention relates to the use asdescribed above, wherein said vomeropherin compound is PH94B or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) vomeropherin compound, preferably PH94B or apro-drug or an active metabolite thereof, or a pharmaceuticallyacceptable salt thereof, as a combined preparation for simultaneous,separate or sequential use for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder which ischosen from the group consisting of anxiety disorders, eating disorders,premenstrual syndrome, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sexual and gender identitydisorders, sleep disorders, adjustment disorders, impulse controldisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect.

Also, the invention relates in particular to the use as describedbefore, wherein said second compound is chosen from the group consistingof fluvoxamine controlled release, phenserine tartrate, atomoxetinehydrochloride, bupropion (controlled-release formulation), ropiniroleHCL (controlled-release formulation), INN 00835, galantamine (extendedrelease formulation), paliperidone, tomoxetine, aprepitant, rivastigminetartrate, ORG 34517/34850, sunepitron, sumanirole, milnacipran,idazoxan, xaliproden, SR 58611, befloxatone, litoxetine, tianeptine,aglomelatine, SPD 503, flesinoxan, bifeprunox, ramelteon, etilevodopa,rasagiline (TVP-1012) and desvenlafaxine.

Also, the invention relates in particular to the use as describedbefore, wherein said second compound is chosen from the group consistingof galantamine (extended release formulation), R121919, risperidone,paliperidone and R228060 (YKP-10A).

100: Combination Therapy with a Dopamine Releaser

The mental disorders which can be treated using compounds having a highselective affinity for the 5-HT2A and D4 receptor, for instancepipamperon, in a combination therapy with a dopamine releaser, arechosen from the group of diseases or disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, adjustment disorders, impulse control disorders,attention-deficit disorders, substance-related disorders, personalitydisorders, problems related to abuse or neglect, pain disorders andParkinson disease.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders,adjustment disorders, impulse control disorders, attention-deficitdisorders, substance-related disorders, personality disorders andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of adopamine releaser compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said dopaminereleaser compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a dopamine releaser compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said dopamine releaser compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.

The present invention thus relates to the use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a dopaminereleaser compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said dopamine releasercompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.

According to a preferred embodiment, the invention relates to the usesas described above, wherein said dopamine (receptor) agonist compound isamantadine, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof. Preferably, amantadine is tobe administered in a daily dose of between 100 and 300 mg of the activeingredient.

The invention also relates to a pharmaceutical composition comprising(a) pipamperon, and (b) a dopamine (receptor) agonist, preferablyamantadine, or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of a mental disease or disorder which is chosenfrom the group of diseases or disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, adjustment disorders, impulse control disorders,attention-deficit disorders, substance-related disorders, personalitydisorders, problems related to abuse or neglect, pain disorders andParkinson disease.

The invention also relates to a pharmaceutical composition as describedabove wherein pipamperon is provided in a unitary dose of between 5 and15 mg of the active ingredient and wherein said dopamine (receptor)agonist is amantadine, preferably provided in a unitary dose of between100 and 300 mg of the active ingredient.

From the above it will be apparent that the numbering of the groupingaccording to the action on the pathway or system corresponds to thenumbering of the columns in Table 5 and the numbering of thepharmalogical profile in Table 6.

The disclosure of all patents, publications (including published patentpublications), and database accession numbers and depository accessionnumbers referenced in this specification are specifically incorporatedherein by reference in their entirety to the same extent as if each suchindividual patent, publication, and database accession number, anddepository accession number were specifically and individually indicatedto be incorporated by reference.

The invention, now being generally described, will be more readilyunderstood by reference to the following tables and examples, which areincluded merely for purposes of illustration of certain aspects andembodiments of the present invention and are not intended to limit theinvention.

SHORT DESCRIPTION OF THE TABLES AND FIGURES

Table 1: In Table 1, the pKi values of test compounds are given for eachof the dopamine receptors, 5HT receptors, adrenergic receptors and thehistamine1 receptor.

Table 2: Set-up of a clinical trial comprising for treatment groups.

Table 3: Overview of a placebo, active and period controlled clinicaltrial in a fore-going pipamperon-citalopram treatment in MajorDepressive Disorder.

Table 4: POC process for major depressive disorder.

Table 5: Summary of diseases and disorders relative to knownpsycho-tropics.

Table 6: Overview of Pharmacological grouping, indicatingpharmacological profile numbering (column 2), pharmacological profile(column 3), main indication(s) (column 4), name of the compound (column4), the dose range (column 5), and the company producing or selling saidcompound (column 6). Compounds indicated by hatching are preferred.

FIG. 1: Add-on treatment with pipamperon after treatment withcitalopram.

FIG. 2: HDRS-17 change from baseline: combo treatment pipamperon asadd-on-citalopram vs SNRI (duloxetine) in Major Depression.

FIG. 3: Remission rates (HDRS-17 <=7): combo treatment pipamperon asadd-on-citalopram vs SNRI (venlafaxine) vs SSRIs vs placebo in MajorDepression.

FIG. 4: Fore-going treatment during 1-5 days with pipamperon followedwith the combination treatment of pipamperon and citalopram.

FIG. 5: HDRS-17 change from baseline: combo treatmentpipamperon-citalopram with a fore-going treatment of 4 days withpipamperon vs SNRI (duloxetine) in Major Depression.

FIG. 6: Remission rates (HDRS-17 <=7): combo pipamperon-citalopram witha fore-going treatment of 4 days with pipamperon vs SNRI (venlafaxine)in Major Depression.

FIG. 7: Fore-going treatment during 6-8 days with pipamperon followedwith the combination treatment of pipamperon and citalopram.

FIG. 8: HDRS-17 change from baseline: combo treatmentpipamperon-citalopram with a fore-going treatment of 7 days withpipamperon vs SNRI (duloxetine) in Major Depression.

FIG. 9: Fore-going and add-on treatment with pipamperon in MDD.

FIG. 10: HDRS-17 change from baseline: fore-going and add-on treatmentwith pipamperon and citalopram in comparison with the SNRI duloxetine inMajor Depression.

FIG. 11: Remission rates (HDRS-17 <=7): fore-going and add-on treatmentwith pipamperon and citalopram in comparison with the SNRI venlafaxinein Major Depression.

FIG. 12: Y-BOCS total score: fore-going and add-on treatment withpipamperon and citalopram in comparison with the SSRI fluvoxamine inOCD.

FIG. 13: Y-BOCS obsession score: fore-going and add-on treatment withpipamperon and citalopram in comparison with the SSRI fluvoxamine inOCD.

FIG. 14: Y-BOCS compulsion score: fore-going and add-on treatment withpipamperon and citalopram in comparison with the SSRI fluvoxamine inOCD.

FIG. 15: CGI-severity score: fore-going and add-on treatment withpipamperon and citalopram in comparison with the SSRI in panic disorder.

TABLE 1 D 1 D 2 D 3 D 4 5HT_(1A) 5HT_(1B) 5HT_(1D) 5HT_(1E) 5HT_(1F)5HT_(2A) 5HT_(2B) 5HT_(2C) ORG5222 8-9 8-9 8-9 8-9 8-9 8-9 8-9 7-80 >9 >9   >9 Zotepine 0 8-9 8-9 7-8 6-7 7-8 7-8 6-7 0 8-9 0   0Fluparoxan 0 <6 <6   0 6-7 <6 <6 0 0 <6 0 <6 Olanzapine 7-8 7-8 7-8 7-8<6 6-7 6-7 <6 6-7 8-9 8-9 8-9 Clozapine 7-8 6-7 6-7 7-8 6-7 6-7 6-7 6-76-7 8-9 8-9 7-8 S16924 0 7-8 7-8 7-8 8-9 0 0 0 0 >9 8-9 7-8 S18327 7-87-8 6-7 8-9 7-8 0 0 0 0 8-9 0 6-7 Amperozide 6-7 6-7 6-7 <6 <6 0 0 0 08-9 0 <6 GGR218231 <6   7-8 >9 <6 6-7 <6 <6 0 0 <6 <6   <6 Sertindole7-8 8-9 8-9 7-8 6-7 7-8 7-8 6-7 6-7 >9 0 8-9 MDL100.907 6-7 <6 <6 6-7 <60 0 0 0 >9 0 7-8 Haloperidol 8-9 >9 8-9 8-9 <6 6-7 <6 <6 <6 6-7 <6   <6Tiospirone 7-8 8-9 8-9 8-9 8-9 0 0 0 0 >9 0 8-9 Raciopride <6   8-9 8-9<6 <6 0 0 0 0 6-7 0 <6 Fluspirilene 0 >9 8-9 8-9 7-8 <6 <6 <6 0 <6 0   0Ocaperidone 7-8 >9 8-9 8-9 7-8 0 0 0 0 >9 0 7-8 Risperidone 7-8 8-9 7-88-9 6-7 8-9 6-7 <6 <6 >9 0 7-8 S33084 6-7 7-8 >9 <6 <6 6-7 6-7 0 0 6-76-7 7-8 L741626 6-7 8-9 7-8 6-7 <6 <6 <6 0 0 6-7 6-7 <6 Seroquel 6-7 6-76-7 <6 6-7 <6 <6 <6 <6 6-7 6-7 6-7 Yohimbine 0 6-7 <6   0 7-8 6-7 7-8 00 <6 0 <6 Ziprasidone 8-9 8-9 7-8 7-8 8-9 >9 8-9 6-7 0 >9 8-9 8-9Pipamperon 0 6-7 6-7 8-9 <6 6-7 6-7 <6 <6 8-9 0   0 5HT₆rat 5HT₇ratAlpha1A Alpha2A Alpha2B Alpha2C Beta1 Beta2 H1 ORG5222 >9   >9   >98-9 >9   7-8 <6 <6 >9   Zotepine 0 0   0 6-7 8-9 6-7 <6 <6 >9  Fluparoxan 0 0 6-7 8-9 8-9 8-9 0 0 0 Olanzapine 7-8 6-7 7-8 6-7 6-7 6-7<6 <6 >9   Clozapine 7-8 7-8 8-9 7-8 7-8 7-8 <6 <6 >9   S16924 7-8 7-88-9 6-7 7-8 6-7 <6 <6 0 S18327 0 0 >9 6-7 0 0 0 0 0 Amperozide 0 0 7-8<6 0 0 0 0 0 GGR218231 0 0 <6 <6 0 0 0 0 0 Sertindole 0 0 >9 6-7 6-7 6-7<6 <6 6-7 MDL100.907 0 0 <6 <6 0 0 0 0 0 Haloperidol <6   6-7 8-9 <6 6-7<6   <6 <6 6-7 Tiospirone 0 0 >9 6-7 0 0 0 0 0 Raciopride 0 0 <6 <6 0 00 0 0 Fluspirilene 0 0   0 6-7 7-8 7-8 6-7 6-7 7-8 Ocaperidone 0 0 >9  0 0 0 0 0 0 Risperidone 0 0 >9 7-8 8-9 8-9 <6 <6 7-8 S33084 0 0 6-7 <60 0 0 0 0 L741626 0 0 6-7 <6 0 0 0 0 0 Seroquel 0 6-7 7-8 <6 7-8 6-7 <6<6 8-9 Yohimbine 0 0 6-7 8-9 8-9 >9   <6 <6 0 Ziprasidone 7-8 8-9 8-96-7 7-8 7-8 <6 <6 7-8 Pipamperon 0 0   0 6-7 7-8 6-7 <6 <6 <6  

TABLE 2 ACUTE PHASE** EXTENSION PHASE*** VISITS V1 V2 V3 V4 V5 V6 V7 V8V9 V10 Day/Week/Month Screen Baseline minus D 7 D 0 D 4 D 7 W 2 W 3 W 4W 6 W 8 W 10 TREATMENTGROUP Group Pip-Active/D7 A B B C GroupPip-Active/D4 A B C Group Pip-Active/D0 A C Group Plc-Activc/D0 A DInformed Consent x NECT* x x x x x x x x x x Vital Signs/Weight x LAB xECG x Phys Exam x Alc/Drugs Screen x CGI-S**** x x x x x x x x x xQ-LES-Q***** EXTENSION PHASE*** FOLLOW-UP PHASE VISITS V11 V12 V13 V14V15 V16 V17 V18 V19 Day/Week/Month W 12 W 16 W 20 W 24 M 8 M 10 M 12 W 1W 2 TREATMENTGROUP Group Pip-Active/D7 A A Group Pip-Active/D4 A A GroupPip-Active/D0 A A Group Plc-Activc/D0 A A Informed Consent NECT* x x x xx x x x x Vital Signs/Weight x x x LAB x x x ECG x x x Phys ExamAlc/Drugs Screen x x x CGI-S**** x x x x x x x x x Q-LES-Q*****Treatment regimen: A: PLC + PLC B: 2x(PLC + PIP(4 mg))/d C: 2x(CIT(10mg) + PIP(4 mg))/d D: 2x(CIT(10 mg) + PLC)/d *Neuronal E-Clinical Trial= Vesalius Expert Development for this Trial which includes thebottom-up measurement of: **Entering Acute Phase: only NON-placeboresponders as defined by the DSM-IV criteria of efficacy ***EnteringExtension Phase: only remittors as defined by the DSM-IV criteria ofefficacy ****CGI-S: Clinical Global Impressions-Improvement Scale*****Q-LES-Q: Quality of Life, Enjoyment and Satisfaction Questionnaire

TABLE 3 FOREGOING PIPAMPERON- CITALOPRAM TREATMENT IN MAJOR DEPRESSIVEDISORDER A PLACEBO, ACTIVE AND PERIODE CONTROLLED CLIINICAL TRIAL ACUTEPHASE** EXTENSION PHASE*** VISITS V1 V2 V3 V4 V5 V6 V7 V8 V9DAY/WEEK/MONTH SCREEN BASELINE minus D 7 D 0 D 4 D 7 W 2 W 3 W 4 W 6 W 8TREATMENTGROUP Group Pip - Active/Day 4 PLC + PLC 2x(PLC + PIP(4 mg))/d2x(CIT(10 mg) + PIP(4 mg))/d Group Pip - Active/Day 0 PLC + PLC2x(CIT(10 mg) + PIP(4 mg))/d Group Plc - Active/Day 0 PLC + PLC2x(CIT(10 mg) + PLC)/d Group Placebo PLC + PLC Informed Consent x NECT*x x x x x x x x x Vital Signs/Weight x x x x x x x x x LAB x x ECG xPhys Exam x x Alc/Drugs Screen x CGI-S x x x x x x x x x ****Q-LES-Q x xx x x x x x EXTENSION PHASE*** FOLLOW-UP PHASE VISITS V10 V11 V12 V13V14 V15 V16 V17 V18 V19 DAY/WEEK/MONTH W 10 W 12 W 16 W 20 W 24 M 8 M 10M 12 W 1 W 2 TREATMENTGROUP Group Pip - Active/Day 4 PLC + PLC PLC + PLCGroup Pip - Active/Day 0 PLC + PLC PLC + PLC Group Plc - Active/Day 0PLC + PLC PLC + PLC Group Placebo PLC + PLC PLC + PLC Informed ConsentNECT* x x x x x x x x x x Vital Signs/Weight x x x x x x x x x x LAB x xx x ECG x x x x Phys Exam x x x x Alc/Drugs Screen x x x x CGI-S x x x xx x x x x x ****Q-LES-Q x x x x x x x x x *Neuronal E-Clinical Trial =Vesalius Expert Development for this Trial which includes the bottom-upmeasurement of: In- and exclusioncriteria Functional status evaluationMedical history (Pre-)treatment signs & symptoms DSM-IV rules fordiagnosis & efficacy Rating Scales: HDRS-28, MADRS, HAMA Medicalresource utulisation Pre-trial & Concomittant medication Drugadministration (Serious) Adverse events Admission to the acute andextension phase of treatment Right flow of the trial **Entering AcutePhase: only NON-placebo responders as defined by the DSM-IV criteria ofefficacy ***Entering Extension Phase: only remittors as defined by theDSM-IV criteria of efficacy ****Q-LES-Q: Quality of Life, Enjoyment andSatisfaction Questionnaire

TABLE 4 DAY TREATMENTGROUP minus D 7 D 0 =>D 4 Placebo (PLC) PLC + PLC2x(PLC + PLC) 2x(PLC + PC) PIP - Active/Day 4 PLC + PLC 2x(PLC + PIP (4mg))/d 2x(CIT (10 mg) + PIP (4 mg))/d PIP - Active/Day 0 PLC + PLC2x(CIT (10 mg) + PIP (4 mg))/d 2x(CIT (10 mg) + PIP (4 mg))/d PLC -Active/Day 0 PLC + PLC 2x(CIT (10 mg) + PLC)/d 2x(CIT (10 mg) + PLC)/d

TABLE 5 *SEE GLOSSARY HEREUNDER MEDICAMENT 92 91 90 85 60 62 61 82 51 34 5 6 7 8 9 COMBO's 5-HT2A/D4*-Antagonist + CNS Compound MONO MAO-A* &5-HT2A/D4* MAO-B* 5-HTA1* 5-HT1B* 5-HT2B* 5-HT2C* 5HT3* 5HT6* MEDICALAntag- reuptake 5-HTA1* antag- antag- antag- antag- antag- antag-INDICATION onist SSRI* SNRI* SNDRI* SDRI* NARI* NDRI* NaSSA* RIMA*inhibitor agonist onist onist onist onist onist onist DISORDER X X X X XX X X X X X X X X X X X WITH AN UNDERLYING EMOTION DYSREGU- LATIONNON-COGNI- TIVE MENTAL DISORDERS (excl. Pain Disorder) mood X X X X X XX X X X X X X disorders anxiety X X X X X X X X X X X X X X disorderspsychotic disorders eating X X X X X X X X X X X X disorderspremenstrual X X X X X X X X X X X X syndrome somatoform X X X X X X X XX X X X disorders (excluding Pain Disorder) factitious X X X X X X X X XX X X disorders dissociative X X X X X X X X X X X X disorders sexualand X X X X X X X X gender identity disorders sleep X X X X X X X X X Xdisorders adjustment X X X X X X X X X X X X X X disorders impulsecontrol X X X X X X X X X X X X disorders pervasive X developmentdisorders attention- X X X X X X X deficit disorders disruptive Xbehaviour disorders substance- X X X X X X X X X X X related disorderspersonality X X X X X X X X X X X X X X disorders psychological Xfactors affecting medical conditions malingering X antisocial X X X X XX X X X X X X X X behaviour bereavement X X X X X X X X X X X X X Xoccupational X X X X X X X X X X X X X X problem identity X problemphase of X life problem academic X problem problems X X X X X X X X X XX X X X related to abuse or neglect PAIN X X X X X X X X X X X DISORDERCOGNITIVE DISORDERS delirium X X X Alzheimer X X X X Disease substance-X X X X induced persisting dementia vascular X X X X dementia dementiadue to X X X X HIV disease dementia due to X X X X head trauma dementiadue to X X X X Parkinson Disease dementia due to X X X X HuntingtonDisease dementia due to X X X X Pick Disease dementia due to X X X XCreutzfeldt- Jacob Disease amnestic X X X X X disorders due to a generalmedical condition substance- X X X X X induced persisting amnesticdisorder mild cognitive X X X X X impairment disorder other cognitive XX X X X disorders PARKINSON DISEASE MEDICAMENT 2 1 44 93 69 95 76 55 5641 26 40 54 19 14 COMBO's 5-HT2A/D4*-Antagonist + CNS compound MONO5-HT1* Sub- MCH*- beta-3- 5-HT2A/D4* auto- 5-HT* Increase brain stance PNK2* tachykinin receptor GR* CRF-1* GPCR* MC4* adreno- alpha 2 MEDICALAntag- receptor reuptake concentrations Antag- Antag- antag- antag- MT*antag- antag- modu- antag- ceptor antag- INDICATION onist agonistenhancer of 5-HT* onist onist onist peptide onist agonist onist onistlator onists agonist onists DISORDER X X X X X X X X X X X X X X X XWITH AN UNDERLYING EMOTION DYSREGU- LATION NON-COGNI- TIVE MENTALDISORDERS (excl. Pain Disorder) mood X X X X X X X X X X X X X X Xdisorders anxiety X X X X X X X X X X X X X X X X disorders psychotic Xdisorders eating X X X X X X X X X X X X X X X X disorders premenstrualX X X X X X X X X X X X X X X X syndrome somatoform X X X X X X X X X XX X X X X X disorders (excluding Pain Disorder) factitious X X X X X X XX X X X X X X X X disorders dissociative X X X X X X X X X X X X X X X Xdisorders sexual and X X X X X X X X X X X X X X X X gender identitydisorders sleep X X X X X X X X X X X X X X X X disorders adjustment X XX X X X X X X X X X X X X X disorders impulse control X X X X X X X X XX X X X X X X disorders pervasive X X development disorders attention- Xdeficit disorders disruptive X X behaviour disorders substance- X X X XX X X X X X X X X X X X related disorders personality X X X X X X X X XX X X X X X X disorders psychological X factors affecting medicalconditions malingering X antisocial X X X behaviour bereavement X X X XX X X X X X X X X X X X occupational X X X X X X X X X X X X X X X Xproblem identity X problem phase of X life problem academic X problemproblems X X X X X X X X X X X X X X X X related to abuse or neglectPAIN X X X X X X X X X X X X X X X DISORDER COGNITIVE DISORDERS deliriumAlzheimer X Disease substance- X induced persisting dementia vascular Xdementia dementia due to X HIV disease dementia due to X head traumadementia due to X Parkinson Disease dementia due to X Huntington Diseasedementia due to X Pick Disease dementia due to X Creutzfeldt- JacobDisease amnestic X X disorders due to a general medical conditionsubstance- X X induced persisting amnestic disorder mild cognitive X Ximpairment disorder other cognitive X X disorders PARKINSON DISEASEMEDICAMENT 13 86 97 12 71 75 98 83 78 88 39 57 67 35 COMBO's5-HT2A/D4*-Antagonist + CNS compound MONO X Voltage-gated Glutamatenicotinic 5-HT2A/D4* alpha 1 Second V1B* Adrenergic NMDA* calciumchannel SCT-11* Prodrug sigma receptor acetylcholine GABA-A* MEDICALAntag- antag- messenger antag- transmitter antag- PDE4* alpha(2)deltasubunit modu- of receptor antag- mGluR* receptor modu- INDICATION onistonists beta agonist onist releaser onist inhibitor modulator lationuridine agonist onist agonist antagonist lator DISORDER X X X X X X X XX X X X X X X WITH AN UNDERLYING EMOTION DYSREGU- LATION NON-COGNI- TIVEMENTAL DISORDERS (excl. Pain Disorder) mood X X X X X X X X X Xdisorders anxiety X X X X X X X X X X X X X X X disorders psychoticdisorders eating X X X X X X X X X X X X disorders premenstrual X X X XX X X X X X X X syndrome somatoform X X X X X X X X X X X X X X Xdisorders (excluding Pain Disorder) factitious X X X X X X X X X X X X XX X disorders dissociative X X X X X X X X X X X X X X X disorderssexual and X X X X X X X X X X X X gender identity disorders sleep X X XX X X X X X disorders adjustment X X X X X X X X X X X X X X X disordersimpulse control X X X X X X X X X X X X X X X disorders pervasive Xdevelopment disorders attention- X X deficit disorders disruptive Xbehaviour disorders substance- X X X X X X related disorders personalityX X X X X X X X X X X X X X X disorders psychological X factorsaffecting medical conditions malingering X antisocial X behaviourbereavement X X X X X X X X X X X X X X X occupational X X X X X X X X XX X X X X X problem identity X problem phase of X life problem academicX problem problems X X X X X X X X X X X X X X X related to abuse orneglect PAIN X X X X X X X X X X X X X DISORDER COGNITIVE DISORDERSdelirium Alzheimer X X Disease substance- X X induced persistingdementia vascular X X dementia dementia due to X X HIV disease dementiadue to X X head trauma dementia due to X X Parkinson Disease dementiadue to X X Huntington Disease dementia due to X X Pick Disease dementiadue to X X Creutzfeldt- Jacob Disease amnestic X X X disorders due to ageneral medical condition substance- X X X induced persisting amnesticdisorder mild cognitive X X X impairment disorder other cognitive X X Xdisorders PARKINSON DISEASE MEDICAMENT 36 99 74 77 89 94 87 84 28 29 7065 21 COMBO's 5-HT2A/D4*-Antagonist + CNS compound MONO Phospholipasesigma neurotensin 5-HT2A/D4* GABA-B* A2 inhibtor receptor Secretin D2*-D3*- NK3* receptor CB1* MEDICAL Antag- antag- opoid with caspase antag-pancreatic antag- antag- antag- antag- antag- INDICATION onist onistvomeropherin agonist inhibitor activity onist sulfonamide hormone SDA*onist onist onist onist onist DISORDER X X X X X X X X X X X X X X WITHAN UNDERLYING EMOTION DYSREGU- LATION NON-COGNI- TIVE MENTAL DISORDERS(excl. Pain Disorder) mood X X X X X X X X disorders anxiety X X X X X XX X X X X disorders psychotic X X X X X X X X X X X disorders eating X XX X X X disorders premenstrual X X X X X X syndrome somatoform X X X X XX X X X X X X X X disorders (excluding Pain Disorder) factitious X X X XX X X X X X X X X X disorders dissociative X X X X X X X X X X X X X Xdisorders sexual and X X X X X X gender identity disorders sleep X X X XX X X X X X X X X X disorders adjustment X X X X X X X X X X X X X Xdisorders impulse control X X X X X X X X X X X X X X disorderspervasive X X X X X X X X X X X development disorders attention- Xdeficit disorders disruptive X X X X X X X X X X X behaviour disorderssubstance- X X X X X X X X X X X X related disorders personality X X X XX X X X X X X X X X disorders psychological X X X X X X X X X factorsaffecting medical conditions malingering X X X X X X X X X antisocial XX X X X X X X X behaviour bereavement X X X X X X X X X X X X X Xoccupational X X X X X X X X X X X X X X problem identity X X X X X X XX X problem phase of X life problem academic X problem problems X X X XX X X X X X X X X X related to abuse or neglect PAIN X X X X X X X X X XDISORDER COGNITIVE DISORDERS delirium X X X X X X X X X X AlzheimerDisease substance- induced persisting dementia vascular dementiadementia due to HIV disease dementia due to head trauma dementia due toParkinson Disease dementia due to Huntington Disease dementia due to XPick Disease dementia due to X Creutzfeldt- Jacob Disease amnestic Xdisorders due to a general medical condition substance- X inducedpersisting amnestic disorder mild cognitive impairment disorder othercognitive disorders PARKINSON X DISEASE MEDICAMENT 15 34 18 79 81 16 7327 38 50 43 10 23 66 58 COMBO's 5-HT2A/D4*-Antagonist + CNS compoundMONO gluco- acetyl- 5-HT2A/D4* AMPA* androgen prosta- opioid D1*corticoid MAO* Hormonal cholin- choline mimics the MEDICAL Antag-receptor GABA-A* receptor glandin Psycho- amphet- receptor receptorsynthesis reuptake Sub- estrase uptake effects of INDICATION onistmediator agonist modulator E1 stimulant amine inhibitor agonistinhibitor inhibitor stance inhibitor enhancer NGF* NGF* DISORDER X X X XX X X X X X X X X X X X WITH AN UNDERLYING EMOTION DYSREGU- LATIONNON-COGNI- TIVE MENTAL DISORDERS (excl. Pain Disorder) mood X disordersanxiety X X disorders psychotic X disorders eating X X disorderspremenstrual X X X syndrome somatoform X X disorders (excluding PainDisorder) factitious X X disorders dissociative X X disorders sexual andX X X X gender identity disorders sleep X X X X disorders adjustment X Xdisorders impulse control X X disorders pervasive X X developmentdisorders attention- X X X X deficit disorders disruptive X X behaviourdisorders substance- X X X X X X X related disorders personality X Xdisorders psychological X X factors affecting medical conditionsmalingering X X antisocial X X behaviour bereavement X X occupational XX problem identity X X problem phase of X life problem academic Xproblem problems X X related to abuse or neglect PAIN X DISORDERCOGNITIVE DISORDERS delirium X Alzheimer X X X X X Disease substance- XX X X X induced persisting dementia vascular X X X X X dementia dementiadue to X X X X X HIV disease dementia due to X X X X X head traumadementia due to X X X X X Parkinson Disease dementia due to X X X X XHuntington Disease dementia due to X X X X X Pick Disease dementia dueto X X X X X Creutzfeldt- Jacob Disease amnestic X X X X X X disordersdue to a general medical condition substance- X X X X X X inducedpersisting amnestic disorder mild cognitive X X X X X X impairmentdisorder other cognitive X X X X X X disorders PARKINSON X X X X DISEASEMEDICAMENT 59 17 80 45 68 33 32 42 20 48 31 100 52 30 COMBO's5-HT2A/D4*-Antagonist + CNS compound MONO Muscannic protect 5-HT2A/D4*receptor amyloid dopaminergic increasing nicotinic H3* Calcium DA*MEDICAL Antag- partial aggregation and cholinergic insulin receptorGABA* ERK* Antag- Channel Dopamine Dopamine MAO-B*- uptake INDICATIONonist agonist inhibitor neurons sensitivity agonists agonist activationonist Modulator Levodopa agonist releaser inhibitor inhibitor DISORDER XX X X X X X X X X X X X X X WITH AN UNDERLYING EMOTION DYSREGU- LATIONNON-COGNI- TIVE MENTAL DISORDERS (excl. Pain Disorder) mood X X Xdisorders anxiety X X X X disorders psychotic disorders eating X X X Xdisorders premenstrual X X X X syndrome somatoform X X X X disorders(excluding Pain Disorder) factitious X X X X disorders dissociative X XX X disorders sexual and X gender identity disorders sleep X disordersadjustment X X X X disorders impulse control X X X X disorders pervasiveX development disorders attention- X X X X deficit disorders disruptiveX behaviour disorders substance- X X X X X related disorders personalityX X X X disorders psychological X factors affecting medical conditionsmalingering X antisocial X behaviour bereavement X occupational Xproblem identity X problem phase of X life problem academic X problemproblems X X X X related to abuse or neglect PAIN X X X DISORDERCOGNITIVE DISORDERS delirium Alzheimer X X X X X X X X X Diseasesubstance- X X X X X X X X X induced persisting dementia vascular X X XX X X X X X dementia dementia due to X X X X X X X X X HIV diseasedementia due to X X X X X X X X X head trauma dementia due to X X X X XX X X X Parkinson Disease dementia due to X X X X X X X X X HuntingtonDisease dementia due to X X X X X X X X X Pick Disease dementia due to XX X X X X X X X Creutzfeldt- Jacob Disease amnestic X X X X X X X X X Xdisorders due to a general medical condition substance- X X X X X X X XX X induced persisting amnestic disorder mild cognitive X X X X X X X XX X impairment disorder other cognitive X X X X X X X X X X disordersPARKINSON X X X X X X X DISEASE MEDICAMENT 49 63 64 37 46 11 24 25 72 4722 96 53 COMBO's 5-HT2A/D4*-Antagonist + CNS compound Glial-cellinhibitor of adenosine COX*- interleukin-1 MAO-B* 5-HT2A 5-HT2A MONOLipid- neuro- Line Derived the mixed A2a inhibiting beta cathepsin re-Antagonist + Antag- 5-HT2A/D4* DNA immuno- neuro- Neuro- lineagereceptor COX2* nitric (nitric converting K uptake D4-Antag- onist +MEDICAL Antag- Com- philin modu- trophic kinase antag- inhib- oxideoxide) enzyme inhib- un- inhibi- onist + CNS D4-Antag- INDICATION onistplex ligands lator Factor family onist itor donators NSAID* inhibitoritor known tion Compound onist DISORDER X X X X X X X X X X X X X X WITHAN UNDERLYING EMOTION DYSREGU- LATION NON-COGNI- TIVE MENTAL DISORDERS(excl. Pain Disorder) mood X disorders anxiety X X disorders psychotic Xdisorders eating X X disorders premenstrual X X syndrome somatoform X Xdisorders (excluding Pain Disorder) factitious X X disordersdissociative X X disorders sexual and X X gender identity disorderssleep X X disorders adjustment X X disorders impulse control X Xdisorders pervasive X X development disorders attention- X X deficitdisorders disruptive X X behaviour disorders substance- X X relateddisorders personality X X disorders psychological X X factors affectingmedical conditions malingering X X antisocial X X behaviour bereavementX X occupational X X problem identity X X problem phase of X X lifeproblem academic X X problem problems X X related to abuse or neglectPAIN X X X X X X DISORDER COGNITIVE DISORDERS delirium X Alzheimer X XDisease substance- X induced persisting dementia vascular X dementiadementia due to X HIV disease dementia due to X head trauma dementia dueto X Parkinson Disease dementia due to X Huntington Disease dementia dueto X Pick Disease dementia due to X Creutzfeldt- Jacob Disease amnesticX X disorders due to a general medical condition substance- X X inducedpersisting amnestic disorder mild cognitive X X impairment disorderother cognitive X X disorders PARKINSON X X X X X X X X DISEASE GLOSSARY5-HT = serotonin 5-HT1 = serotonin 1 receptor 5-HT1A = serotonin 1Areceptor 5-HT1B = serotonin 1B receptor 5-HT2A/D4 = serotonin 2A endopamine D4 receptor 5-HT2B = serotonin 2B receptor 5-HT2C = serotonin2C receptor 5HT3 = serotonin 3 receptor 5HT6 = serotonin 6 receptor AMPA= alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate CB1 = cannabioidreceptor 1 CINODs = COX-inhibiting nitric oxide donators COX =cyclooxigenase COX-2 = cyclooxigenase 2 CRF-1 = Corticotropin-ReleasingFactor Receptor 1 D1 = Dopamine 1 D2 = Dopamine 2 D2 = Dopamine 3 DA =Dopamine ERK = extracellular signal-related kinase GABA =gamma-aminobutyric acid GABA-A = gamma-aminobutyric acid A receptorGABA-B = gamma-aminobutyric acid B receptor GPCR = G-Protein-CoupledReceptor GR = glucocorticoid receptor H3 = histamine H3 receptor MAO =mono-amine oxydase MAO-A = mono-amine oxydase A MAO-B = mono-amineoxydase B MC4 = melanocortin-4 receptor MCH = Melanin concentratinghormone MgluR = metabotropic glutamate receptor MT = melatonin receptorNARI = selective nor-adrenaline re-uptake inhibitor NaSSA =noradrenergic/specific serotonergic antidepressant NDRI = selectivenor-adrenaline and dopamine re-uptake inhibitor NGF = Nerve GrowthFactor NGF = nerve growth factor NK1 = neurokinin 1 receptor NK2 =neurokinin 2 receptor NK3 = neurokinin 3 receptor NMDA =N-Methyl-D-aspartate NSAID = Non-steroidal anti-inflammatory drugs PDE4= phosphodiesterase-4 RIMA = reversible inhibitor of mono-amine oxydaseA SCT-11 = G protein-coupled receptor SDA = Serotonin/DopamineAntagonist SDRI = selective serotonin and dopamine reuptake inhibitorSNDRI = selective serotonin, nor-adrenaline and dopamine reuptakeinhibitor SNRI = selective serotonin and nor-adrenaline reuptakeinhibitor SSRI = selective serotonin reuptake inhibitor V1B =vasopressin 1B receptor

TABLE 6 nr. PH. PHARMACOLOGICAL MAIN DOSE PROF. PROFILE INDICATIONSCOMPOUND RANGE COMPANY PHARMAC. GROUP (see overview hereunder)Monoaminergic 1 5-HT reuptake enhancer Depression/Anxiety Tianeptine 25to 50 mg daily Servier Transmitter Systems Monoaminergic 2 5-HT1autoreceptor agonist. Depression/Anxiety SUNEPITRON unknown PfizerTransmitter Systems Monoaminergic 3 5HT1A agonist Anxiety MN-305MediciNova Transmitter Systems 5-HT1A agonist Depression/AnxietyBuspirone Bristol-Myers Squibb 5-HT1A agonist Depression bupropion(controlled-release 150 mg to 450 mg GlaxoSmithKline formulation,once-day 5-HT1A agonist Depression gepirone 20 mg to 60 mg Organon daily5-HT1A agonist Alzheimer's Disease xaliproden 1 to 2 mg dailySanofi-Synthelabo 5-HT1A agonist Depression/Anxiety Flesinoxan unknownSolvay 5-HT1A agonist Anxiety lesopitron Esteve 5-HT1A agonistDepression VPI-013 (also known Vela. Otsuka as OPC-14523) 5-HT1A agonistDepression/Anxiety metanospirone ? 5-HT1A agonist Depression/Anxiety EMD68843 EMD Pharmaceuticals 5-HT1A agonist Depression/Anxiety alnespironeServier 5-HT1A agonist Depression/Anxiety tandospirone Sumitomo 5-HT1Aagonist Depression/Anxiety zalospirone Weyth 5-HT1A agonist Parkinson'sDisease sarizotan unknown EMD Pharmaceuticals 5-HT1A agonist ADHDPRX-00023 Predix 5-HT1A agonist Anxiety PRX-00023 Predix Monoaminergic 45-HT1A antagonist Depression robalzotan unknown AstraZeneca TransmitterSystems tartrate hydrate 5-HT1A antagonist Depression NAD299 AstraZenecaMonoaminergic 5 5-HT1B antagonist Depression/Anxiety AR-A2 AstraZenecaTransmitter Systems 5-HT1B antagonist Depression/Anxiety elzasonanunknown Pfizer 5-HT1B antagonist Depression/Anxiety A2D1134 AstraZenecaMonoaminergic 6 5-HT2B antagonist Depression/Anxiety Agomelatine 25 to50 mg daily Servier Transmitter Systems Monoaminergic 7 5-HT2Cantagonist Depression/Anxiety Agomelatine 25 to 50 mg daily ServierTransmitter Systems 5-HT2C antagonist Depression/Anxiety SB 243213GlaxoSmithKline Monoaminergic 8 5-HT3 antagonist Cocaine Dependenceondansetron 8 to 32 mg daily National Institute Transmitter Systems onDrug Abuse Monoaminergic 9 5-HT6 antagonist Alzheimer's DiseaseSB-271046 GlaxoSmithKline Transmitter Systems 5-HT6 antagonistAlzheimer's Disease 271046 GlaxoSmithKline 5-HT6 antagonist Alzheimer'sDisease 742457 GlaxoSmithKline Excitatory Amino 10 acetylcholinesteraseinhibitor Alzheimer's Disease dichlorvos Bayer Acid Systemacetylcholinesterase inhibitor Alzheimer's Disease metritonate Bayeracetylcholinesterase inhibitor Alzheimer's Disease physostigmineLundbeck/Forest Laboratories acetylcholinesterase inhibitor Alzheimer'sDisease rivastigmine Novartis Pharmaceuticals acetylcholinesteraseinhibitor Alzheimer's Disease lacrine Parke Davis acetylcholinesteraseinhibitor Alzheimer's Disease donezepil Pfizer acetylcholinesteraseinhibitor Alzheimer's Disease galantamine (extended 6 to 24 mg dailyJohnson & Johnson release formulation) Pharmaceuticalacetylcholinesterase inhibitor Alzheimer's Disease phenserine tartrate20 to 30 mg daily Axonyx acetylcholinesterase inhibitor Alzheimer'sDisease huperzine A Interneuron acetylcholinesterase inhibitorAlzheimer's Disease rivastigmine tartrate 3 to 12 mg daily NovartisPharmaceuticals acetylcholinesterase inhibitor Alzheimer's Diseaseanseculin hydrochloride Schwabe Adenosine Transmitter 11 adenosine A2areceptor antagonist Parkinson's Disease KW-6002 40 to 80 mg daily KyowaPharmaceutical System Monoaminergic 12 Adrenergic transmitter releaserDepression Piporazole 30 to 60 mg daily Sarget Transmitter SystemsMonoaminergic 13 alpha 1 adrenoreceptor antagonist Depression/AnxietyFlesinoxan unknown Solvay Transmitter Systems alpha 1 adrenoreceptorantagonist Parkinson's Disease SDZ NVI 085 unknown Sandoz Monoaminergic14 alpha 2 adrenoreceptor antagonist. Depression Mirtazapine OrganonTransmitter Systems alpha 2 adrenoreceptor antagonist. DepressionIdazoxan 20 mg daily Reckitt and Colman alpha 2 adrenoreceptorantagonist. Schizophrenia Idazoxan 20 mg daily Reckitt and Colman alpha2 adrenoreceptor antagonist. Depression/Anxiety SUNEPITRON unknownPfizer alpha 2 adrenoreceptor antagonist Depression fluparoxanGlaxoSmithKline alpha 2 adrenoreceptor antagonist. Depression/Anxiety(R)-A 75200 Abbott alpha 2 adrenoreceptor antagonist. Depression/AnxietyA 75200 Abbott alpha 2 adrenoreceptor antagonist Insomnia MirtazepineOrganon alpha 2 adrenoreceptor antagonist. Depression UK-14304 ?Excitatory Amino 15 AMPA receptor mediator Alzheimer's Disease ampakineCX-516 Cortex Pharmaceuticals/ Acid System Organon AMPA receptormediator Alzheimer's Disease ampakine CX-717 unknown CortexPharmaceuticals/ Organon AMPA receptor mediator Schizophrenia ampakineORG unknown Organon 24448/CX-619 AMPA receptor mediator DepressionAmpakine CX-691 unknown Cortex Pharmaceuticals/ Organon Excitatory Amino16 amphetamine ADHD methylphenidate Noven Pharmaceuticals Acid Systemtransdermal system Pathogenic Mechanisms of 17 amyloidaggregation-inhibitor Alzheimer's Disease Alzhemed 200 to 300 mgNeurochem Dementia of the daily Alzheimer Type amyloidaggregation-inhibitor Alzheimer's Disease APAN Praecis PharmaceuticalEndocrine System 18 androgen receptor modulator Female SexualDysfunction LGD2226 Ligand Pharmaceuticals Monoaminergic 19 beta 3adrenoreceptor agonist Depression/Anxiety SR 58611 unknownSanofi-Synthelabo Transmitter Systems Other/Unknown 20 Calcium ChannelModulator Alzheimer's Disease MEM 1003 Memory Pharmaceuticals CalciumChannel Modulator Parkinson's Disease safinamide Newron PharmaceuticalsMonoaminergic 21 cannabioid receptor antagonist Schizophrenia SR 141716unknown Sanofi-Synthelabo Transmitter Systems Enzymatic System 22cathepsin K inhibitor Pain 462795 GlaxoSmithKline Excitatory Amino 23choline uptake enhancer Alzheimer's Disease MKC-231 20 to 160 mg dailyMitsubishi Pharma Acid System Enzymatic System 24 COX-2 inhibitor Paincelecoxib Pfizer COX-2 inhibitor Pain rofecoxib Pfizer COX-2 inhibitorPain valdecoxib Pfizer COX-2 inhibitor Pain etoricoxib 20 to 120 mgdaily Merck COX-2 inhibitor Pain COX 189 100 to 800 mg Novartis dailyPharmaceuticals COX-2 inhibitor Pain parecoxib 20 to 80 mg daily PfizerCOX-2 inhibitor Pain ABT-963 Abbott Enzymatic System 25 COX-inhibitingnitric Pain AZD3582 375 mg daily AstraZeneca oxide donators (CINODs)COX-inhibiting nitric Pain AZD4717 AstraZeneca oxide donators (CINODs)Endocrine System 26 CRF1 antagonist Depression AAG 561 unknown NovartisPharmaceuticals CRF1 antagonist Depression/Anxiety R121919 5 to 8O mgdaily Johnson & Johnson Pharmaceutical CRF1 antagonistDepression/Anxiety elzasonan unknown Pfizer CRF1 antagonist Depression723620 GlaxoSmithKline CRF1 antagonist Depression/Anxiety NBI-34041Neurocrine Biosciences CRF1 antagonist Depression/Anxiety CP-154-526Pfizer CRF1 antagonist Depression/Anxiety CP-448, 187 PfizerMonoaminergic 27 D1 receotor agonist Cocaine Dependence DAS-431 unknownDrug Abuse Sciences Transmitter Systems Monoaminergic 28 D2 receptorantagonist Schizophrenia amisulpride off patent Transmitter Systems D2receptor antagonist Schizophrenia bifeprunox unknown SolvayMonoaminergic 29 D3 antagonist Cocaine Dependence BSF-201540 ?Transmitter Systems D3 antagonist Cocaine Dependence PD 58491 ? D3antagonist Parkinson's Disease BSF-201640 ? D3 antagonist Parkinson'sDisease PD 58491 ? D3 antagonist schizophrenia BSF-201640 ? D3antagonist schizophrenia PD 58491 ? Monoaminergic 30 DA uptake inhibitorCocaine Dependence GBR 12909 National Institute Transmitter Systems onDrug Abuse DA uptake inhibitor Parkinson's Disease safinamide NewronPharmaceuticals Monoaminergic 31 dopamine agonist Parkinson's Diseasesumanirole 4 to 16 mg daily Pfizer Transmitter Systems dopamine agonistParkinson's Disease, rotigotine CDS (Once-a-Day 4 5 to 13 5 mg SchwarzPharma Early and Advanced Transdermal Patch) daily dopamine agonistParkinson's Disease ropinirole HCL (controlled- 0 75 to 24 mgGlaxoSmithKline Restless Leg release formulation) daily dopamine agonistCocaine Dependence cabergoline Abbott dopamine agonist Parkinson'sDisease sarizotan EMD Pharmaceuticals dopamine agonist Parkinson'sDisease pramipexole Pfizer dopamine agonist Parkinson's Disease DAB452Weyth dopamine agonist Parkinson's Disease, SLV 308 Solvay Comorbiddopamine agonist Depression/Anxiety S32504 Servier dopamine agonistParkinson's Disease S32504 Servier dopamine agonist Parkinson's Diseasebromocriptine Novartis Pharmaceuticals dopamine agonist Parkinson'sDisease alaptide VU-Res Inst. Pharm Biochem (CZ) dopamine agonistParkinson's Disease cabergoline 1 to 4 mg daily Pharmacia dopamineagonist Parkinson's Disease lisuride 0.6 to 5 mg daily Shering dopamineagonist Parkinson's Disease pergolide 2 to 3 mg daily Lilly EnzymaticSystem 32 ERK activation Alzheimer's Disease CPI-1189 50 to 100 mg dailyCentaur Pharmaceuticals Inhibitory Amino 33 GABA agonist Alzheimer'sDisease Nefiracetam unknown DaiiChi Seiyaku, Acid System JPN Nattermann,BRD Inhibitory Amino 34 GABA-A agonist Insomnia Gaboxadol 5 to 20 mgdaily Lundbeck Acid System Inhibitory Amino 35 GABA-A modulator Insomniaeszopiclone 2 to 3 mg daily Sepracor Acid System GABA-A modulatorInsomnia Zolpidem MR sustained- 10 to 20 mg daily Sanofi-Synthelaborelease version GABA-A modulator Insomnia indiplon 10 to 20 mg dailyDOV/Neurocone GABA-A modulator Anxiety Pagoclone 30 mg daily IndevusGABA-A modulator Insomnia Zaleplon extended-release 10 mg daily KingPharmaceuticals GABA-A modulator Anxiety SEP174559 Sepracor GABA-Amodulator Anxiety, muscular SL 65 1498 Sanofi-Synthelabo contractionsGABA-A modulator Insomnia CP-730,330 (NGD 96-3) Neurogen GABA-Amodulator Insomnia NGD 96-3 Neurogen GABA-A modulator Anxiety Ocinaplon10 to 60 mg daily DOV Inhibitory Amino 36 GABA-B antagonistDepression/Anxiety AVE 7398 unknown Aventis Acid System NeurotrophicSystem 37 Glial-cell Line Derived Parkinson's Disease GDNF 15 mg dailyAmgen Neurotrophic Factor Endocrine System 38 glucocorticoid synthesisCocaine Dependence metyrapone National Institute inhibitor on Drug AbuseExcitatory Amino 39 Glutamate receptor Anxiety LY354740 Eli Lilly AcidSystem antagonist Other/Unknown 40 GPCR modulator Depression/AnxietyR1204 Roche Endocrine System 41 GR antagonist depression (psychotic)Mifepristone 600 to 1200 mg Corcept daily GR antagonist Depression ORG34517/34850 unknown Organon Monoaminergic 42 H3 Antagonist Alzheimer'sDisease ABT-239 Abbott Transmitter Systems H3 Antagonist Alzheimer'sDisease ABT-834 Abbott Endocrine System 43 Hormonal SubstancePremenstrual Syndrome drospirenone 3 mg/ethinyl see formula BerlexLaboratories estradiol 0 020 mg tablets Hormonal Substance Female SexualDysfunction female testosterone patch Procter & Gamble PharmaceuticalsHormonal Substance Premenstrual Syndrome synthetic conjugated 0 3 mgdaily Barr Laboratories estrogen A Hormonal Substance Female SexualDysfunction testosterone gel BioSante Pharmaceuticals Hormonal SubstanceFemale Sexual Dysfunction testosterone gel Cellegy PharmaceuticalsHormonal Substance Female Sexual Dysfunction methyltestosterone NovenPharmaceuticals Hormonal Substance Female Sexual Dysfunctionestrogens/methyltestosterone Solvay Hormonal Substance Female SexualDysfunction testosterone transdermal spray VIVUS Monoaminergic 44Increase brain Depression/Anxiety KW 6055 ? Transmitter Systemsconcentrations of 5-HT Increase brain Depression/Anxiety PMD 145 ?concentrations of 5-HT Increase brain Depression/Anxiety SP 186 ?concentrations of 5-HT Increase brain Depression/Anxiety Triptotosine ?concentrations of 5-HT Endocrine System 45 increasing insulinAlzheimer's Disease rosiglitazone maleate GlaxoSmithKline sensitivityEnzymatic System 46 inibitor of the mixed Parkinson's Disease CEP-1347unknown Cephalon lineage kinase family Enzymatic System 47 interleukin-1beta Pain pralnacasan Aventis converting enzyme inhibitor Monoaminergic48 levodopa/decarboxylase inhibitor Parkinson's Diseaselevadopa/carbidopa 250 to 600/25 Merck Transmitter Systems to 150 mgdaily 48 levodopa/decarboxylase inhibitor Parkinson's Diseaselevadopa/benserazide 100 to 600/25 Roche to 150 mg daily 48levodopa/decarboxylase inhibitor Parkinson's Diseaseetilevodopa/carbidopa unknown TEVA Pharmaceuticals USA 48levodopa/decarboxylase inhibitor Parkinson's Diseaseetilevodopa/benserazide unknown TEVA Pharmaceuticals USA Other/Unknown49 Lipid-DNA Complex Parkinson's Disease GR213487B ValentisMonoaminergic 50 MAO reuptake inhibitor Cocaine Dependence NS 2359National Institute Transmitter Systems on Drug Abuse Monoaminergic MAOreuptake inhibitor ADHD NS 2359 NeuroSearch Transmitter SystemsMonoaminergic 51 MAO-A & MAO-B reuptake inhibitor ADHD SPD473 unknownShire Pharmaceutical Transmitter Systems Development Monoaminergic 52MAO-B inhibitor Depression EmSam (transdermal Somerset TransmitterSystems selegiline) MAO-B inhibitor Parkinson's Disease selegiline 5 to10 mg daily Amarin Pharmaceuticals MAO-B inhibitor Parkinson's Diseaserasagiline (TVP-1012) 1 to 2 mg daily TEVA Pharmaceuticals USA/LundbeckMonoaminergic 53 MAO-B re-uptake inhibition Parkinson's Diseasesafinamide Newron Pharmaceuticals Transmitter Systems Peptidergic 54 MC4antagonists Depression/Anxiety MCL0129 Taisho Transmitter SystemPeptidergic 55 MCH receptor antagonist Depression SNAP-7941 SynapticTransmitter System Endocrine System 56 melatonin receptor agonistInsomnia Ramelteon unknown Takeda melatonin receptor agonistDepression/Anxiety Agomelatine 25 to 50 mg daily Servier ExcitatoryAmino 57 MgluR agonist Anxiety PRE703 Prescient Acid System NeurotrophicSystem 58 mimics the effects of NGF Alzheimer's Disease Xaliproden 1 to2 mg daily Sanofi-Synthelabo Excitatory Amino 59 Muscarinic receptorAlzheimer (JP)/Sjogren Sevimeline unknown DaiiChi Seiyaku Acid Systempartial agonist (US) Monoaminergic 60 NARI Depression/Anxiety reboxetinePfizer Transmitter Systems NARI ADHD atomoxetine hydrochloride 40 to 100mg daily Eli Lilly NARI Depression reboxetine 6 to 12 mg daily PfizerMonoaminergic 61 NaSSA Insomnia ORG 4420 unknown Organon TransmitterSystems Monoaminergic 62 NDRI Depression (bipolar disorder) GW353162 20to 60 mg daily GlaxoSmithKline Transmitter Systems Neuroimmunophilin 63neuroimmunophilin ligands Parkinson's Disease GPI 1485 200 to 1000 mgGuilford System daily Pharmaceuticals Adenosine 64 neuromodulatorParkinson's Disease adenosine Schering-Plough Transmitter SystemPeptidergic 65 neurotensin receptor antagonist Schizophrenia SR 48692 9Oto 300 mg daily Sanofi-Synthelabo Transmitter System Neurotrophic System66 NGF (nerve growth factor) Alzheimer's Disease nerve growth factorCeregene (NGF) gene therapy Excitatory Amino 67 nicotinic acetylcholineAnxiety SEP174559 unknown Sepracor Acid System receptor antagonistExcitatory Amino 68 nicotinic receptor agonists Alzheimer's DiseaseABT-089 4 to 40 mg daily Abbott Acid System Peptidergic 69 NK2antagonist Depression/Anxiety saredutant 100 mg daily Sanofi-SynthelaboTransmitter System Peptidergic 70 NK3 antagonist Schizophrenia osanetantSanofi-Synthelabo Transmitter System NK3 antagonist Schizophrenia/IBS/talnetant 5 mg daily GlaxoSmithKline Overactive bladder Excitatory Amino71 NMDA antagonist Anxiety SEP174559 Sepracor Acid System NMDAantagonist Alzheimer's Disease memantine 20 mg daily Lundbeck/ForestLaboratories NMDA antagonist Depression memantine 20 mg dailyLundbeck/Forest Laboratories NMDA antagonist Pain memantine 20 mg dailyLundbeck/Forest Laboratories NMDA antagonist Depression Delucemine NPSEnzymatic System 72 NSAID Pain meloxicam Boehringer-IngelheimPharmaceutical NSAID Pain piroxicam off patent NSAID Alzheimer's DiseaseFlurizan (pure R-enanborner unknown Myriad Genetics form offlurbiprofen) NSAID Pain MX-1094 Medinox Excitatory Amino 73 opoidantagonist Alcohol/Drug Dependence naltrexone depot 192 to 384 mg DrugAbuse Sciences Acid System opoid antagonist Opiate/Alcohol Dependencedepot naltrexone Biotek microcapsules Excitatory Amino 74 opoid agonistAnxiety Siramesine unknown Lundbeck/Forest Acid System opoid agonistCocaine Dependence cyclazocine National Institute on Drug Abuse opoidagonist Schizophrenia E-5842 Esteve Enzymatic System 75 PDE4 inhibitorDepression ND1251 Neuro3d PDE4 inhibitor Alzheimer's disease MEM 1917(R1497) Roche/Memory Pharm PDE4 inhibitor Depression MEM 1917 (R1497)Roche/Memory Pharm Peptidergic 76 peptide Depression INN 00835 18 to 160mg daily Innapharma Transmitter System peptide Autism secretin 0 2 to 04 Repligen mg/kg daily peptide Female Sexual Dysfunction PT-141 PalatinTechnologies peptide Alzheimer's Disease beta-sheet breaker peptideSerono Enzymatic System 77 Phospholipase A2 inhibitor DepressionLAX-101c unknown Laxdale with caspase inhibitor activity PhospholipaseA2 inhibitor Depression (bipolar disorder) LAX-101b Laxdale with caspaseinhibitor activity Phospholipase A2 inhibitor Schizophrenia LAX-101aLaxdale with caspase inhibitor activity Nucleosides 78 Prodrug ofuridine depression (bipolar disorder) RG2133 (triacetyluridine) unknownRepligen Endocrine System 79 prostaglandin E 1 Female Sexual Dysfunctionalprostadil gel 50 to 300 VIVUS microgram/ application Prostaglandin E1Female Sexual Dysfunction alprostadil cream NexMed Neurotrophic System80 protect dopaminergic and Alzheimer's Disease SR 57667 unknownSanofi-Synthelabo cholinergic neurons Excitatory Amino 81Psychostimulant ADHD modafinil 200 to 600 mg Cephalon Acid System dailyPsychostimulant ADHD SPD 503 unknown Shire Pharmaceutical DevelopmentPsychostimulant Hypersomnia r-modafinil Cephalon Psychosomulant CocaineDependence modafinil National Institute on Drug Abuse Monoaminergic 82RIMA Depression/Anxiety moclobemide Roche Transmitter Systems RIMADepression/Anxiety toloxatone Sanofi-Synthelabo RIMA Depression/AnxietyBefloxatone 10 mg daily Sanofi-Synthelabo RIMA Depression caroxazone F I6654 Farmitalia RIMA Depression/Anxiety cimoxatone MD RIMADepression/Anxiety RS 8359 Sankyo Other/Unknown 83 SCT-11 modulationDepression SNEC-2 Synaptic Monoaminergic 84 SDA Schizophrenia quetiapineAstraZeneca Transmitter Systems SDA Schizophrenia aripiprazoleBristol-Myers Squibb SDA Schizophrenia risperidone Johnson & JohnsonPharmaceutical SDA Schizophrenia zotepine Knoll/BASF SDA Schizophreniaolanzapine Lilly SDA Schizophrenia clozapine Novartis PharmaceuticalsSDA Schizophrenia ziprasidone Pfizer SDA Depression (Bipolar olanzapineEli Lilly Maintainence) SDA Schizophrenia perospirone unknown SumitomoSDA Schizophrenia blonanserin unknown Almirall Prodesfama SDAAlzheimer's Disease olanzapine Eli Lilly SDA Alzheimer's Diseasearipiprazole Bristol-Myers Squibb SDA Schizophrenia quetiapine fumarateAstraZeneca (granules) SDA Schizophrenia quetiapine fumarate AstraZeneca(sustained release) SDA Schizophrenia paliperidone 3 to 15 mg dailyJohnson & Johnson Pharmaceutical SDA Schizophrenia sertindole 12 to 24mg daily Lundbeck SDA Schizophrenia iloperidone Novartis PharmaceuticalsSDA Schizophrenia asenapine 10 mg daily Organon SDA Schizophrenia SL 910177 unknown Sanofi-Synthelabo SDA Schizophrenia bifeprunox unknownSolvay SDA Schiznphienia ocaperidone Neuro3d SDA Schizophrenia SM-1349GSumitomo SDA Schizophrenia LU 31-131 Lundbeck SDA SchizophreniaBSF-190555 ? SDA Schizophrenia S-18327 Servier Monoaminergic 85 SDRIDepression/Anxiety Bazinapeine Sanofi-Synthelabo Transmitter SystemsMonoaminergic 86 Second messenger beta agonist Depression rolipram 1 5to 3 mg daily Shering Transmitter Systems Second messenger beta agonistDepression SR 57227 Sanofi-Synthelabo Second messenger beta agonistDepression eplivanserin Sanofi-Synthelabo Second messenger beta agonistInsomnia eplivanserin Sanofi-Synthelabo Endocrine System 87 Secretinpancreatic hormone Axiety RG1068 unknown Repligen Secretin pancreatichormone Schizophrenia RG1068 unknown Repligen Excitatory Amino 88 sigmareceptor agonist Depression VPI-013 (also known unknown Vela. OtsukaAcid System as OPC-14523) sigma receptor agonist ADHD PRX-00023 Predixsigma receptor agonist Anxiety PRX-00023 Predix Excitatory Amino 89sigma receptor antagonist Depression/Anxiety EMD 68843 20 mg daily EMDPharmaceuticals Acid System Sigma receptor antagonist Schizophrenia SR31742 unknown Sanofi-Synthelabo Monoaminergic 90 SNDRI Alzheimer'sDisease NS 2330 unknown Boehringer-Ingelheim Transmitter SystemsPharmaceuticals SNDRI Depression/Anxiety DOV 216,303 unknown DOV SNDRIAlzheimer's disease DOV 21,947 DOV SNDRI Depression DOV 21,947 DOV SNDRIDepression McN 5652 McNeil Monoaminergic 91 SNRI Depression milnacipran50 to 200 mg daily Pierre Fabre Transmitter Systems SNRIDepression/Anxiety nelazodone Mead Johnson SNRI Depression/Anxietyamoxapine Weyth SNRI Depression/Anxiety venlafaxine 75 to 300 mg dailyWyeth SNRI Depression/Anxiety duloxetine 40 to 60 mg daily Eli LillySNRI ADHD tomoxetine 1 9 mg/kg/day Lilly SNRI Depression/Anxietydesvenlafaxine unknown Wyeth SNRI Depression talsupram Lundbeck SNRIDppression talopram Lundbeck/Weyth SNRI Depression tandamine Wyeth SNRIDepression LY 113 821 Lilly Monoaminergic 92 SSRI Depression/Anxietyparoxetine GlaxoSmithKline Transmitter Systems SSRI Depression/Anxietyescitalopram 10 to 20 mg daily Lundbeck/Forest Laboratories SSRIDepression/Anxiety citalopram 10 to 40 mg daily off patent SSRIDepression/Anxiety fluoxetine off patent SSRI Depression/Anxietyfluvoxamine off patent SSRI Depression/Anxiety sertraline Pfizer SSRIAnxiety (OCD/Soc Phobia) fluvoxamine 100 to 300 mg Solvay controlledrelease daily SSRI Depression/Anxiety litoxetine unknownSanofi-Synthelabo SSRI Depression/Anxiety femoxetine Ferrosan SSRIDepression/Anxiety ifoxetine Novartis Pharmaceuticals SSRI DepressionVPI 013 (also Vela. Otsuka known as OPC-14523) SSRI Depression/AnxietyEMD 68843 EMD Pharmaceuticals SSRI Depression/Anxiety cericlamineJouveinal SSRI Depression Lu 35-138 Lundbeck SSRI Depression/OCD/Pain LY214 281 Lilly SSRI Depression LU AA 21-004 Lundbeck SSRIDepression/Anxiety cyanodothepine ? SSRI Depression/Anxietyademethionine/s- Sampl-Gibipharma adenosylmethionine SSRIDepression/Anxiety YM 992 Yamanouchi Peptidergic 93 Substance P receptor(NK1) antagonist Depression/Anxiety aprepitant 40 to 160 mg MerckTransmitter System daily Substance P receptor (NK1) antagonistDepression/Anxiety TAK-637 Takeda/Abbott Substance P receptor (NK1)antagonist Depression/Anxiety GW597599 GlaxoSmithKline Substance Preceptor (NK1) antagonist Depression/Anxiety vestipitant GlaxoSmithKlineSubstance P receptor (NK1) antagonist Depression/Anxiety CP-122,721Pfizer Substance P receptor (NK1) antagonist Depression/Anxiety R673Roche Substance P receptor (NK1) antagonist Depression/Anxiety GW679769GlaxoSmithKline Substance P receptor (NK1) antagonist Depression/AnxietyGW823296 GlaxoSmithKline Substance P receptor (NK1) antagonistDepression/Anxiety 679769 GlaxoSmithKline Substance P receptor (NK1)antagonist Depression/Anxiety 823296 GlaxoSmithKline Other/Unknown 94sulfonamide Mania zonisamide 100 to 600 mg Elan Pharmaceuticals dailyPeptidergic 95 tachykinin antagonists Depression/Anxiety SR 48960unknown Sanofi-Synthelabo Transmitter System Other/Unknown 96 unknownAlzheimer’s Disease DP 543 unknown Bristol Myers Squibb unknownDepression R228060 (YKP-10A) unknown Johnson & Johnson Parmaceuticalunknown Parkinson’s Disease palanpanel unknown IVAX unknown PremenstrualSyndrome ORG 39479/PH80 unknown Organon unknown Depression ORG 34167Organon unknown Dppression CJ-017,493 Pfzier Endocrine System 97 V1Bantagonist Depression/Anxiety SSR149415 Sanofi-Synthelabo InhibitoryAmino 98 modulator Depression/Anxiety Pregabalin 50 to 600 mg PfizerAcid System daily modulator Pain Pregabalin 50 to 600 mg Pfizer dailymodulator Insomnia PD-200,390 Pfizer Other/Unknown 99 vomeropherinAnxiety Acute PH94B Pherin Pharmaceuticals Monoaminergic 100 dopaminerelease stimulation Parkinson’s disease amantadine 100 to 300 mgTransmitter Systems daily dopamine release stimulation Depressionamantadine 100 to 300 mg daily Neurotrophic System 66 NGF (nerve qrowthfactor) Alzheimer’s Disease xaliproden unknown Sanofi PHARMACOLOGICALGROUPS: COMPOUNDS WORKING ON THE Amino Acid Transmitter SystemMonoaminergic 1 Transmitter System Excitatory Amino 2 Acid SystemInhibitory Amino 3 Acid System Peptidergic 4 Transmitter SystemAdenosine 5 Transmitter System Endocrine System 6 Enzymatic System 7Nerve Cell Function System Neurotrophic System 9 Neuroimmunophilin 10System Pathogenic Mechanisms 11 of Dementia of the Alzheimer Type

EXAMPLES Example 1 Measuring pKi Values of Test Compounds

In Table 1, the pKi values of test compounds are given for each of thedopamine receptors, 5HT receptors, adrenergic receptors and thehistamine1 receptor. The affinity of test compounds for the respectivereceptors has been performed according to conventional procedures knownin the art.

An indication “0” means that no affinity has been measured between thetest compound and the receptor.

The columns displaying the pKi values for the D4 and the 5-HT2A receptorare filled with dark grey. pKi values between 8 and 9 and higher than 9are represented by light grey boxes.

Example 2 Foregoing Pipamperon-Citalopram Treatment in Major DepressiveDisorder: a Placebo and Active Controlled Period Finding Clinical Trial

Table 2 represents the set-up of a clinical trial comprising fortreatment groups:

Group Plc—Active/Day 0 represents the group receiving 10 mg citalopram,twice a day, starting the first day (Day 0) of active treatment in theclinical trial. This administration regime is also indicated as the monotherapy.

Group Pip—Active/Day 0 represents the group receiving a combination of 4mg pipamperon and 10 mg citalopram, twice a day, starting the first day(Day 0) of active treatment in the clinical trial. This administrationregime is also indicated as the non-foregoing combo therapy.

Group Pip—Active/Day 4 represents the group receiving 4 mg pipamperon,twice a day, starting the first day (Day 0) of active treatment in theclinical trial, followed by a combination of 4 mg pipamperon and 10 mgcitalopram, twice a day, starting the fifth (Day 4) day of activetreatment in the clinical trial. This administration regime is alsoindicated as the foregoing therapy with combination therapy startingafter 4 days of active treatment.

Group Pip—Active/Day 7 represents the group receiving 4 mg pipamperon,twice a day, starting the first day (Day 0) of active treatment in theclinical trial, followed by a combination of 4 mg pipamperon and 10 mgcitalopram, twice a day, starting the eight (Day 7) day of activetreatment in the clinical trial. This administration regime is alsoindicated as the foregoing therapy with combination therapy startingafter 7 days of active treatment.

All subjects also undergo a placebo (PLC) run-in therapy, administeredduring a period of about 7 days before the active treatment starts.

During daily (D), weekly (W) or monthly (M) visits, several parametersare measured.

Under NECT is to be understood: Neuronal E-clinical Trial=VesaliusExpert development for this trial which includes the bottom-upmeasurement of:

-   -   In- and exclusion-criteria    -   Functional status evaluation    -   Medical history    -   (Pre-)treatment signs & symptoms    -   DSM-IV rules for diagnosis & efficacy    -   HDRS-28 (Hamilton Depression Rating Scale-28 items)    -   Medical resource utilisation    -   Pre-trial & Concomittant medication    -   Drug administration    -   (Serious) Adverse events    -   Admission to the acute and extension phase of treatment    -   Right flow of the trial

Example 3 Combo Pipamperon-Citalopram: Therapeutic Use in MajorDepression Purpose

Pipamperon(1′-[3-(p-Fluorobenzoyl)propyl]-[1,4′-bipiperidine]-4′-carboxamide), theactive ingredient of Dipiperon (Janssen-Cilag B.V), administered topatients in a dose ranging between 8 and 12 mg is claimed via itsspecific pharmacological properties to be a booster of theantidepressant effect of the selective serotonin re-uptake inhibitorcitalopram. Preferably, pipamperon is administered daily at least 4-5days before administering said antidepressant. The mechanism of boostingof pipamperon has to deal with (i) the selective affinity for thedopamine-4 (D4) receptor with a pKi value equal to or higher than 8towards the D4 receptor and less than 8 towards other dopaminereceptors, and (ii) the selective affinity for the 5-HT2A receptor witha pKi value equal to or higher than 8 towards the 5-HT2A receptor andless than 8 towards other 5HT receptors. This semi-naturalistic openlabel study investigated the efficacy and tolerability of the combopipamperon-citalopramin the treatment of patients with major depression.

Details

-   Design: Semi-naturalistic i.e. inclusion of every ‘natural’ patient    in an outpatient practice but without concomitant use of mood    enhancing drugs, open label-   Control: No-   Phase: Phase IIa—preliminary Proof of Concept-   Location: Belgium—Research Centre ANIMA, Alken-   End Points: Assessment scale scores, Hamilton Depression Rating    Scale 17 items, Reduction, Response, Remission-   Medication: Exclusion of mood stabilisers, antipsychotics (typical    and atypical) and other antidepressants

Subjects

Type No. Sex Age Patients 23 10 male & 13 female 23-80 (mean 47) years

Characteristics: patients had a major depressive disorder according toDSM-IV criteria, with or without a chronic course and a treatmentrefractory state towards another SSRI then citalopram.

Treatments

PIP-CIT¹ Add-on: Citalopram from Day Minus 60-20-Pipamperon from Day 0

Treatment Drug Dose Route Frequency Duration Pipamperon¹ +Pip.: 8-12mg/day - PO bid 8 weeks Citalopram¹ Cit.: 20-40 mg/day ¹Pipamperon (Pip)and citalopram (Cit) dosage was adjusted according to clinical response.

PIP-CIT¹ Fore-Going 1-5: Pipamperon from Day 0-Cital from Day 1-5

Treatment Drug Dose Route Frequency Duration Pipamperon¹ +Pip.: 8-12mg/day - PO bid 8 weeks Citalopram¹ Cit.: 20-40 mg/day ¹Pipamperon (Pip)and citalopram (Cit) dosage was adjusted according to clinical response.

PIP-CIT¹ Fore-Going 6-8: Pipamperon from Day 0-Citalopram from Day 6-8

Treatment Drug Dose Route Frequency Duration Pipamperon¹ +Pip.: 8-12mg/day - PO bid 8 weeks Citalopram¹ Cit.: 20-40 mg/day ¹Pipamperon (Pip)and citalopram (Cit) dosage was adjusted according to clinical response.

Results

PIP-CIT add-on PIP-CIT foregoing After 20-60 DAYS 1-5 DAYS 6-8 DAYS(mean 33) (mean 4) (mean 7) (n = 5 ) (n = 15) (n = 3) Mean UsedMedication Pipamperone 9 mg/day 10 mg/day 11 mg/day Citalopram 30 mg/day26 mg/day 30 mg/day Depression scale scores HDRS 17-item total scorebaseline 29 23 28 endpoint (week 8)  4  5 11 diminishment at week 8 −25(+8/−9) −18 (+8/−8) −17 (+17/−17) % reduction at week 8 86 (+14/−12) 80(+20/−30) 61 (+39/−61) response¹ at week 8 5 (100%) 15 (100%) 2 (67%)remission² at week 8 4 (80%) 10 (67%) 1 (33%) ¹Response = ≧50% reductionin HDRS 17-item score; ²Remission = HDRS 17-item score <8

Notably, the results obtained are highly significant since thevariability in every group is distributed evenly around the mean.

Add-on PIP-CIT

FIG. 1 schematically depicts the “add-on” treatment with pipamperon 8-12(mean 9) mg (bid) after treatment with citalopram 10-20 (mean 30) mg(bid) during 20-60 (mean 33) days (PIPCIT ADD-ON) with HDRS-17.Totalscore is 29 at baseline in MDD in comparison with the standardefficacy of antidepressants in clinical trials according to Khan et al.(2000), in “Symptom Reduction and Suicide Risk in Patients Treated WithPlacebo in Antidepressant Clinical Trials” (Arch. of General Psychiatry,Vol. 57, April 2000).

FIG. 2 schematically depicts the HDRS-17 change from baseline in thecombo pipamperon as “add-on” to citalopram vs. SNRI (duloxetine) inMajor Depression. Treatment with pipamperon 8-12 (mean 9 mg/day) during20-60 (mean 33) days after treatment with SSRI (n=5). The SNRI(duloxetine) treatment was 40-120 mg/day (n=152) according to Goldsteinet al., (Clin. Psychiatry, in press).

FIG. 3 schematically depicts the remission rates (HDRS-17 <=7) with thecombo pipamperon as “add-on” to citalopram vs SNRI (venlafaxine) vsSSRIs vs placebo in Major Depression. Treatment with pipamperon 8-12(mean 9 mg/day) during 20-60 (mean 33) days after treatment with SSRI(n=5). Treatment with the SNRI venlafaxine is according to ameta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241).Treatment with SSRIs is according to a meta-analysis of Thase et al.(Br. J. Psychiatry (2001) 178:234-241). Treatment with placebo isaccording to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001)178:234-241).

Fore-Going 1-5 PIP-CIT

FIG. 4 schematically depicts the “fore-going” treatment during 1-5 (mean4) days with pipamperon 8-12 (mean 10) mg (bid), followed with thecombination treatment of pipamperon and citalopram 20-50 (mean 26)mg/day (bid) (PIPCIT FG 1-5) in MDD (HDRS-17 at BL=23) in comparisonwith the standard efficacy of antidepressants in clinical trialsaccording to Khan et al. (2000), in “Symptom Reduction and Suicide Riskin Patients Treated With Placebo in Antidepressant Clinical Trials”(Arch. of General Psychiatry, Vol. 57, April 2000).

FIG. 5 schematically depicts the HDRS-17 change from baseline in thecombo pipamperon-citalopram treatment with a “fore-going” treatment of 4days with pipamperon (10 mg/day) vs SNRI (duloxetine) in MajorDepression. Treatment with the combo pipamperon-citalopram withpipamperon 8-12 (mean 10 mg/day) (bid) 1-5 (mean 4) days beforetreatment with SSRI (n=15). The SNRI (duloxetine) treatment was 40-120mg/day (n=152) according to Goldstein et al., (Clin. Psychiatry, inpress).

FIG. 6 schematically depicts the remission rates (HDRS-17 <=7) with thecombo pipamperon with a “fore-going” treatment of 4 days with pipamperon(10 mg/day) vs SNRI (venlafaxine) in Major Depression. Treatment withthe combo pipamperon-citalopram was with pipamperon 8-12 (mean 10mg/day) during 1-5 (mean 4) days before treatment with the SSRI (n=5).Treatment with the SNRI venlafaxine is according to a meta-analysis ofThase et al. (Br. J. Psychiatry (2001) 178:234-241). Treatment withSSRIs is according to a meta-analysis of Thase et al. (Br. J. Psychiatry(2001) 178:234-241). Treatment with placebo is according to ameta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241).

Fore-Going 6-8 PIP-CIT

FIG. 7 schematically depicts the “fore-going” treatment during 6-8 (mean7) days with pipamperon 8-12 (mean 11) mg/day (bid), followed with thecombination treatment of pipamperon and citalopram 20-40 (mean 30)mg/day (bid) (PIPCIT FG 6-8) in MDD (HDRS-17 at BL=28) in comparisonwith the standard efficacy of antidepressants in clinical trialsaccording to Khan et al. (2000), in “Symptom Reduction and Suicide Riskin Patients Treated With Placebo in Antidepressant Clinical Trials”(Arch. of General Psychiatry, Vol. 57, April 2000).

FIG. 8 schematically depicts the HDRS-17 change from baseline in thecombo pipamperon-citalopram treatment with a “fore-going” treatment of 7days with pipamperon (11 mg/day) vs SNRI (duloxetine) in MajorDepression. Treatment with the combo pipamperon-citalopram withpipamperon 8-12 (mean 11 mg/day) (bid) 6-8 (mean 7) days beforetreatment with SSRI (n=3). The SNRI (duloxetine) treatment was 40-120mg/day (n=152) according to Goldstein et al., (Clin. Psychiatry, inpress).

Comparison “Add-on” Vs “Fore-Going”

FIG. 9 schematically depicts a comparison between “fore-going” and“add-on” treatments with pipamperon (8-12 mg/day; bid) and citalopram(20-40 mg/day; bid) in MDD in comparison with the standard efficacy ofantidepressants in clinical trials according to Khan et al. (2000), in“Symptom Reduction and Suicide Risk in Patients Treated With Placebo inAntidepressant Clinical Trials” (Arch. of General Psychiatry, Vol. 57,April 2000).

FIG. 10 schematically depicts a comparison between “fore-going” and“add-on” treatments. In particular, the HDRS-17 change from baselinebetween “fore-going” and “add-on” treatment with pipamperon (8-12mg/day; bid) and citalopram (20-40 mg/day; bid) in comparison with theSNRI duloxetine in Major Depression is depicted. Treatment with thecombo pipamperon as “add-on” to citalopram, with pipamperon 8-12 mg/day(mean 9 mg/day) 20-60 (mean 33) days after treatment with the SSRI(n=5). Treatment with the combo pipamperon-citalopram, with pipamperon8-12 mg/day (mean 11 mg/day; bid) 6-8 days (mean 7 days) beforetreatment with the SSRI (n=15). Treatment with the combopipamperon-citalopram, with pipamperon 8-12 mg/day (mean 10 mg/day; bid)1-5 days (mean 4 days) before treatment with the SSRI (n=15). The SNRI(duloxetine) treatment was 40-120 mg/day (n=152) according to Goldsteinet al., (Clin. Psychiatry, in press).

FIG. 11 schematically depicts the remission rates (HDRS-17 <=7) in acomparison between “fore-going” and “add-on” treatment with pipamperon(8-12 mg/day; bid) and citalopram (20-40 mg/day; bid) in comparison withthe SNRI venlafaxine in Major Depression. Treatment with the combopipamperon-citalopram was with pipamperon 8-12 (mean 10 mg/day) during1-5 (mean 4) days before treatment with the SSRI (n=15). Treatment withthe SNRI venlafaxine is according to a meta-analysis of Thase et al.(Br. J. Psychiatry (2001) 178:234-241). Treatment with pipamperon as“add-on” to citalopram, with pipamperon 8-12 (mean 9 mg/day) during20-60 (mean 33) days after treatment with SSRI (n=5).

The intention-to-treat/last-observation-carried-forward analysis showeda high therapeutic efficacy according HDRS 17-item in all the treatmentgroups. This was especially true for the ‘add-on’ group probably causedby the longer treatment with an active antidepressant (+33 days). Thehuge therapeutic effect observed in the ‘PIP-CIT 1-5’ group present forat a mean dosage of pipamperon of 10 mg per day and administered thefirst four days of treatment without an active antidepressant, indicatesthe boosting effect of pipamperon on the SSRI citalopram at an extremelyand thus unconventional low dose. Only 1 patient discontinued treatmentdue to a lost of follow-up.

Adverse Events

PIP-CIT add-on PIP-CIT foregoing After 20-60 DAYS 1-5 DAYS 6-8 DAYS(mean 33) (mean 4) (mean 7) Side effects (patients) (n = 5) (n = 15) (n= 3) Discontinued treatment 0 0 0 due to adverse events By system: bodyas a whole 0 0 0 central and peripheral 1 (20%) 4 (26.6%) 0 nervoussystem gastrointestinal 1 (20%) 5 (33%) 2 (66.6%) musculoskeletal 1(20%) 3 (20%) 0 psychiatric 0 0 0 respiratory 0 1 (6.6%) 0 skin andappendages 1 (20%) 2 (13.3%) 1 (33.3%) vascular 0 1 (6.6%) 0 urinary 0 1(6.6%) 0

Laboratory parameters, ECG, bodyweight and vital signs were not measuredsince this was a naturalistic study.

Assessment Outcome

Efficacy: the 4-day fore-going combo pipamperon 8-12 mg/d-citalopram20-40 mg/day is comparable to the add-on combo pipamperon-citalopram.

Efficacy: the 4-day fore-going combo pipamperon 8-12 mg/d-citalopram20-40 mg/day is larger than the 7-day fore-going combo pipamperon 8-12mg/d-citalopram 20-40 mg/day.

Efficacy: the combo pipamperon 8-12 mg/d-citalopram 20-40 mg/day islarger than the in the art known antidepressants SSRIs.

Tolerability

Tolerability: the 4-day fore-going treatment is comparable to the 7-dayfore-going combo is comparable to add-on combo pipamperon-citalopram.

Tolerability: no discontinued treatment due to adverse events.

Study Messages

The boosting effect of pipamperon at an extremely unconventional lowdose on a SSRI is indicated since the efficacy of the ‘add-on’ and‘4-day fore-going’ combo ‘pipamperon 8-12 mg/d-citalopram 20-40 mg/day’is in this study as twice higher as known in the art in the treatment ofpatients with major depression.

The combo pipamperon-citalopram is generally well tolerated in patientswith depression i.e. at least no specific added adverse events wereoccurring by adding pipamperon at the doses used in the study.

Example 4 Combo Pipamperon-Citalopram: Therapeutic Use inObsessive-Compulsive Disorder (OCD) Purpose

Pipamperon(1′-[3-(p-Fluorobenzoyl)propyl]-[1,4′-bipiperidine]-4′-carboxamide), theactive ingredient of Dipiperon (Janssen-Cilag B.V), administered to apatient in a dose ranging between 8 and 12 mg is claimed via itsspecific pharmacological properties to be a booster of the effect of theselective serotonin re-uptake inhibitor citalopram towards OCD.Preferably, pipamperon is administered daily at least 4-5 days beforeadministering said antidepressant. The mechanism of boosting ofpipamperon has to deal with (i) the selective affinity for thedopamine-4 (D4) receptor with a pKi value equal to or higher than 8towards the D4 receptor and less than 8 towards other Dopaminereceptors, and (ii) the selective affinity for the 5-HT2A receptor witha pKi value equal to or higher than 8 towards the 5-HT2A receptor andless than 8 towards other 5HT receptors. This semi-naturalistic openlabel study investigated the efficacy and tolerability of the combopipamperon-citalopram in the treatment of patients with OCD.

Details

-   Design: Semi-naturalistic i.e. inclusion of every ‘natural’ patient    in an outpatient practice but without concomitant use of mood    enhancing drugs, open label-   Control: No-   Phase: Phase IIa—preliminary Proof of Concept-   Location: Belgium—Research Centre ANIMA, Alken-   End Points: Assessment scale scores, Yale-Brown Obsessive-Compulsive    Scale, Reduction, Remission-   Medication: Exclusion of mood stabilisers, antipsychotics (typical    and atypical) and other antidepressants

Subjects

Type No. Sex Age Patients 7 1 male & 7 female 20-63 (mean 33) years

Characteristics: patients had an obsessive-compulsive disorder accordingto DSM-IV criteria, with or without a chronic course and a treatmentrefractory state towards another SSRI then citalopram.

Treatments

PIP-CIT¹ Add-on: Citalopram from Day Minus 730-60-Pipamperon from Day 0

Treatment Drug Dose Route Frequency Duration Pipamperone¹ +Pip.: 8-16mg/day - PO bid 12 weeks Citalopram¹ Cit.: 30-80 mg/day ¹Pipamperone(Pip) and Citalopram (Cit) dosage was adjusted according to clinicalresponse.PIP-CIT¹ Fore-Going 4-6: Pipamperon from Day 0-Citalopram from Day 4-6

Treatment Drug Dose Route Frequency Duration Pipamperone¹ +Pip.: 8-16mg/day - PO bid 12 weeks Citalopram¹ Cit.: 30-80 mg/day ¹Pipamperone(Pip) and Citalopram (Cit) dosage was adjusted according to clinicalresponse.

Results

PIP-CIT add-on after 730-60 DAYS (mean 241) (n = 6) with mean Cit. 54mg/d and Pip. 11 mg/d PIP-CIT foregoing 4-6 DAYS (mean 5) (n = 2) Y-BOCSscore with mean Cit. 60 mg/d and Pip. 10 mg/d Baseline Total 31Obsessions 18 Compulsions 13 Endpoint (week 12) Total 15 diminishment−16 (+16/−11) % reduction 53 Obsessions total  8 diminishment −10(+9/−7) % reduction 57 Compulsions total  7 diminishment −6 (+7/−6) %reduction 45 % Remission YBOCS score ≦8 29 BOCS score ≦16 57

Notably, the results obtained are highly significant since thevariability in every group is distributed evenly around the mean.

FIG. 12 schematically depicts the Y-BOCS total score: “fore-going” and“add-on” treatment with pipamperon (8-15 mg/day; bid) and citalopram(30-80 mg/day; bid) in comparison with the SSRI fluvoxamine in OCD.Treatment with the combo pipamperon-citalopram (n=7). Treatment withfluvoxamine (controlled release) mean 271 mg/day (n=253) is according toHollander et al. (2003).

FIG. 13 schematically depicts the Y-BOCS obsession score: “fore-going”and “add-on” treatment with pipamperon (8-15 mg/day; bid) and citalopram(30-80 mg/day; bid) in comparison with the SSRI fluvoxamine in OCD.Treatment with the combo pipamperon-citalopram (n=7). Treatment withfluvoxamine (controlled release) mean 271 mg/day (n=253) is according toHollander et al. (2003).

FIG. 14 schematically depicts the Y-BOCS compulsion score: “fore-going”and “add-on” treatment with pipamperon (8-16 mg/day; bid) and citalopram(30-80 mg/day; bid) in comparison with the SSRI fluvoxamine in OCD.Treatment with the combo pipamperon-citalopram (n=7). Treatment withfluvoxamine (controlled release) mean 271 mg/day (n=253) is according toHollander et al. (2003).

The intention-to-treat/last-observation-carried-forward analysis showeda high therapeutic efficacy according Y-BOCS total score, obsession andcompulsion scores. This indicates the boosting effect of pipamperon onthe SSRI citalopram at an extremely and thus unconventional low dose. Nopatient discontinued treatment.

Assessment

Efficacy: the combo pipamperone 8-16 mg/d-citalopram 30-80 mg/day >thein the art known compounds effective towards OCD (Hollander E, Koran LM, Goodman W K, Greist J H, Ninah P T, et al. A double-blind,placebo-controlled study of the efficacy and safety ofcontrolled-release fluvoxamine in patients with obsessive-compulsivedisorder. Journal of Clinical Psychiatry 64: 640-647, June 2003 MountSinai School of Medicine, New York, N.Y., USA; Solvay PharmaceuticalsInc., Marietta, Ga., USA).

Study Messages

The boosting effect of pipamperon at an extremely unconventional lowdose on a SSRI is indicated since the efficacy of the ‘add-on’ and‘fore-going’ combo ‘pipamperon 8-15 mg/d-citalopram 30-80 mg/day’ is inthis study as twice higher as known in the art in the treatment ofpatients with obsessive-compulsive disorder.

Example 5 Combo Pipamperon-Citalopram: Therapeutic Use in Panic DisorderPurpose

Preliminary examination of a “fore-going” and “add-on” treatment withpipamperon and citalopram in comparison with the SSRI in Panic Disorder.

Results

The results are indicated in FIG. 15. FIG. 15 schematically depicts theCGI-severity score: “fore-going” and “add-on” treatment with pipamperon(8 mg/day; bid) and citalopram (20-40 mg/day; bid) in comparison withthe SSRI in Panic Disorder. Treatment with the combopipamperon-citalopram (n=3). Treatment with paroxetine is according tothe Journal of Clinical Psychiatry (2004) 65: 405-413. Treatment withSertraline is according to the Journal of Clinical Psychiatry (2004) 65:405-413.

Conclusion

Notably, although a small test group has been used (n=3), thedistribution around the mean is good. It will further be apparent fromFIG. 15 that the effect of the combo treatment of pipamperon andcitalopram is twice as high as the standard treatments with paroxetineor sertraline.

Example 6 POC Process for Mayor Depressive Disorder

Concept: Combo of the High Selective 5-HT2A/D4 Antagonist Pipamperonwith:

-   -   a compound active towards the Amino Acid Transmitter,        Peptidergic Transmitter, Adenosine Transmitter, Endocrine and/or        Enzymatic System;    -   a fore-going admission during 4 days of pipamperon;    -   a dose of pipamperon of 12 mg/day        Objectives: Demonstrating that this Combo Therapy has:    -   the potency of being a treatment standard for depression by        having an added value of reducing the total score of the        Hamilton Depression Rating Scale-17 items (HDRS-17) after 8        weeks of therapy with a least 20% more than reached with the        conventional known antidepressants, i.e. 60% versus 40%. This        stands for an added medium demission of 5 points on the total        score of the HDRS-17 and by this will be very highly significant        since the mean difference in all recent clinical trials between        placebo and active treatment is 2.5;    -   a more sustained therapeutic effect than the conventional mono        therapy by preventing significant more relapses during 48 weeks        following the acute treatment; and/or    -   a complete neutral safety profile, e.g. there are no more        adverse events in the combo therapy then in mono admission of        the in the combo used antidepressant compound.        Process: the Following Different Steps were Implemented to Reach        Out for these Objectives (See Also Tables 3 and 4):

-   (1) an naturalistic open label study (n=>20) on a depressive    population with a normal variability of medical and psychiatric    history, course of depression, earlier and concomitant therapy    admitting the golden standard antidepressant citalopram 20-40 mg/day    and a dose of 8-12 mg/day of pipamperon in a foregoing, simultaneous    or add-on use.

-   (2) a 16 weeks placebo controlled randomised four armed study of    each 36 patients with a mayor depressive disorder admitting:    -   from day 0: placebo or pipamperon (PIP) 10 mg/day or an active        antidepressant compound or the combination of the last two;    -   from day 4: placebo or pipamperon 10 mg/day combined with an        active antidepressant compound or an active antidepressant        compound without pipamperon.

-    By including rigorous control groups (placebo and active    comparator; see Tables 3 and 4) this clinical trial is evaluated as    a proof of concept of the added value of the combo and the foregoing    treatment method since the inclusion/exclusion of:    -   a negative trial, i.e. no significant difference between the        placebo and active treatment with the comparator;    -   a failed trial, i.e. no significant difference between the        active and the studied treatment i.e. the combo.

-   (3) an active controlled randomised relapse prevention study    following the POC trial during another 36 weeks with three arms of    each 36 patients which is formed by:    -   continuation of the active mono therapy;    -   randomising the patients with a combo therapy in a group with an        active mono therapy and with a continuation of the combo        treatment.

1. Use of pipamperon for the preparation of a medicament for treating adisease or disorder with an underlying dysregulation of the emotionalfunctionality, wherein said pipamperon is administered to a patient in adose ranging between 5 and 15 mg of the active ingredient, and wherein asecond compound is administered simultaneously with, separate from orsequential to said pipamperon to augment the therapeutic effect of saidsecond compound.
 2. Use according to claim 1, wherein said pipamperon isadministered daily at least one day before administering said secondcompound.
 3. Use according to any of claims 1 to 2, wherein said secondcompound affects the monoaminergic transmitter system.
 4. Use accordingto claim 3, wherein said second compound is selected from the groupcomprising: 5-HT reuptake enhancer, 5-HT1 autoreceptor agonist, 5HT1Areceptor agonist, 5-HT1A receptor antagonist, 5-HT1B receptorantagonist, 5-HT2B receptor antagonist, 5-HT2C receptor antagonist,5-HT3 receptor antagonist, 5-HT6 receptor antagonist, adrenergictransmitter releaser, α1 adrenoreceptor antagonist, α2 adrenoreceptorantagonist, β3 adrenoreceptor agonist, cannabioid receptor antagonist,D1 receptor agonist, D2 receptor antagonist, D3 receptor antagonist, DAuptake inhibitor, dopamine receptor agonist, H3 receptor antagonist,compounds which increase brain concentrations of 5-HT, levodopa, MAOreuptake inhibitor, MAO-A & MAO-B reuptake inhibitor, MAO-B inhibitor,MAO-B re-uptake inhibitor, NARI, NaSSA, NDRI, RIMA, SDA, SDRI, Secondmessenger beta agonist, SNDRI, SNRI and SSRI.
 5. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases or disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorder, personalitydisorders, antisocial behaviour, bereavement, occupational problem andproblems related to abuse or neglect and pain disorders, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a 5-HT (serotonin) reuptake enhancer compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said 5-HT (serotonin) reuptake enhancer compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 6. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases or disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders, substancerelated disorder, personality disorders, antisocial behaviour,bereavement, occupational problem, problems related to abuse or neglectand pain disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a 5-HT1autoreceptor agonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said 5-HT1autoreceptor agonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.
 7. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, attention-deficit disorders, substance-relateddisorder, personality disorders, antisocial behaviour, bereavement,occupational problem, problems related to abuse or neglect and paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a 5-HT1A (serotonin 1A) receptoragonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said 5-HT1A (serotonin) 1Areceptor agonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.
 8. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a non-cognitive mental diseaseor disorder selected from the group of diseases and disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender disorders,adjustment disorders, impulse control disorders, substance-relateddisorder, personality disorders, antisocial behaviour, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a 5-HT1A receptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said 5-HT1A receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 9. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender disorders, sleep disorders, adjustmentdisorders, impulse control disorders, substance-related disorder,personality disorders, antisocial behaviour, bereavement, occupationalproblem and problems related to abuse or neglect, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a 5-HT1B receptor antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said 5-HT1B receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 10. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender disorders, sleep disorders, adjustmentdisorders, impulse control disorders, substance-related disorder,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorderscharacterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a 5-HT2B receptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said 5-HT2B receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 11. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender disorders, sleep disorders, adjustmentdisorders, impulse control disorders, substance-related disorder,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a 5-HT2C receptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said 5-HT2C receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 12. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of substance-related disorders, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a 5-HT3 receptor antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said 5-HT3 receptor antagonist compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.
 13. Use ofpipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a cognitive disorder selected from the group ofdiseases and disorders consisting of Alzheimer Disease,substance-induced persisting dementia, vascular dementia, dementia dueto HIV disease, dementia due to head trauma, dementia due to ParkinsonDisease, dementia due to Huntington Disease, dementia due to PickDisease, dementia due to Creutzfeldt-Jacob Disease, amnestic disordersdue to a general medical condition, substance-induced persistingamnestic disorder, mild cognitive impairment disorder and othercognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a 5-HT6 receptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said 5-HT6 receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 14. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, adjustmentdisorders, impulse control disorders, personality disorders,bereavement, occupational problem, problems related to abuse or neglectand pain disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of an adrenergictransmitter releaser compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said adrenergictransmitter releaser compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.
 15. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, personality disorders, bereavement,occupational problem, problems related to abuse or neglect and paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a alpha 1 adrenoreceptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said alpha 1 adrenoreceptorantagonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 16. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a non-cognitive mental diseaseor disorder selected from the group of diseases and disorders consistingof mood disorders, anxiety disorders, psychotic disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a alpha 2adrenoreceptor antagonist compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said alpha 2adrenoreceptor antagonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 17. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a beta 3adrenoreceptor agonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said beta 3adrenoreceptor agonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 18. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting mood disorders, anxiety disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem and problems related to abuse or neglect, paindisorders and delirium, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a cannabioidreceptor 1 antagonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said cannabioidreceptor 1 antagonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.
 19. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofsubstance related disorders and Parkinson disease, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a D1 receptor agonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said D1 receptor agonist compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.
 20. Use ofpipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting mood disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem and problems related to abuse or neglect, paindisorders and delirium, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a D2 receptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said D2 receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 21. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting ofpsychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem, problems related to abuse or neglect, paindisorders and delirium, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a D3 receptorantagonist compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said D3 receptor antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 22. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of substance related disorders and Parkinsondisease, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a DA (dopamine) uptake inhibitorcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said DA (dopamine) uptake inhibitorcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 23. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, adjustment disorders, impulse control disorders,attention-deficit disorders, substance-related disorders, personalitydisorders and problems related to abuse or neglect, pain disorder andParkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a dopaminereceptor agonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said dopaminereceptor agonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.
 24. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a cognitive mental disease ordisorder selected from the group of diseases and disorders consisting ofAlzheimer Disease, substance-induced persisting dementia, vasculardementia, dementia due to HIV disease, dementia due to head trauma,dementia due to Parkinson Disease, dementia due to Huntington Disease,dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease,amnestic disorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a histamineH3receptor antagonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said histamineH3receptor antagonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.
 25. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of a noncognitive mental disease or disorder selected from the group of diseasesand disorders consisting of mood disorders, anxiety disorders, eatingdisorders, premenstrual syndrome, somatoform disorders (excluding paindisorders), factitious disorders, dissociative disorders, sexual andgender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem, problems related to abuseor neglect and pain disorder, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compound whichincreases brain concentrations of 5-HT (serotonin) to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said compound which increases brain concentrations of 5-HT(serotonin), further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 26. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of Parkinson Disease, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a levodopa/decarboxylase inhibitor compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said levodopa/decarboxylase inhibitor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 27. Apharmaceutical composition comprising (a) pipamperon, and (b) alevodopa/decarboxylase inhibitor compound, preferably is(eti)levodopa/carbidopa, or a pro-drug or an active metabolite thereof,or a pharmaceutically acceptable salt thereof in combination withentacapone, which is an inhibitor of catechol-O-methyltransferase(COMT), or a pro-drug or an active metabolite thereof, or apharmaceutically acceptable salt thereof, as a combined preparation forsimultaneous, separate or sequential use for treating the underlyingemotion dysregulation of Parkinson Disease.
 28. A pharmaceuticalcomposition according to claim 27, wherein pipamperon is provided in aunitary dose of between 5 and 15 mg of the active ingredient and whereinsaid levodopa/decarboxylase inhibitor compound is levodopa/carbidopa,preferably provided in a unitary dose of between 250 to 600 mg and 25 to150 mg of the active ingredients.
 29. A pharmaceutical compositionaccording to claim 27, wherein pipamperon is provided in a unitary doseof between 5 and 15 mg of the active ingredient and wherein saidlevodopa/decarboxylase inhibitor compound is levodopa/benserazide,preferably provided in a unitary dose of between 100 to 600 mg and 25 to150 mg of the active ingredients.
 30. A pharmaceutical compositionaccording to any of claim 27 or 28, wherein pipamperon is provided in aunitary dose of between 5 and 15 mg of the active ingredient and whereinsaid levodopa/decarboxylase inhibitor compound is levodopa/carbidopa oretilevodopa/carbidopa in combination with entacapone, of which thelatter is preferably provided in a unitary dose of between 500 mg and100 mg of the active ingredient.
 31. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofnon-cognitive mental disease or disorder which are substance relateddisorders and Parkinson disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of amonoamine oxidase (MAO) reuptake inhibitor compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said monoamine oxidase (MAO) reuptake inhibitor compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 32. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, adjustmentdisorders, impulse control disorders, attention-deficit disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorder,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a monoamine oxidase A (MAO-A) and a monoamineoxidase B (MAO-B) reuptake inhibitor compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidmonoamine oxidase A (MAO-A) and a monoamine oxidase B (MAO-B) reuptakeinhibitor compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 33. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a non-cognitive mental diseaseor disorder selected from the group of diseases and disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorders,personality disorders, problems related to abuse or neglect, paindisorder and Parkinson disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a monoamineoxidase B (MAO-B) inhibitor compound to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said monoamineoxidase B (MAO-B) inhibitor compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 34. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofParkinson Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a monoamineoxidase B (MAO-B) reuptake inhibitor to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said monoamineoxidase B (MAO-B) reuptake inhibitor, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 35. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,adjustment disorders, attention-deficit disorders, personalitydisorders, antisocial behaviour, bereavement, occupational problem,problems related to abuse or neglect and pain disorder, characterized inthat pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a selective nor-adrenaline re-uptake inhibitor (NARI)compound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said selective nor-adrenaline re-uptakeinhibitor (NARI) compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.
 36. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a non-cognitive mental diseaseor disorder selected from the group of diseases and disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a noradrenergic/specific serotonergicantidepressant (NaSSA) compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of saidnoradrenergic/specific serotonergic antidepressant (NaSSA) compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 37. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, adjustment disorders, attention-deficitdisorders, personality disorders, antisocial behaviour, bereavement,occupational problem, problems related to abuse or neglect and paindisorders, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a selective nor-adrenaline anddopamine re-uptake inhibitor (NDRI) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidselective nor-adrenaline and dopamine re-uptake inhibitor (NDRI)compound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 38. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, adjustmentdisorders, impulse control disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a compound whichis a reversible inhibitor of mono-amine oxydase A (RIMA) to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said compound which is a reversible inhibitor of mono-amineoxydase A (RIMA), further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 39. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a non-cognitive mental diseaseor disorder selected from the group of diseases and disorders consistingof mood disorders, anxiety disorders, psychotic disorders, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem, problems related to abuse or neglect, pain disorder anddelirium, characterized in that pipamperon or said pharmaceuticallyacceptable salt thereof is administered simultaneously with, separatefrom or prior to the administration of a serotonin/dopamine antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said serotonin/dopamine antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 40. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sleep disorders, adjustment disorders, impulsecontrol disorders, substance-related disorders, personality disorders,antisocial behaviour, bereavement, occupational problem, problemsrelated to abuse or neglect, pain disorders, delirium, AlzheimerDisease, substance-induced persisting dementia, vascular dementia,dementia due to HIV disease, dementia due to head trauma, dementia dueto Parkinson Disease, dementia due to Huntington Disease, dementia dueto Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnesticdisorders due to a general medical condition, substance-inducedpersisting amnestic disorder, mild cognitive impairment disorder andother cognitive disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin and dopamine re-uptake inhibitor (SDRI) compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said selective serotonin and dopamine re-uptake inhibitor(SDRI) compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 41. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a non-cognitive mental diseaseor disorder selected from the group of diseases and disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sexual and gender identity disorders,sleep disorders, adjustment disorders, impulse control disorders,personality disorders, bereavement, occupational problem, problemsrelated to abuse or neglect and pain disorders, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a second messenger beta agonist compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said second messenger beta agonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 42. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, attention-deficit disorders, substance-related disorders,personality disorders, antisocial behaviour, bereavement, occupationalproblem, problems related to abuse or neglect and pain disorders,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a selective serotonin, nor-adrenaline anddopamine re-uptake inhibitor (SNDRI) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidselective serotonin, nor-adrenaline and dopamine re-uptake inhibitor(SNDRI) compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 43. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of a non-cognitive mental diseaseor disorder selected from the group of diseases and disorders consistingof mood disorders, anxiety disorders, eating disorders, premenstrualsyndrome, somatoform disorders (excluding pain disorders), factitiousdisorders, dissociative disorders, sleep disorders, adjustmentdisorders, impulse control disorders, attention-deficit disorders,substance-related disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said selective serotonin and nor-adrenalinere-uptake inhibitor (SNRI) compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 44. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, antisocialbehaviour, bereavement, occupational problem, problems related to abuseor neglect and pain disorders, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin re-uptake inhibitor (SSRI) compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidselective serotonin re-uptake inhibitor (SSRI) compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 45. Useaccording to claim 1 or 2, wherein said disease or disorder is Alzheimerdisease.
 46. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of Alzheimer Disease, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a 5-HT6 antagonist compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of said5-HT6 antagonist compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.
 47. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of Alzheimer Disease, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of an acetylcholinesterase inhibitor compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said acetylcholinesterase inhibitor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 48. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of anAMPA receptor mediator compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said AMPA receptormediator compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 49. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of Alzheimer Disease, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of an amyloid aggregation-inhibitor compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said amyloid aggregation-inhibitor compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 50. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of acalcium channel modulator compound to augment the therapeutic effect orto provide a faster onset of the therapeutic effect of said calciumchannel modulator compound, further characterized in that pipamperon isto be administered to a patient in a daily dose ranging between 5 and 15mg of the active ingredient.
 51. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of Alzheimer Disease, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a choline uptake enhancer compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said choline uptake enhancer compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.
 52. Use ofpipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of acompound that activates ERK (extracellular signal-related kinase) toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said compound that activates ERK (extracellularsignal-related kinase), further characterized in that pipamperon is tobe administered to a patient in a daily dose ranging between 5 and 15 mgof the active ingredient.
 53. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of Alzheimer Disease, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a GABA agonist compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidGABA agonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 54. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of Alzheimer Disease, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a histamine H3-receptor antagonist compound to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said histamine H3-receptor antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 55. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of acompound which increases insulin sensitivity to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidcompound which increases insulin sensitivity, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.
 56. Use ofpipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of acompound which mimics the effect of nerve growth factor (NGF) to augmentthe therapeutic effect or to provide a faster onset of the therapeuticeffect of said compound which mimics the effect of nerve growth factor(NGF), further characterized in that pipamperon is to be administered toa patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 57. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of Alzheimer Disease, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a muscarinic receptor partial agonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said muscarinic receptor partial agonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 58. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of Alzheimer Disease, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a selective nor-adrenaline and dopamine re-uptakeinhibitor (NDRI) compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said selectivenor-adrenaline and dopamine re-uptake inhibitor (NDRI) compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 59. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to nerve growth factor (NGF)gene therapy, to augment the therapeutic effect or to provide a fasteronset of the therapeutic effect of said nerve growth factor (NGF) genetherapy, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 60. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of Alzheimer Disease, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a nicotinic receptor agonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said nicotinic receptor agonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 61. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of anN-Methyl-D-aspartate (NMDA) antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said N-Methyl-D-aspartate (NMDA) antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 62. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of anon-steroidal anti-inflammatory drug to augment the therapeutic effector to provide a faster onset of the therapeutic effect of said anon-steroidal anti-inflammatory drug, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 63. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofAlzheimer Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of aphosphodiesterase-4 (PDE4) inhibitor compound to augment the therapeuticeffect or to provide a faster onset of the therapeutic effect of saidphosphodiesterase-4 (PDE4) inhibitor compound, further characterized inthat pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.
 64. Use ofpipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of Alzheimer Disease, characterized in that pipamperon orsaid pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of apeptidic compound to augment the therapeutic effect or to provide afaster onset of the therapeutic effect of said peptidic compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 65. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of Alzheimer Disease, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a compound which protects dopaminergic and cholinergicneurons to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said compound which protects dopaminergicand cholinergic neurons, further characterized in that pipamperon is tobe administered to a patient in a daily dose ranging between 5 and 15 mgof the active ingredient.
 66. Use of pipamperon or a pharmaceuticallyacceptable salt thereof for the preparation of a medicament for treatingthe underlying emotion dysregulation of Alzheimer Disease, characterizedin that pipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a selective serotonin and dopamine reuptake inhibitor(SDRI) compound to augment the therapeutic effect or to provide a fasteronset of the therapeutic effect of said selective serotonin and dopaminereuptake inhibitor (SDRI) compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 67. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation ofAlzheimer Disease, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a selectiveserotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI)compound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said selective serotonin, nor-adrenalineand dopamine re-uptake inhibitor (SNDRI) compound, further characterizedin that pipamperon is to be administered to a patient in a daily doseranging between 5 and 15 mg of the active ingredient.
 68. Use ofpipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance relateddisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of aCRF1 antagonist compound to augment the therapeutic effect or to providea faster onset of the therapeutic effect of said CRF1 antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 69. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a GR antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said GR antagonist compound, further characterized in thatpipamperon is to be administered to a patient in a daily dose rangingbetween 5 and 15 mg of the active ingredient.
 70. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,eating disorders, premenstrual syndrome, somatoform disorders (excludingpain disorders), factitious disorders, dissociative disorders, sexualand gender identity disorders, sleep disorders, adjustment disorders,impulse control disorders, substance-related disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a melatoninreceptor (MT) agonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said melatoninreceptor (MT) agonist compound, further characterized in that pipamperonis to be administered to a patient in a daily dose ranging between 5 and15 mg of the active ingredient.
 71. Use of pipamperon or apharmaceutically acceptable salt thereof for the preparation of amedicament for treating the underlying emotion dysregulation of anon-cognitive mental disease or disorder selected from the group ofdiseases and disorders consisting of mood disorders, anxiety disorders,psychotic disorders, somatoform disorders (excluding pain disorders),factitious disorders, dissociative disorders, sleep disorders,adjustment disorders, impulse control disorders, pervasive developmentdisorders, disruptive behaviour disorders, substance-related disorders,personality disorders, psychological factors affecting medicalconditions, malingering, antisocial behaviour, bereavement, occupationalproblem, identity problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a neurotensin receptor antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said neurotensin receptor antagonist compound,further characterized in that pipamperon is to be administered to apatient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 72. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders,substance-related disorders, personality disorders, bereavement,occupational problem and problems related to abuse or neglect,characterized in that pipamperon or said pharmaceutically acceptablesalt thereof is administered simultaneously with, separate from or priorto the administration of a neurokinin 2 receptor (NK2) antagonistcompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said neurokinin 2 receptor (NK2) antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 73. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, psychotic disorders, somatoform disorders(excluding pain disorders), factitious disorders, dissociativedisorders, sleep disorders, adjustment disorders, impulse controldisorders, pervasive development disorders, disruptive behaviourdisorders, substance-related disorders, personality disorders,psychological factors affecting medical conditions, malingering,antisocial behaviour, bereavement, occupational problem, identityproblem and problems related to abuse or neglect, characterized in thatpipamperon or said pharmaceutically acceptable salt thereof isadministered simultaneously with, separate from or prior to theadministration of a neurokinin 3 receptor (NK3) antagonist compound toaugment the therapeutic effect or to provide a faster onset of thetherapeutic effect of said neurokinin 3 receptor (NK3) antagonistcompound, further characterized in that pipamperon is to be administeredto a patient in a daily dose ranging between 5 and 15 mg of the activeingredient.
 74. Use of pipamperon or a pharmaceutically acceptable saltthereof for the preparation of a medicament for treating the underlyingemotion dysregulation of a non-cognitive mental disease or disorderselected from the group of diseases and disorders consisting of mooddisorders, anxiety disorders, eating disorders, premenstrual syndrome,somatoform disorders (excluding pain disorders), factitious disorders,dissociative disorders, sexual and gender identity disorders, sleepdisorders, adjustment disorders, impulse control disorders, personalitydisorders, bereavement, occupational problem and problems related toabuse or neglect, characterized in that pipamperon or saidpharmaceutically acceptable salt thereof is administered simultaneouslywith, separate from or prior to the administration of a peptidiccompound to augment the therapeutic effect or to provide a faster onsetof the therapeutic effect of said peptidic compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 75. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of asubstance P receptor (NK1) antagonist compound to augment thetherapeutic effect or to provide a faster onset of the therapeuticeffect of said substance P receptor (NK1) antagonist compound, furthercharacterized in that pipamperon is to be administered to a patient in adaily dose ranging between 5 and 15 mg of the active ingredient.
 76. Useof pipamperon or a pharmaceutically acceptable salt thereof for thepreparation of a medicament for treating the underlying emotiondysregulation of a non-cognitive mental disease or disorder selectedfrom the group of diseases and disorders consisting of mood disorders,anxiety disorders, eating disorders, premenstrual syndrome, somatoformdisorders (excluding pain disorders), factitious disorders, dissociativedisorders, sexual and gender identity disorders, sleep disorders,adjustment disorders, impulse control disorders, substance-relateddisorders, personality disorders, bereavement, occupational problem andproblems related to abuse or neglect, characterized in that pipamperonor said pharmaceutically acceptable salt thereof is administeredsimultaneously with, separate from or prior to the administration of atachykinin antagonist compound to augment the therapeutic effect or toprovide a faster onset of the therapeutic effect of said tachykininantagonist compound, further characterized in that pipamperon is to beadministered to a patient in a daily dose ranging between 5 and 15 mg ofthe active ingredient.
 77. Use according to any of claim 1 to 4 or 7,wherein said second compound is gepirone.
 78. A method for preparing acompound having a selective D4 and 5-HT2A antagonist, reverse agonist orpartial agonist activity comprising the following steps: (a) measuringthe selective affinity of a test compound to the D4 receptor andselecting a compound that has a pKi value equal to or greater than 8towards the D4 receptor in respect to all the other D receptors, andmeasuring the selective efficacy of the selected compound to the D4receptor and selecting a compounds which is a selective antagonist,inverse agonist or partial agonist of the D4 receptor; (b) measuring theselective affinity of a test compound to the 5-HT2A receptor andselecting a compound that has a pKi value equal to or greater than 8towards the 5-HT2A receptor in respect to all the other 5HT receptors,and measuring the selective efficacy of the selected compound to the5-HT2A receptor and selecting a compounds which is a selectiveantagonist, inverse agonist or partial agonist of the 5-HT2A receptor;(c) identifying a compound which is selected in (a) and (b), (d)preparing the compound identified in (c).
 79. Compound prepared by themethod of claim
 78. 80. Use according to any of claim 1, 2 or 7, whereinsaid second compound is chosen from the group consisting of fluvoxaminecontrolled release, phenserine tartrate, atomoxetine hydrochloride,bupropion (controlled-release formulation), ropinirole HCL(controlled-release formulation), INN 00835, galantamine (extendedrelease formulation), paliperidone, tomoxetine, aprepitant, rivastigminetartrate, ORG 34517/34850, sunepitron, sumanirole, milnacipran,idazoxan, xaliproden, SR 58611, befloxatone, litoxetine, tianeptine,aglomelatine, SPD 503, flesinoxan, bifeprunox, ramelteon, etilevodopa,rasagiline (TVP-1012) and desvenlafaxine.
 81. Use according to any ofclaim 1, 2 or 7, wherein said second compound is chosen from the groupconsisting of galantamine (extended release formulation), R121919,risperidone, paliperidone and R228060 (YKP-10A).